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MICA: MHC class 1 chain related gene A
m-RNA: messenger RNA
nFAT: nuclear factor of activated T-cells
NK cells: natural killer cells
NSAID: non steroidal anti inﬂammatory drug
PASI: psoriasis area and severity index
PBMC: peripheral blood mononuclear cells
PPP: psoriasis pustulosa palmoplantaris
PUVA: psoralen and ultraviolet A
RANTES: regulated upon expression normal 
T-cell expressed and secreted
SCID mouse: severe combined immune 
deﬁcient mouse
SLE: systemic lupus erythematodes
TCR: T-cell receptor
Th1: type 1 helper T-cells
Tc1: type 1 cytotoxic T-cells
TNF-α: tumor necrosis factor α
UVA: ultraviolet A
UVB: ultraviolet B
VCAM: vascular cell adhesion molecule
VDR: vitamin D receptor
VLA: very late antigen
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1.1 EPIDEMIOLOGY AND CLINICAL PRESENTATION 
Psoriasis is a frequently occurring disorder affecting approximately 2-4 % of the 
world’s population. It is a polygenic disease and several triggering factors may elicit 
or aggravate skin manifestations seen in psoriasis.1. 
 Psoriasis is clinically characterized by sharply demarcated erythemato-
squamous lesions.2 Nevertheless, within the spectrum of cutaneous manifestations 
of psoriasis, several expressions are seen. The size of the lesions may vary from pin-
point (psoriasis guttata) to large plaques (psoriasis vulgaris) or even erythroderma 
(erythrodermic psoriasis). Whether these manifestations belong to one single disease 
entity is still an unresolved question. 
1.1.1 Psoriasis vulgaris (chronic plaque psoriasis)
This manifestation is the most common form of psoriasis, and occurs in 90% of 
adult patients. Its lesions are indurated and have polycyclic outlines, indicating 
that they are composed of several smaller units. Another characteristic is the sharp 
demarcation of the lesions without any gradual transition into the symptomless skin 
surrounding them. (ﬁgure 1) Sometimes a blanching ring can be seen around the 
plaque. This is called the Woronoff ring, referring to the physician who ﬁrst described 
this phenomenon.3 The scales of a psoriatic lesion may have a silvery appearance and 
have a characteristic coherence. If one tries to remove these, it is as if one is scratching 
on a wax candle (“signe de la tache de bougie”) With repeated scratching scales can 
be removed, leaving a wet surface with characteristic pinpoint bleedings (Auspitz 
Figure 1. Some characteristic features of the psoriatic 
lesion are seen. Sharply delineated erythemato-
squamous plaques characterize the psoriatic plaque.
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phenomenon), although this is not speciﬁc for psoriasis. This phenomenon happens 
to be wrongly attributed to Auspitz, since it was earlier mentioned by Robert Willan, 
Joseph Plenck and Daniel Turner.4-7 The histopathological equivalent of the ”signe de 
la tache de bougie” is parakeratosis, whereas the “Auspitz phenomenon” is equivalent 
to the upward proliferation of dermal papillae with vasodilatation. Predilection sites 
of the lesions are the elbows, knees, scalp and sacral region. The course of the disease 
is usually chronic with exacerbations and remissions.
1.1.2 Psoriasis guttata
Small pinpoint lesions dominate the clinical picture of guttate psoriasis. The droplet-
like lesions are erythematous and scaly and are disseminated over the body. Guttate 
psoriasis can progress, and the droplet-like lesions can merge into larger and scalier 
lesions as seen in chronic plaque psoriasis. Guttate psoriasis often develops after a 
throat infection with β-hemolytic streptococci.7;8
1.1.3 Erythrodermic psoriasis
This condition is characterized by scaling and erythema of the entire skin, with severe 
itching.(ﬁgure 2) In some severe cases, erythrodermic psoriasis can be complicated 
by dehydration, hypothermia/ hyperthermia, protein loss and imbalance of electrolyte 
metabolism.9 Because erythroderma is potentially life threatening, admission to an 
inpatient department is necessary. Erythrodermic psoriasis can be luxated by drugs 
known to induce psoriasis, but also by withdrawal from corticosteroids
Figure 2. Both legs of a patient with erythrodermic 
psoriasis are shown. A large part of the body 
is covered with intense erythema and severe 
desquamation. Because of the inﬂammation 
extremities show edema.
Chapter 1 - General Introduction
13
1.1.4 Pustular psoriasis
Forms of psoriasis characterized by macroscopic pustules are classiﬁed as pustular 
psoriasis, which can be divided into localized and generalized forms.10;11 Localized 
forms include pustulosis palmoplantaris (ﬁgure 3) and acrodermatitis of Hallopeau, 
whereas generalized forms include acute generalized pustular psoriasis of von 
Zumbusch, impetigo herpetiformis, annular pustular psoriasis and juvenile and 
infantile pustular psoriasis. 
1.1.5 Flexural psoriasis
Predilection sites of the lesions are the axillae, groins, submammary region, perianal 
region and the retro-auricular folds in ﬂexural psoriasis. This manifestation might be 
a response to bacterial or mycotic infections in these localizations. In chapter 4, both 
ﬂexural and plaque psoriasis are compared by immunohistochemistry. 
1.1.6 Scalp psoriasis and facial psoriasis
Scalp psoriasis is characterized by erythematosquamous plaques on the scalp.12 
Psoriatic lesions may advance beyond the scalp margin, transgressing into facial 
psoriasis. Hair loss due to scalp psoriasis is rare, but may occur. Several forms of 
facial psoriasis can be distinguished, each of them considerably impairing quality 
of life. These forms are often a marker for severe psoriasis.13;14 The most frequent 
manifestation of facial psoriasis is “hairline psoriasis”, which sometimes extends to 
the entire forehead. When seborrhoeic site is involved, such as the nasolabial furrow, 
it is called “sebopsoriasis”. A rare clinical form of facial psoriasis is “facial plaque 
psoriasis”, involving the central area of the face. (ﬁgure 4) Of all forms, facial plaque 
psoriasis is the most difﬁcult to treat, although the application of topical calcineurin 
inhibitor, such as tacrolimus ointment and pimecrolimus cream, seems to be a very 
Figure 3. Erythema and desquamation of the 
palm of the right hand is depicted. Furthermore 
several pustules are shown.
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promising treatment.15-18
1.1.7 Nail psoriasis or psoriasis unguium
Nail psoriasis is a common manifestation in psoriasis, and frequencies vary between 
10 and 55 % in the literature.19;20 Nail abnormalities either originate from the nail bed 
or from the nail plate. Typical signs are nail pitting (ﬁgure 5), discoloration of the 
nail bed or “ől-ﬂeck phenomenon”, subungual hyperkeratosis, distal onycholysis and 
less frequently splinter haemorrhage.21;22 Nail psoriasis has traditionally been treated 
with topical corticosteroids or vitamin D3 derivatives. Nowadays, topical cyclosporin 
is used to treat nail psoriasis and proved to have efﬁcacy.23;24 Topical tacrolimus is 
currently being tested as a therapeutical option for nail psoriasis.
1.1.8 Psoriasis related diseases
Psoriasis is associated with several other diseases. These associations may result from 
an etiological common trunk. In this respect it is important that at least 7% of the 
population of patients with psoriasis has signs and symptoms of psoriatic arthritis.25 
Furthermore, rare associations have been reported. These include Crohn’s disease26, 
vascular occlusive diseases and diabetes2. On the other hand, treatments may cause 
comorbidities. For example, long-term treatment with photo-chemo therapy may 
result in skin cancers 27, methotrexate may induce hepatic steathosis/cirrhosis 28 and 
long-term treatment with cyclosporine may cause kidney dysfunction.29 
 It can be difﬁcult to make a distinction between psoriasis and various other 
erythemato-squamous diseases. For example, it can be hard to distinguish seborrheic 
disease from ﬂexural psoriasis and scalp psoriasis.30 As already mentioned, some 
conditions have been suggested to share etiological factors with psoriasis, although 
consensus on the etiology has not yet been reached. In this respect, the position of 
Figure 5 A psoriatic nail is shown with typical 
pitting of the nail plate.
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inﬂammatory linear verrucous epidermal nevus has not yet been established.  
1.1.9 Inﬂammatory Linear Verrucous Epidermal Nevus (ILVEN)
Inﬂammatory linear verrucous epidermal nevus (ILVEN) is a rare skin disease 
characterized by unilateral lichenoid, verrucous or psoriasiform lesions. These lesions 
coalesce to form plaques and linear bands and may have a clinical resemblance to 
psoriasis.31;32
 This makes it difﬁcult to distinguish between the aforementioned skin 
diseases. In chapter 3 patients with plaque psoriasis, ILVEN, and ILVEN cum 
psoriasis are described and lesions are immunohistochemically analysed. We tried to 
delineate both psoriasis and ILVEN by examining T-cell subsets and proliferation and 
differentiation markers in lesional skin. 
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1.2 (IMMUNO) PATHOGENESIS OF PSORIASIS
In the following paragraph the pathogenesis of psoriasis will be described focussing 
on the role of T-cells. Psoriasis is a polygenic multifactorial disease.33;34 Furthermore, 
systemic triggering factors may play a role in the pathogenesis of psoriasis. Evidence 
indicating that systemic factors play a role in the pathogenesis of psoriasis comes 
from the existence of the Koebner phenomenon. This phenomenon is the appearance 
of a psoriatic lesion after injury to the skin. 
 There are several systemic factors which may aggravate psoriasis: for 
instance smoking and alcohol abuse35, focal infections7 (streptococcal infection of 
the throat) and drugs (Lithium, anti-malarials and β-blockers, NSAID’s, systemic 
corticosteroids).36
 
1.2.1 Dermal and epidermal characteristics of the psoriatic lesion
Several prominent histopathological abnormalities occur in the psoriatic lesion. (ﬁgure 
6) The psoriatic lesion is characterized by epidermal hyperproliferation accompanied 
by an accumulation of several types of immunocytes. Important subpopulations are 
polymorphonuclear leucocytes (PMN), several T-cell subsets and dendritic cells, 
monocytes/macrophages, NK-cells and NK-T cells. In vivo studies have shown that 
these immunocytes, present in the psoriatic lesion, are activated.37;38 In the following 
section the aforementioned immunocytes will be described.
Figure 6. Histopathology of lesional psoriatic skin with acanthosis, high reaching dermal 
papillae, mono-nuclear cell inﬁltrate in as well papillary dermis as epidermis, para- and 
orthokeratosis and proliferation of dermal vessels. 
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1.2.2 Polymorphonuclear leucocytes
In the psoriatic lesion the PMN are activated and are distributed in a speciﬁc way. 
The exocytosis of polymorphonuclear leucocytes into the epidermis with eosinophilic 
strands of keratinocytes is known as the micropustulus of Kogoj. When these 
micropustules reach the stratum corneum they are referred to as micro-abscesses 
of Munro.39;40 PMN show more adhesion capacity in the psoriatic lesion than in 
normal skin, especially in areas with pronounced expression of intracellular adhesion 
molecule 1 (ICAM-1). A large group of mediators of inﬂammation inﬂuence the state 
of the PMN.  Furthermore, the production of IL-8 by PMN and other cells residing in 
the epidermis, is believed to play a role in the formation of micro-abscesses of Munro 
and micropustulus of Kogoj.41;42
1.2.3 T-Lymphocytes and dendritic cells
Several decades ago, prior to the 1980s, it was believed that psoriasis was only a disease 
of the keratinocyte. The concomitant inﬁltrate with several lesional immunocytes, 
especially T-cells were thought to be the result of a reactive phenomenon in the 
psoriatic lesion. A major paradigm swift occurred when cyclosporin, a calcineurin 
inhibitor, proved capable of improving psoriatic lesions in patients with psoriatic 
arthritis.43 In another double blind placebo controlled study, cyclosporin also turned 
out to be effective in reducing psoriatic lesions.44 Because cyclosporin prevents T-cell 
activation, arguments began to arise that an enhanced immune response is the initial 
factor in the disease expression of psoriasis.45  Although, it was still not known that 
cyclosporin could not inhibit epidermal hyper-proliferation at therapeutically relevant 
concentrations.46 Moreover, depletion of lesional T-cell subsets by PUVA was found 
to correlate with disease improvement.47;48
  In psoriatic lesions the cellular inﬁltrate is mainly composed of CD8+ T-cells 
(cytotoxic T-cells) and CD4+ T-cells (helper T-cells). The abbreviation “CD” stands 
for “cluster of differentiation”. There are three conventions concerning the naming 
of leucocytes, with the third, mostly accepted convention stating that leucocyte cell 
surface molecules have a name corresponding to their cluster of differentiation antigen 
number. Furthermore, antibodies having the same selectivity and reactivity pattern 
with leucocyte populations as the aforementioned leucocyte surface molecules, have 
the same CD classiﬁcation.49;50
 The distribution of cytotoxic and helper T-cells is remarkable, with a 
predominance of CD8+ T-cells in the epidemis and of CD4+ T-cells in the dermis.38;51 
Because of the occurrence of CD4+ and CD8+ T-cells, it has been hypothesized that 
psoriasis is a chronic inﬂammatory disease caused by a persistent stimulation of T-
cells by immunogens of epidermal origin. The activated state of the present lesional T-
cells also supports this theory.52 Activated T-cells produce several cytokines enabling 
them to interact with keratinocytes, which produce HLA-DR as a result. Some studies 
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indicate that clearance of CD4+ T-cells correlates with clinical improvement,45;48;53 
whereas another study found that a reduction in the number CD8+ T-cells correlates 
with resolution of psoriasis.54 In this respect it is interesting to note that in psoriatic 
lesions mainly CD8+ T-cells show clonal expansion.55 Furthermore, 80% of the T-
cells in the epidermis have a CD8 positive phenotype. Which of the two T-cell subsets 
is more important remains to be clariﬁed, but it is possible that both CD4+ T-cells and 
CD8+ T-cells play an important role.  Furthermore, both T lymphocyte phenotypes are 
activated, i.e express HLA-DR (a late marker of activation) or CD25 (an early marker 
of activation) and are differentiated towards type 1 T-cells.56;57
1.2.4 The process of T-lymphocyte activation
After capturing an antigen, a naive dendritic cell in the epidermis starts maturing, and 
migrates to a skin draining lymph node. Naive T-cells (CD45RA), which are resident 
in skin draining lymph nodes, become activated by mature dendritic cells, upon 
which antigens of epidermal origin are presented. This is followed by differentiation 
and proliferation of T-cells and subsequent migration to the dermis and epidermis. 
(ﬁgure 7) Only T-cells with a speciﬁc T-cell receptor relevant to the type of immune 
response needed, will expand. Extravasation of memory effector T-cells (CD45RO+) 
can take place by a special set of adhesion molecules, directing these T-cells towards 
dermis and epidermis. When a patient has a normal cutaneous immune response, the 
antigen is eliminated by an immune mechanism appropriate to the inciting agent, as 
DC
DC
TH1
TH2
Lymph-node
TC1
TC2
CD45RA
TC1
Psoriasis
Atopic
dermatits
TC1
bloodvessel
T-cell activation
Figure 7. Hypothesis concerning T-cell activation in psoriasis is depicted in the above ﬁgure. 
An immature dendritic cell captures an antigen of still unknown origin and matures. The mature 
dendritic cell migrates to a skin draining lymph node to activate naive T-cells. In psoriasis, the 
process of T-cell activation is skewed in a TH-1 manner. Activated memory effector T-cells 
migrate back to the epidermis, with the help of the skin homing receptor CLA and integrins 
and selectins.
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just described. In psoriasis T-cell activation also follows the same pathway, except 
that fully mature dendritic cells, which are present in lesional psoriatic skin, sustain 
the immune response. 
  As mentioned above, the process of T-cell activation takes place in the skin 
draining lymph nodes. Besides stimulation of the T-cell receptor (TCR) several co-
stimulatory molecules are necessary to activate a naive T-cell. Three steps are needed 
for proper T-cell activation. The primary signal is the interaction between the TCR 
originating from either a T-helper cell (CD4) or a cytotoxic T-cell (CD8) and an antigenic 
peptide in the MHC I or II cleft of antigen presenting cells (APC). MHC-I typically 
presents intracellular antigens, whereas MHC II is typical for extracellular antigens. 
When an antigenic peptide interacts with a corresponding TCR, accompanying co-
stimulatory molecules such as LFA-1 and ICAM-1, several intracellular pathways 
are activated. Protein phosphorylation, calcium entry, calcineurin activation (the 
calcineurin pathway is described in paragraph 1.5.1.2) and the subsequent production 
of transcription factors are processes that occur after TCR binding and co-stimulation. 
This complex set of biochemical signals ultimately leads towards the production of 
several pro-inﬂammatory cytokines, such as IL2, TNF-α and IFNγ.
 The second critical step in the activation of T-cells is the occurrence of 
accessory or co-stimulatory signals. For instance CD28 (on T-cells) binds to 2 distinct 
B7 molecules on antigen presenting cells (APC). The combination of binding of the 
TCR and CD28 inﬂuences the production of several cytokines important for T-cell 
activation.58 Other interactions relevant to T-cell activation are the ICAM1/LFA1, 
LFA-3/CD2 and CD40/CD40L interactions.59
 The third signal consists of the effects induced by IL-2 and IL-12. IL-2 induces 
proliferation of T-cells, whereas IL-12 induces differentiation towards type 1 helper/
cytotoxic T-cells in psoriasis.60-62 Type 1 T-cells produce type 1 cytokines including 
IFN-γ, IL-2 and TNF-α.57 It is generally believed that psoriasis is a type 1 disease, 
which is characterized by the production of type 1 cytokines, as already mentioned. 
In contrast a type 2 disease like atopic dermatitis is characterized by the production 
of type 2 cytokines such as IL-4, IL-6 and IL-10.63 The precise mechanism that 
determines the Th1/Th2 balance is unknown. It is believed that the local concentration 
of cytokines inﬂuences the differentiation into type-1 T-cells or type-2 T-cells. Thus, 
a high concentration of IL-12 produces type-1 T-cells, whereas high concentrations 
of IL-4 produce type-2 T-cells. Effective immune responses often correlate with a 
type-1 differentiation, and are specialized in eliminating pathogenic bacteria such 
as Mycobacteria. It is also an type 1 differentiated immune response that generates 
an adequate immune response in tuberculosis.64 In this respect, it is interesting to 
note, that a type 1 skewed inﬂammatory response in Mycobacterium leprae infected 
patients, leads to lepra tuberculosa, whereas a type 2 differentiated immune response 
induces lepra lepromatosa.65 So, type-2 differentiated T-cells are less effective in 
generating immunity against certain bacterial pathogens. They are believed to be 
effective in eliminating infections with helminths and other extracellular parasites.66 
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Nevertheless, as already mentioned, psoriasis is a type 1 differentiated disease and the 
Vβ restriction of the TCR suggests that psoriasis might be an antigen driven disease, 
since only one speciﬁc T-cell population with the Vβ TCR is upregulated.55;67
 After the process of T-cell activation and maturation, T-cells express speciﬁc 
surface antigens that enable them to leave the vessels and migrate into the skin. For 
extensive information on T-cell trafﬁcking in inﬂammatory diseases the reader is 
referred to a review by Schon et al.68 Cutaneous Lymphocyte Antigen (CLA) is a 
glycoprotein that plays an important role in T-cell trafﬁcking to the skin.69 Furthermore, 
this surface antigen plays a fundamental role in the initial tethering of T-cells to the 
endothelium in cutaneous postcapillary venules. Tethering causes a slow down of T-
cells, followed by a complete arrest and subsequent diapedesis into the skin. During 
cutaneous inﬂammation the endothelium abundantly expresses both E-selectin and 
P-selectin, interacting with CLA on activated T-cells.70 After tethering has taken place, 
T-cells roll onto the endothelial surface. In this way, they are exposed to chemokines 
produced by endothelial cells and keratinocytes. Chemokines induce a modiﬁcation of 
integrins on T-cells, which allows binding to their ligands. Modiﬁcations of integrins 
on T-cells, induced by chemokines, allow the consequent binding to their ligands. 
For instance, LFA-1 and very late antigen 4 (VLA-4) on T-cells can bind to ICAM-1 
and vascular adhesion molecule (VCAM)-1 on endothelial cells respectively. These 
interactions enable the T-cell to arrest and ﬂatten and extravasate to the skin.71
 Chemokines have a chemotactic effect on T-cells. IFNγ and TNF-α, produced 
by activated T-cells, stimulate various cell types to produce chemokines that direct 
T-cells towards dermis and epidermis. For instance CCR6, a chemokine selectively 
expressed on CLA+ T-cells, has a ligand MIP3-α, which attracts T-cells to the skin.72 
RANTES (RegulAted upon expression, Normal T-cell Expressed and Secreted) binds 
CCR5 and in this way activates type 1 T-cells. 73;74 Moreover, T-cells expressing 
CCR4 and CXCR3 receptors are increased in lesional psoriatic skin, and their ligands 
upregulated.75 
 The interaction between keratinocytes (transient amplifying cells and/or 
stem cells) and type-1 T-cells is responsible for the histopathological characteristics of 
the psoriatic lesion. IFN-γ and TNF-α are released by type-1 T-cells. Both cytokines 
are potent inducers of ICAM-1, CD40 and MHC-II (HLA-DR) proteins on epidermal 
keratinocytes.76 T-cells are able to migrate into the epidermis by means of the αeβ7 
integrin and E-cadherin interaction. Moreover, the LFA-1/ICAM-1 interaction also 
plays a role by the migration of LFA-1+ T-cells into the epidermis. It is possible 
that some inﬂammatory cytokines are able to induce epidermal hyperproliferation and 
disturbed differentiation. This idea is supported by the observation that human skin 
transplanted on a SCID mouse and injected with cytokines show increased epidermal 
growth, although not completely identical to the epidermal hyperproliferation seen 
in psoriasis.77 Another phenomenon observed in psoriasis is the accumulation of 
neutrophils. Interleukin-8 (IL-8) is an important chemo-attractant cytokine for 
neutrophils, and IL-8 is released by keratinocytes. Since neutrophils have a short 
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lifespan, their ongoing trafﬁcking may injure basement membrane junctions and 
desmosomes. T-lymphocytes as well may cause injury to the desmosomes between 
keratinocytes. The subsequent induction of a wound repair response might cause the 
release of several mitogenic cytokines, resulting in epidermal hyperproliferation as 
seen in psoriasis.78
1.2.5 Monocytes and Macrophages
Monocytes are able to differentiate towards macrophages and dendritic cells. The 
function of dendritic cells has already been described in paragraph 1.2.4. Monocytes 
and macrophages are present in the psoriatic lesion. They can be observed immediately 
beneath the tips of the rete ridges. Because they are located immediately beneath the 
basement membrane, they are sometimes called “lining cells”.79 Lining macrophages 
strongly express HLA-DR, which may indicate that they are in an activational state.80 
Electron microscopy has revealed that macrophages have cellular protrusions through 
the basement membrane and are connected to basal keratinocytes. It is possible that 
macrophages directly inﬂuence keratinocyte growth by the production of cytokines 
(IL-6 and IL-8).81 
1.2.6 Regulatory T-cells 
Regulatory T-cells (Treg) are believed to play an important role in autoimmunity.82;83 
The classic function of CD4+ T-cells is to assist cytotoxic T-cells or other helper 
T-cells in an effective immune response. However, a subset of these helper T-cells 
are regulatory T-cells and expresses CD25 (the α unit of the IL-2 receptor), CTLA-4 
(cytotoxic T lymphocyte antigen-4) Foxp-3 (Forkhead box P3; a transcripton factor 
exogenously expressed) and GITR (glucocorticoid induced TNF receptor).84;85 They 
are present in the psoriatic lesion and may play a role in the pathogenesis of psoriasis. 
It has been shown that the inhibitory function of the Treg is disturbed in psoriasis.86 
Furthermore, it has been found that depletion of regulatory T-cells is associated with 
a tenfold expansion of the CD8+ T-cell population.87 The dramatic deterioration of 
stable plaque psoriasis in HIV infected patients is thought to be caused by a depletion 
of regulatory CD4+ T-cells, and a subsequent increase in CD8+ T-cells. CD4+CD25+ 
T-cell subsets are able to decrease the number of CD8+ T-cells, whereas CD4+CD25- 
T-cells are able to increase this number. As a consequence in severe AIDS syndrome 
psoriasis ameliorates, since no stimulatory or inhibiting signal is produced, and 
eventually the number of CD8+ T-cells is reduced. Because regulatory T-cells control 
CD8+ T-cells, important in the pathogenesis of psoriasis, development of therapeutic 
agents stimulating this regulatory T-cell subset may be worthwile.88 In this respect, it 
is interesting to note that T-cell subsets in psoriasis also seem to be submitted to other 
regulatory pathways. Natural killer receptors are able to regulate T-cell function as 
well, and this will be described in the following section.
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1.2.7 Cells expressing NK-receptors (NK-cells and NK-T cells)
The classical function of natural killer cells (NK-cells) is to eliminate cells that have 
been infected by pathogens or have been transformed into tumor cells. This function 
belongs to the innate immunity and is the ﬁrst line of defense of our body against 
infection and development of malignancy.89 After the ﬁrst actions induced by innate 
immunity, adaptive immunity participates in a joined effort to eradicate the infected or 
tumor target cells by generating a more speciﬁc immune response.
 NK-cells are a subpopulation of cytotoxic cells and are able to act without 
prior antigenic sensitization.90;91 Cytolysis of target cells by NK-cells, is dictated by the 
ultimate effect, induced by various activatory and inhibitory receptors, expressed on 
the surface of NK-cells.90;91 For instance, killer inhibitory receptors (KIRs) recognize 
their corresponding ligands (MHC class I alleles) on autologous cells and prevent 
cytolysis of the target cell.92;92 In addition, killer cell activating receptors (KARs) are 
able to activate or promote NK-cell mediated lysis of MHC I targets.
 Whereas NK-cells solely express NK-receptors, including CD16, CD56, 
CD161, CD94, CD158a and CD158b, NK-T cells are characterized by the co-
expression of αβ γδ TCRs and the aforementioned NK-receptors.93-95 They are able 
to perform functions belonging to innate immunity as well as adaptive immunity. 
In humans, KIRs and KARs are divided in 2 groups, namely the immunoglobilin 
superfamily (Ig-SF) and the lectin-like molecules.91 
 The complex interaction between genetic predisposition and environmental 
factors (“nature versus nurture”) may induce psoriasis in a way similar to other type-
1 mediated diseases, such as diabetes and multiple sclerosis.64;96-99 Several genetic 
susceptibility loci have been suggested for psoriasis, the most signiﬁcant of which 
appears to be a locus on chromosome 6p.100-102 On this locus the major histocompatibility 
complex (MHC) is present, which is very important for immune regulation. In this 
respect it is very interesting to note that a recent study has suggested an association 
between the A5.1 allele of the MHC class 1 chain related gene A (MICA) with psoriasis 
in a chinese population.103 Both CD8+ T-cells and NK-cells express receptors for the 
MICA ligand (NKG2R).
 The important role of NK-cells and NK-T cells in the pathogenesis of 
psoriasis is shown by several studies, although the precise function of these cell types 
is still unknown. Several models are used to investigate cells expressing NK-receptors, 
and these will be described in the following paragraphs. First the SCID (severely 
combined immunodeﬁcient) mouse model by Nickoloff will be discussed, followed 
by several studies investigating cells expressing NK receptors in human peripheral 
blood and lesional psoriatic skin.
 Nickoloff et al. found that blood-derived psoriatic immunocytes were able 
to transform human pre-psoriatic skin, engrafted on a SCID mouse, into a psoriatic 
lesion.104 Because no graft versus host disease was found around the engrafted psoriatic 
skin, they searched for cells expressing NK-receptors, to ﬁnd an explanation for the 
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lack of any cytopathic reaction. Receptors classically expressed on NK-cells, such as 
CD94, CD158a, CD158b, NKB1 and CD161 turned out to be present in the engrafted 
psoriatic lesion. First, this study indicated, that the primary defect in psoriasis, is likely 
to be of immunological origin, rather than epidermal origin. It was further proposed 
that, since several KIRs and KARs recognize MHC I alleles, and the important genetic 
susceptibility loci are linked to the MHC I alleles, especially T-cells expressing these 
receptors play an important role in the pathogenesis of psoriasis. 
Nickoloff continued his studies with the above mentioned SCID mouse model and 
found that especially CD4+ T-cells, but not CD8+ T-cells, were capable of creating a 
psoriatic plaque out of engrafted pre-psoriatic skin.105
 In another study, Nickoloff et al. found that injection of CD94+/CD161+ T-
cells in pre-psoriatic skin transplanted onto a SCID mouse, could induce a psoriatic 
plaque.106 In vitro studies with the same NK-T cells showed that incubation with CD1d 
positive keratinocytes produces high levels of IFN-γ and IL-13. Finally, this study 
demonstrated that T-cells expressing NK-receptors were able to directly provoke 
psoriasis, a Th1 disease, in a mouse model.106
 Koreck et al. found a signiﬁcant reduction of CD3+CD56+ NK-T cells in 
peripheral blood of patients with psoriasis.107 Low levels of CD3+CD56+ NK-T cells 
may represent an intrinsic feature of these patients, since after therapy the levels of 
NK-T cells stay decreased. The results of the study by Koreck et al. might be taken 
to suggest that NK-T cells play a role in the development of this type 1 mediated 
(auto)immune disease. Support for this comes from the fact that rheumatoid arthritis, 
another type 1 mediated disease, is also characterized by a signiﬁcant reduction of 
NK-T cells.108 Aractingi et al. showed that HLA-G and NK receptors are expressed in 
psoriatic skin.109 HLA-G binds to various natural killer receptors and is able to inhibit 
T-cell function. It is expressed upon the exposition of IFN-γ, a cytokine abundantly 
present in psoriasis. RNAs for HLA-G1 and HLA-G5 have been found in lesional 
psoriatic skin. Moreover, HLA-G has been found in psoriatic lesions, but this ligand 
of the NK receptor was not found in normal skin. CD68+/CD11c+ macrophages 
expressed HLA-G. Furthermore CD4+ T-cells expressed ILT-2, a NK receptor with 
HLA-G as ligand. It was concluded that presence of HLA-G and ILT-2 expression 
in psoriatic skin suggests that this pathway possibly acts as an inhibitory feed back 
mechanism in psoriasis.  
 Cameron et al. investigated the presence of several NK cells and NK-T cells 
in lesional psoriatic skin and in non-lesional skin and skin of healthy volunteers.110 
Their study demonstrated that cells expressing NK receptors are present in lesional 
psoriatic skin, and signiﬁcantly more abundant than in uninvolved skin or skin of 
healthy individuals. However, in another study Cameron et al. found reduced levels 
of NK cells, not NK-T cells in peripheral blood of psoriatic patients.111
 Thus, it is still unclear whether NK receptors play an inhibitory role, or 
rather initiating role in the pathogenesis of psoriasis. The literature does not provide 
a conclusive answer concerning the role of cells expressing NK-receptors in the 
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pathogenesis of psoriasis. Whereas the study by Koreck et al. reported decreased 
levels of NK-T cells in psoriasis107, the study by Cameron et al. reported reduced 
levels of NK cells but not NK-T cells in peripheral blood.111 Nevertheless, several 
animal models of a variety of established autoimmune diseases exist, with a reduced 
number of cells expressing NK-receptors in peripheral blood. These include models 
of multiple sclerosis112, type 1 diabetes mellitus113, and SLE114. The aforementioned 
diseases are all characterized by a type 1 differentiation of T-lymphocytes.112;113;115 It 
has been hypothesized that NK cells normally counteract the action of type 1 cytokines, 
by producing type 2 cytokines. In this way cells expressing NK receptors perform a 
regulatory function in auto-immunity.90;110;116 In a mouse model of multiple sclerosis it 
was shown that NK-cell depletion increased susceptibility to experimentally induced 
encephalomyelitis.117 NK-cells were also found to inhibit the activity of CD4+ T-cells 
in a mouse model of colitis.118 
 As stated earlier, MICA, a ligand for the NK-receptor NKG2D has been 
associated with psoriasis in a Chinese population.103 Susceptibility to NK-cell depletion 
may be genetically determined.119 It is therefore possible that genetically susceptible 
individuals have NK cell interactions that predispose them to psoriasis. 
Whether the reduction of cells expressing NK-receptors is primary or secondary in 
psoriasis is still unclear. It is possible that the reduced number of circulating NK-cells 
in patients with psoriasis is secondary to active inﬂammation. On the other hand, it is 
possible that the reduced level of cells expressing NK receptors is primary, and one of 
the initiating factors in the pathogenesis of psoriasis. 
Chapter 1 - General Introduction
25
1.3 TOPICAL TREATMENT OF PSORIASIS 
The topical treatment is the mainstay in the therapeutic management of psoriasis. 
This section describes current topical treatments for chronic plaque psoriasis and 
their efﬁcacy, mode of action and side effects will be described shortly. Vitamin D
3
 
derivatives, corticosteroids and dithranol are therapeutic options described in more 
detail, because of their relevance to this thesis. Furthermore the in vivo biological 
effects of these topical treatments are described in the following sections.
1.3.1 Emollients and keratolytics.
Greasy ointments and emollients are suitable to treat dry and scaly skin. Both lesional 
and unaffected psoriatic skin may beneﬁt from these substances.120 Ointments containing 
keratolytics, such as salicylic acid, are used to descale the thick hyperkeratotic plaques 
seen in psoriasis. Keratolytics enhance the efﬁcacy of other topical treatments by 
increasing their bioavailability. The application of salicylic acid should be restricted, 
since excessive use may induce salicylic acid intoxication.121 It is important to note, 
that salicylic acid may undo the effects of some treatments(e.g. calcipotriol).
1.3.2 Dithranol
Dithranol treatment is a traditional anti-psoriatic therapy, which is highly effective 
and safe. Since repeated application of dithranol induces habituation, clinical efﬁcacy 
is maintained by increasing its concentration. The concentration is increased with a 
maximum of 3 times a week, with the aim to induce slight irritation of perilesional 
skin for optimal efﬁcacy. 
1.3.2.1 Mode of action
Dithranol affects epidermal growth and differentiation and interferes with inﬂammation, 
at least in vitro. Formation of free radicals, by oxidation of the methylene group of 
dithranol is responsible for both the antipsoriatic and irritative effect of dithranol. 
Dithranol reduces neutrophil functioning and induces immunosuppression at least in 
vitro.122
 Several study reports have shown that dithranol inﬂuences epidermal growth. 
In particular, dithranol inhibits DNA synthesis, mitotic rate and repair, glucose-6-
phosphate dehydrogenase, ornithine decarboxylase and calmoduline.122-126 Dithranol 
also interferes with mitochondria and cyclic nucleotides.127;128 
 Furthermore in vitro data indicate that dithranol interferes with arachidonic 
acid metabolism and inhibits granulocyte and lymphocyte function.129;130 In addition, 
Mrowietz et al. showed that dithranol induces a dose-dependent inhibition of cytokine 
secretion by stimulated human monocytes in vitro.131 However, other investigators 
Chapter 1 - General Introduction
26
found that dithranol stimulates the in vitro keratinocyte-derived pro-inﬂammatory 
cytokines (normal human keratinocytes were stimulated).132 A study by Farkas et 
al. showed that dithranol upregulates IL-10 receptors on cultured keratinocytes.133 
Bonnekoh et al. showed that dithranol is able to suppress the IFN-γ induced 
upregulation of cytokeratin 17.134 
 Swinkels et al. did ﬁnd a signiﬁcant reduction of Ki67 positive keratinocytes, 
and less pronounced reduction of PMN, after 12 days of high dose dithranol treatment.135 
No effect on lesional T-cells or ﬁllagrin expression was observed. Nevertheless, van 
der Vleuten et al. found that short-contact ditranol therapy led to a complete restoration 
of ﬁlagrin-positive cell layers, reappearance of the stratum granulosum with decreased 
hyperkeratosis and loss of parakeratosis. Effects on PMN were not observed.136 
1.3.2.2 Efﬁcacy and side effects 
Twenty-four-hours application of dithranol is very effective, inducing remissions in 
almost all patients with extensive psoriasis. Although very effective, this treatment 
is time-consuming. Therefore a new principle was introduced, with short application 
times: the short contact principle.137 It is possible to use this principle at a day-care 
centre or at home.  
 Dithranol is not associated with serious adverse events,138 although irritation 
of perilesional skin may be a therapeutical challenge for the clinician. Treatment with 
topical tar solutions may be effective in reducing erythema and increasing therapeutic 
efﬁcacy. However, Swinkels et al. have found that strong potency corticosteroids are 
a better way to reduce dithranol irritation than coal tar solutions.139 
1.3.3 Vitamin D
3
 analogues
Vitamin D3 deravitives are currently the ﬁrst-line treatment for psoriasis. The active 
form of vitamin D
3
 (1,25-dihydroxyvitamin D
3
, 1,25(OH)
2
D
3
) plays an important 
role in the regulation of intestinal calcium absorption, bone mineralization and 
the prevention of rickets. Furthermore, the biological effects of vitamin D
3 
include 
stimulation of cellular differentiation, inhibition of proliferation 140;141 and immune 
modulation.142 The following case prompted researchers to investigate the possible 
antipsoriatic features of vitamin D3 deravitives: a patient who received vitamin D
3
 
for her osteoporosis, experienced a dramatic improvement of her severe psoriasis.143 
Later on, the development of topical vitamin D3 derivatives with low calcemic effects 
was started. 
 Calcipotriol is an analogue of naturally occurring vitamin D
3
. This topical 
agent is available as an ointment, cream or lotion and has a concentration of 50 μg/g 
(Daivonex®, Leo Pharmaceutical Products, Denmark). Twice daily applications provide 
the most effective clinical response. Another topical agent is calcitriol (1,25(OH)
2 
vitamin D
3
), which is available as an ointment with a concentration of 3 μg/g. (Silkis®, 
Galderma, France). Calcitriol is also applicated twice daily. Tacalcitiol (1,24(OH)
2
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vitamin D
3 
) is an ointment with a concentration of 4-μg/g (Curatoderm®, Hermal, 
Germany and Boots Healthcare, UK) and is not (yet) available in the Netherlands. 
Tacalcitol is applied once daily for optimal clinical results.
1.3.3.1 Mode of action 
The vitamin D receptor (VDR) is member of the superfamily of nuclear receptors. 
This superfamily is also consisting of the retinoid, thyroid and steroid receptors.144 
The VDR is a ligand inducible transcription factor, which is bound by active vitamin 
D3. Subsequently, activated VDR binds to vitamin D response elements. These 
response elements are present in the promotor region of certain vitamin D target 
genes.144 Vitamin D signalling takes place together with RXR signalling. This retinoid 
receptor, following ligand activation, binds to the activated VDR. The VDR-RXR 
heterodimer complex is largely responsible for vitamin D biological activity.145 The 
VDR is expressed on several cell types in the skin, including cultured keratinocytes146, 
langerhans cells147, melanocytes148, ﬁbroblasts149 and endothelial cells150. Moreover, 
the VDR is also expressed on monocytes and activated T-cells142;151, which take part in 
the psoriatic inﬂammatory process. 
1.3.3.2 Calcipotriol
In vitro studies show that calcipotriol inhibits cell proliferation and normalizes 
differentiation in an human lymphoma cell line 152 and in cultured human 
keratinocytes.141 Moreover, several in vivo studies have shown that calcipotriol 
has an effect on epidermal hyperproliferation, disturbed differentiation and 
inﬂammation.153;154 Mozannica et al showed that calcipotriol could induce a signiﬁcant 
reduction of memory effector T-cells after 2 weeks of therapy.155 Furthermore, de Jong 
et al. showed a reduction of CD2+ T-cells, monocytes and PMN after calcipotriol 
treatment, together with a reduction of epidermal hyperproliferation156 In addition, 
it has been shown that topical application of calcipotriol for 4 days suppresses the 
number of Langerhans cells as well as their accessory function.147 
 Placebo controlled investigations have been conducted to assess the efﬁcacy 
and safety of calcipotriol.157 After a period of 6-8 weeks it was found that twice a 
day applications of calcipotriol ointment resulted in a PASI reduction of 55-72%. 
Calcipotriol cream is somewhat less effective inducing a PASI reduction of 49-50%.158 
Some studies indicate that Tacalcitol once daily, short contact dithranol and coal tar 
are less effective than calcipotriol ointment twice daily.159 Cunliff et al. found that 
calcipotriol ointment has an efﬁcacy comparable with betamethasone valerate.160
 The scalp or intertriginous areas are preferentially treated with lotions and 
creams. Treatment of scalp psoriasis with calcipotriol lotion twice daily for a period 
of 8 weeks decreased the scalp severity index from 18.4 to 5.6 in a large group of 
patients (3.396).161 Although some reports indicate that vitamin D
3
 analogues may 
cause improvements in ﬂexural and facial psoriasis,162 irritation of the skin can be a 
serious problem at these sites.
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Calcipotriol is a safe topical treatment with respect to the calcemic effects, when 
the dose is kept beneath 100 g per week for the ointment or cream. For the lotion a 
maximum dose of 60 ml per week is within safety limits. When calcipotriol cream or 
ointment is combined with the lotion, the total dose may not exceed 5 mg calcipotriol 
per week to be safe. Irritation has been found among 15-20% of patients, 5% of them 
requiring discontinuation of treatment.157 
1.3.3.3 Calcitriol
Lu et al. found a signiﬁcant reduction in the number of CD4+ and CD8+ T-cells after 
8 weeks of Calcitriol treatment. In addition there was a signiﬁcant reduction of HLA-
DR and ICAM-1 expression, as well as the in vitro secretion of IFN-γ was reduced by 
calcitriol.163 Gerritsen et al investigated the effects of calcitriol earlier on after 1, 2 and 
4 weeks of treatment. After 2 weeks already there was a signiﬁcant reduction in the 
number of CD2+ T-cells, followed by a reduction in epidermal CD2+ T-cells after 4 
weeks. There was a signiﬁcant reduction epidermal hyperproliferation After 1 week of 
treatment, and a signiﬁcant normalization of keratinisation was reached after 4 weeks. 
Furthermore, Reichrath et al. found a signiﬁcant reduction of the number of several 
integrins after 8 weeks of calcitriol treatment.164A double blind controlled study 
comparing the effects of calcipotriol and calcitriol shows that calcitriol is somewhat 
less effective as calcipotriol.165 The clinical efﬁcacy of calcitriol was comparable 
with short contact dithranol applied at an outpatient department.166 Calcitriol has 
been reported to be successful in ﬂexural psoriasis.167 Moreover, calcitriol ointment is 
available in the Netherlands as well in most other European countries and can be used 
up to 210 g per week. 
1.3.3.4 Tacalcitol
Clinical and biological effects of Tacalcitol have been investigated in a placebo-
controlled study over a period of 8 weeks. Biopsies from lesions treated with tacalcitol 
showed a statistically signiﬁcant reduction of inﬂammation, epidermal proliferation 
and normalization of keratinization.168 Several investigations have been conducted to 
assess safety and efﬁcacy of tacalcitol in the treatment of psoriasis. A comparative 
study revealed that tacalcitol ointment was somewhat less effective then calcipotriol 
ointment.169 Tacalcitol has been shown to be effective in ﬂexural psoriasis.170 A dose 
of not more then 70 g per week (once daily applications) of Tacalcitol ointment is 
regarded as safe.
1.3.3.5 Combination therapy
Combination treatment of calcipotriol with other topical treatments, in particular 
corticosteroids, has proven to be more effective than the monotherapy.171 A few studies 
have been performed on the biological effects of combination therapy. A study by Glade 
et al. showed that in vivo a combination of calcipotriol and a topical corticosteroid 
has a more pronounced effect on inﬂammation (amount of vimentin positive cells) 
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as compared to calcipotriol monotherapy once or twice daily.172 Furthermore, van 
Rossum et al. found that a new combination of bethamethasone dipropionate and 
calcipotriol (dovobet® Leo Pharma Denmark) was more effective than the respective 
monotherapies in reducing lesional inﬂammation.173   
 Calcipotriol under occlusion is clinically more effective and therefore a good 
option for recalcitrant plaques.174;175 As earlier mentioned, enhancement of clinical 
efﬁcacy is also reached by the combination of calcipotriol once a day with a topical 
corticosteroid once a day, for instance halobetasol or betamethason dipropionate. This 
combination has been studied extensively.176;177 
 Dovobet® has been investigated by Kaufmann et al. in a multicenter study. 
This new formulation either applied once or twice daily was more effective than 
calcipotriol or betamethason dipropionate monotherapy. Nevertheless, the clinical 
efﬁcacy of once a day applications and twice daily applications of Dovobet® did not 
differ signiﬁcantly.178 
 Calcitriol combined with other anti-psoriatic treatments has also been studied. 
One of these investigations indicated that the combination of calcitriol ointment with 
UVB phototherapy permitted a 34% decrease of total UVB exposure.179
1.3.4 Topical corticosteroids
For many years topical corticosteroids have been used as safe and effective compounds 
to treat inﬂammatory skin conditions, such as psoriasis. Depending on their strength 
corticosteroids can be divided in low potency, potent or superpotent corticosteroids. 
1.3.4.1 Mode of action
Corticosteroids are able to bind the corticosteroid receptor, after entering the 
cytoplasm of the target cell. In addition, the complex of the corticosteroid and its 
receptor binds the glucocorticosteroid response elements on DNA, stimulating 
the production of certain mRNA’s, such as the mRNA for the protein lipocortin-1. 
Lipocortin-1 inhibits the action of phospholipase A2, which is responsible for the 
production of arachidonic acid the precursor of pro-inﬂammatory molecules, such as 
prostanoids and leukotrienes. Nevertheless, the production of mRNA of several pro-
inﬂammatory cytokines such as IL-1, IL-2, IL-6 and IFN-α is decreased by binding 
of the corticosteroid receptor complex 180;181 The action of corticosteroids leads to a 
reduction of the number of lymphocytes, monocytes and macrophages in lesional 
psoriatic skin. Furthermore, the production of several vasoactive mediators is reduced 
by corticosteroids resulting in vasoconstriction. Besides interfering with epidermal 
growth and differentiation, proliferation of ﬁbroblasts in the dermis is also inhibited by 
corticosteroids, causing dermal atrophy as a side effect.182 Moreover, corticosteroids 
may also bind the androgen receptor, causing hypertrichosis and acneiform eruptions 
at treated sites. 
 Several investigators have studied the in vivo action of corticosteroids. At 
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the cellular level de Jong et al. found that after 1-3 weeks of budesonide treatment 
mainly epidermal hyperproliferation was reduced, with little effect on the inﬁltrate.183 
Berth-Jones et al. compared the in vivo effect of betamethasone valerate ointment to 
calcipotriol ointment.184 They found that betamethasone valerate induced a signiﬁcant 
improvement of K5 and K10 expression and induced a reduction of K16 expression, 
which correlated signiﬁcantly with a reduction of epidermal thickness. Langerhans 
cells, HLA-DR+ dendritic cells and T-lymphocytes all reduced signiﬁcantly after 
treatment with betamethasone valerate. 
1.3.4.2 Efﬁcacy and side effects
Patients presenting with chronic plaque lesions, may beneﬁt from potent corticosteroids. 
However, psoriasis inversa and facial psoriasis are two expressions treated with low 
potency corticosteroids.     
 The formulation of a topical corticosteroid inﬂuences its clinical efﬁcacy. For 
instance, ointments are clinically more effective than creams or lotions. Sometimes 
an additive is used in the formulation to enhance penetration of a thick hyperkeratotic 
epidermis. Moreover, the onset of clinical effect is fast for corticosteroids, since after 
already 2 weeks of applications a maximum effect is reached. 
 As already mentioned, during treatment of corticosteroids, several side effects 
may occur, especially when not applied intermittently. Atrophy of dermis as well as 
epidermis, perioral dermatitis, striae, and teleangiectasias can be seen frequently. 
Less often acneiform eruptions, contact allergy, hypertrichosis, hypopigmentation, 
ecchymoses, aggravation of cutaneous infections and delayed wound healing are 
seen.185;186 Although teratogenic effects induced by corticosteroids are never proven, 
the minimal needed quantities of established corticosteroids should be used during 
pregnancy. Induction of an adrenocortical syndrome and Cushing syndrome is very 
rare. To avoid these rare complications physicians should not prescribe more than 50g 
of superpotent or 100g of potent topical corticosteroids on the long-term. In children 
superpotent corticosteroids should not be used, whereas potent corticosteroids may be 
used with a maximum of 50g a week.
1.3.5 Topical retinoids
Almost 4 decades ago, the efﬁcacy of an all-trans-retinoic acid (0,3%) formulation, 
as topical treatment of psoriasis was investigated. Nevertheless, efﬁcacy turned out to 
be modest and substantial perilesional irritation occurred.187 A decade ago tazarotene, 
an innovative topical retinoid, became available with efﬁcacy in psoriasis.188;189 
Unfortunately, this topical agent is currently not available in the Netherlands. 
1.3.6 Tar 
For a long time patients have used tar as an antipsoriatic treatment. Although the use 
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of coaltar is restricted to in-patient departments and day-care centres, it is effective 
in reducing the itch and clinical severity of the psoriatic lesion. Tar is currently under 
investigation with respect to its potential carcinogenic effects, although this was never 
proven when tar was applied in a medical setting. 
1.3.7 Photo(chemo)therapy
Topical treatments are not always sufﬁcient when large parts of the body are 
affected. In such cases photo(chemo)therapy is a good alternative. Several forms of 
photo(chemo)therapy exist: UVB phototherapy and PUVA photo(chemo)therapy. For 
a detailed account on photochemotherapy in psoriasis the reader is referred to a review 
article by Zanolli on this topic.190
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1.4 SYSTEMIC TREATMENT OF PSORIASIS
The use of systemic treatments is restricted to those patients, who do not beneﬁt 
from topical treatments anymore, due to reduced efﬁcacy or contraindications. In 
this paragraph we will describe brieﬂy the action, efﬁcacy and side effects of four 
established systemic treatments namely acitretin, methotrexate, cyclosporin and 
fumarates. Concomitant use of topical agents is advised, because this may permit a 
reduced dose of systemic drugs, resulting in reduced toxicity.171
1.4.1 Acitretin
Acitretin (Neotigason®) belongs to the group of mono-aromatic retinoids, and is able 
to bind the retinoid receptor, which belongs to the same nuclear receptor superfamily 
as the already mentioned vitamin D
3
 receptor. After formation of a heterodimer, the 
retinoid receptor complex is able to bind retinoid response elements on the DNA, and 
than exerts its biological activity. 
 In addition, clinical efﬁcacy of acitretin as monotherapy for chronic plaque 
psoriasis is disappointing, because only 17% to 25% of the patients reach >75% PASI 
reduction.191;192 Nevertheless, in patients suffering from generalised pustular psoriasis 
or psoriasis pustulosa palmaplantaris, acitretin should be considered as ﬁrst-line 
choice.193;194 To enhance the clinical efﬁcacy in chronic plaques psoriasis, combinations 
with phototherapy and vitamin D
3
 derivatives or corticosteroids are used. Systemic 
retinoids, such as acitretin are able to reduce the number of proliferative keratinocytes, 
to decrease the number of immunocytes and normalize keratinisation.195;196
 Acitretin may induce side effects, which are dose dependent. These side 
effects include peeling of the skin of palms and soles, dryness of the lips and mucous 
membranes, epistaxis and conjunctivitis amongst others.193 Furthermore, liver 
enzymes, triglycerides and cholesterol may be transiently increased by acitretin. 
Because acitretin accumulates in the fatty tissues and has teratogenic potential, women 
should avoid pregnancy for at least 2 years after stopping the therapy.197 Hyperostotic 
changes in the spine have been observed. Contraindications are active liver disease, 
pre-existing hyperlipidaemia and pregnancy.
1.4.2 Methotrexate
For a period of more than half a century folic acid antagonists, such as methotrexate, 
have been used as systemic antipsoriatic treatment.  
 The enzyme dihydrofolate reductase is inhibited by methotrexate. This 
competitive binding induces a decrease of reduced folates. In turn, DNA synthesis is 
inhibited, resulting in inhibition of purine synthesis. The in vivo effects of methotrexate 
consist of a decrease of the number of skin homing T-cells, although no shift from Th1 
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to Th2 cells is seen.198 
 It is possible to treat all manifestations of psoriasis with methotrexate. 
Only between 1 and 7 weeks a ﬁrst clinical effect may be seen during treatment 
with methotrexate. Maximal improvement is reached after 8-12 weeks of treatment. 
Nyfors et al. found that 90% of 248 patients had an improvement of severity of more 
than 75%.199 Methotrexate may be used after an induction phase with dithranol. 
Maintenance therapy with methotrexate may then result in a long period of psoriasis 
clearance.200     
 Van de Kerkhof and Said have reviewed side effects of methotrexate. 200;201 
Patients may develop one of the following side effects; nausea, vomiting abdominal 
pain, fatigue and headache. Although haematopoietic suppression may occur after 
methotrexate use, this side effect is usually benign and fades away after a short 
period of discontinuation. To prevent the development of hematosuppression, folic 
acid is prescribed on non-methotrexate days. Methotrexate is able to induce several 
mucocutaneous side effects, including oral erosions, hair-loss, and burning sensation 
of the lesions. The most frequent and potentially severe side effect during treatment 
with methotrexate is liver damage. Some investigators found liver cirrhosis among 
more than 25% of patients using methotrexate.202 Furthermore, methotrexate is 
teratogenic and may induce birth defects203, although some investigators do not ﬁnd 
such effect.204
1.4.3 Cyclosporin
Not long after the discovery that cyclosporin has immunosuppressive properties, it 
was found that this drug was able to substantially ameliorate the clinical severity of 
psoriasis.47 This observation also triggered researchers to investigate the role of the 
immune system in psoriasis, especially T-cells.
 Cyclosporin binds to cyclophilin, which is an immunophilin in the cytoplasm 
of T-cells. Its mode of action is comparable to other calcineurin inhibitors such as 
tacrolimus and pimecrolimus, which will be described in the following section. 
The enzyme calcineurin is inhibited by the complex cyclosporin-cyclophilin.205 As 
a consequence the nuclear factor NFAT is not dephosphorylated and not able to 
enter the nucleus of the T-cell. In the absence of cyclosporin binding of the TCR 
leads to entrance of NFAT to the nucleus, and subsequent production of mRNA of 
several pro-inﬂammatory cytokines. Thus, cyclosporin inhibits the production of 
pro-inﬂammatory cytokines such as IL-2.206 IL-2 plays an important role in T-cell 
activation, by providing a co-stimulatory signal and inducing T-cell proliferation.47
 In addition, the chemotactic responses of polymorphonuclear leukocytes and 
the function of antigen presenting cells is decreased by cyclosporin. 207;208 Furthermore 
cyclosporin interferes with the production of the lymphokine IFN-γ, thereby also 
inhibiting a wide range of cytokines and adhesion molecules produced by keratinocytes 
and endothelial cells respectively.209  
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Clinical efﬁcacy of cyclosporin has been shown in several studies. One of these 
investigations showed a PASI reduction of 75% or more in 88% of patients using 
5 mg cyclosporin per kg/day.210 The side effects of cyclosporin include a decrease 
of glomerular ﬁltration rate and hypertension. The long-term use of cyclosporin is 
also associated with the occurrence of squamous cell carcinoma, because it decreases 
immuno-surveillance of the skin. Because of these side effects, cyclosporine is used 
preferentially for a short period of time. 
1.4.4 Fumarates
Since the 1960’s fumarates have been applied in the systemic treatment of psoriasis. 
The precise mode of action of fumarates is still not known. In vitro studies show 
that fumarates, especially the monoethyl ester form, are able to affect polarization 
of dendritic cells, resulting in a decrease of the production of Th1 lymphocytes.211;212 
Furthermore, in vivo studies showed a signiﬁcant reduction of CD4+ and CD8+ 
lymphocytes in human peripheral blood after treatment with fumarates. These 
reductions correlated with clinical improvement of the psoriatic lesions.213
 Fumarates are effective for the treatment of chronic plaque psoriasis as found 
by several investigators.214-218Nevertheless, in the Netherlands this drug is still not 
registered for the treatment of psoriasis.
 Patients who suffer from severe chronic plaque psoriasis and have 
contraindications for the use of cyclosporin or methotrexate could beneﬁt from 
treatment with fumarates. Side effects may consist of renal impairment, ﬂushing, 
gastrointestinal complaints, headache and fatigue.219
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1.5 INNOVATIVE TREATMENTS
In the last few years several new effective compounds have been introduced as 
treatment for psoriasis. The search for innovative treatments is necessary, since 
treatment resistance may easily develop, demanding new approaches to treat this 
chronic skin disorder. Furthermore, side effects may cause patients to switch from 
one treatment to another. Research and development are in this respect important 
to enlarge the range of therapeutic options of the physician, making a tailor-made 
treatment possible. 
 In addition to new topical treatments, innovative systemic treatments 
are being developed. Whereas serendipity used to be the driving force behind the 
development of new antipsoriatic treatments, growing immunological knowledge 
concerning the pathogenesis of psoriasis and the development of bio-engineering, 
now makes it possible to develop rational treatment strategies.78
 Table 1 shows some recently developed antipsoriatic treatments and their 
mode of action. Currently, these treatment modalities are being investigated to assess 
whether they are safe and effective. Some of these treatments will be discussed in 
greater detail below. Rational immuno-therapies, the so-called biologicals target one 
or more steps in the process of T-cell activation. Biological agents are composed of 
proteins, biotechnologically created. Therefore, these agents are nowadays referred to 
as “biologicals”. Biologicals mimick the action of naturally occurring proteins. In this 
way, they are able to modulate and change the course of a pathologic inﬂammatory 
response.220
1.5.1 Innovative topical treatments
The side-effects induced by topical treatments are often less serious than those 
induced by systemic therapy. On the other hand, systemic treatments are generally 
more effective and less time consuming. Therefore, researchers aim to develop topical 
compounds that have high clinical efﬁcacy, few or no side-effects and take little 
application time. In the following section three innovative topical treatments will be 
described namely a new vitamin D
3 
derivative ZK 156942 in SH F597 F ointment and 
the topical calcineurin inhibitor, tacrolimus gel and cream.
1.5.1.1 New vitamin D
3
 derivative: SH F597 F ointment, containing ZK 156942
New promising vitamin D
3
 derivatives are currently being developed. Investigators 
aim to discover topical agents with fewer calcemic and irritative properties, and better 
clinical efﬁcacy than the currently available vitamin D
3
 derivatives. The mode of 
action of vitamin D
3
 derivatives has already been described in paragraph 1.3.4.1. ZK 
156942 is a new vitamin D
3
 derivative developed by Schering. Phase I and II studies 
indicate that this compound may have the advantages mentioned above. Chapter 5 
of this thesis discusses the clinical efﬁcacy of ZK 156942 and compares its effects 
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Therapy Mode of action
Biologicals Anti-CD2 (Siplizumab)221
Anti-CD3 (Visilizumab/
Orthoclone)222;223 
Anti-CD4 (Imuclone)224
Modulation or blockade 
of TCR stimulation
LFA3TIP (Alefacept®)225
CTLA4-Ig226
Anti-CD80 (IDEC 114)227
Blocking accessory 
signals or costimulation
IL-4228
IL-10 (Tenovil®)229
IL-11 (Neumega®)62
Immune deviation; 
Manipulation of T-cell 
differentiation
Anti-CD25 (Daclizumab/
Basiliximab)230;231
Modulation of T-cell 
proliferative signals
Efalizumab (Raptiva®)232 Inhibition of leucocyte 
adhesion and migration
Etanercept (Enbrel®)233
Onercept 234
Inﬂiximab (Remicade®)235
Adalimumab (Humira®)236
Blockade of effector 
cytokines
Non-
biologicals
topical Tacrolimus (Protopic®)237
Pimecrolimus (Elidel®)238
Calcineurin inhibitors
ZK 156942 (Tisocalcitate) Vitamin D
3 
derivative
systemic Leﬂunomide(Arava®)239 Inhibition of dihydro-
orotatedehydrogenasis
Bexarotene (Tazarotene®)188
4 hydroxylation inhibitor 
liarozole (Targretin®)240
Retinoid signalling 
pathway
Rosiglitazone maleate241 Ligand for the 
peroxisome 
proliferators-activated 
receptor-γ
Sirolimus (Rapamycin®)242 mTOR inhibitor
Table 1 Some innovative anti-psoriatic treatments and their mode of action.
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on lesional T-cell subsets and proliferation and differentiation markers with those of 
calcipotriol.
1.5.1.2 Calcineurin inhibitor: topical tacrolimus gel and cream
Calcineurin inhibitors such as tacrolimus and pimecrolimus, but also cyclosporin all 
inhibit T-cell activation by blocking the calcineurin complex.243 In this way T-cell 
activation is inhibited. Although sirolimus binds FKBP12, like pimecrolimus and 
tacrolimus do, the sirolimus-FKBP12 complex does not inhibit calcineurin but mTOR, 
a central kinase that transduces signals from the IL2 receptor and other growth factor 
receptors.244As mentioned earlier in paragraph 1.4.3., the cyclosporin-cyclophillin 
complex inhibits calcineurin, and thereby prevents T-cell activation. It has been found 
that calcineurin inhibitors and sirolimus also exert a T-cell independent effect. For 
instance, together with cyclosporine, they were found to inhibit the proliferation of 
cultured keratinocytes at therapeutically relevant concentrations.245;246 The efﬁcacy, 
side effects and mode of action of tacrolimus will now be described in greater detail. 
In march 1984 tacrolimus was discovered from a strain of bacteria, identiﬁed in a soil 
sample found on mount Tsukuba, Japan. This bacterial strain has since been referred 
to as Streptomyces Tsukubaensis. The generic name of the newly discovered agent 
has been derived from a neologism namely the words Tsukuba, mACROLide and 
IMmUnoSuppression. At ﬁrst, tacrolimus was used to prevent rejection of transplanted 
organs. The efﬁcacy of this calcineurin inhibitor as a systemic treatment in chronic 
plaque psoriasis was discovered in four organ transplant patients with concomitant 
psoriasis, who received systemic tacrolimus.247 Several pilot studies and a phase 
II study proved the efﬁcacy of systemic tacrolimus (Prograf®) in the treatment of 
chronic plaque psoriasis.248 Furthermore, it has recently been shown, that tacrolimus 
ointment is effective in the topical treatment of facial and ﬂexural psoriasis.16 
Although current topical treatments, such as vitamin D3 derivatives, corticosteroids, 
tazarotene, dithranol and coal tar can be successful in treating psoriasis,249 these 
treatments are unfortunately also associated with some disadvantages including 
thinning of the skin and tachyphylaxis (when using corticosteroids), irritation (when 
using dithranol, tazarotene or calcipotriol) and cosmetic limitations (when using coal 
tar). Tacrolimus ointment does not induce skin atrophy and its irritative properties 
are less pronounced as compared to dithranol, tazarotene or calcipotriol.250 Although 
tacrolimus ointment (0.3%) was found to have an anti-psoriatic effect in a double-
blind, vehicle-controlled microplaque assay test 237, Zonneveld et al. found that the 
efﬁcacy of tacrolimus ointment (0.3%) in chronic plaque psoriasis was comparable 
to the placebo ointment.251 This was probably the result of insufﬁcient bioavailability 
of the tacrolimus ointment, in part due to a high molecular weight of 822.5 dalton. 
However, there are more factors that inﬂuence the penetration of substances into the 
skin, such as for example the vehiculum, the skin type and whether occlusion was 
used. Recently, Carroll et al. found that tacrolimus ointment when combined with 
6% salicylic acid is able to reduce the clinical severity of the psoriatic plaque.252 This 
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study points out that insufﬁcient penetration of the ointment may be the cause of 
reduced clinical efﬁcacy. Therefore, topical tacrolimus gel and cream are interesting 
and innovative candidates for the treatment of plaque psoriasis, especially applicable 
in sensitive skin regions. 
 One of the side effects of tacrolimus may be a stinging/burning sensation 
shortly after application at the site of application. Furthermore, the long-term side-
effects of tacrolimus on the skin should be carefully monitored, considering the 
immunosuppressive properties of this compound. In case of a defective skin barrier, 
as in Netherton’s syndrome, one should be very cautious in applying tacrolimus, since 
serum concentrations may exceed safety-levels.253 Nevertheless safety studies of 
patients treated with topical tacrolimus for 1 year, showed that there was no signiﬁcant 
increase in skin infections over the treatment period; there was also no mention of 
any severe related adverse events.254 Furthermore, tacrolimus proved to be a safe and 
effective treatment in children with atopic dermatitis.255
 We will describe the mode of action of tacrolimus in the following section. 
A MHC I or II complex of e.g. a dendritic cell may present an antigen to the T-cell 
receptor (TCR) of a T-lymphocyte, after which several tyrosine kinases are activated. 
This is followed by the activation of the phospholipase C pathway, though other 
pathways are activated as well. Phospholipase C then produces inositol trisphosphate 
(IP3), by hydrolysing phospho-inositol-containing lipids in the plasma membrane. 
IP3 subsequently induces calcium release from the endoplasmic reticulum. Increased 
levels of intracellular calcium stimulate the activation of the calmodulin complex, 
which binds calcineurin. This activated calcineurin complex dephosphorylates the 
cytoplasmic nuclear factor of activated T-cells (NFAT), which is a transcriptional 
factor. This leads to a change in the conformation of NFAT and to unmasking of the 
nuclear import signal, which enables NFAT to be translocated to the nucleus. The 
production of AP-1, another transcriptional factor, is promoted by protein kinase 
C. Protein kinase C is believed to be activated by B7, a co-stimulatory signal. Both 
transcriptional factors are necessary for the production of e.g. interleukin-2 (IL-2) 
mRNA and subsequently IL-2 protein. This pro-inﬂammatory cytokine has been found 
to lead to T-cell activation.243;256-258 In ﬁgure 8 the intracellular processes during T-cell 
activation are depicted. The phospholipase C pathway, mentioned above is inhibited by 
tacrolimus and proceeds as follows. Tacrolimus binds FKBP12, a cytoplasmic protein. 
The FKBP12-Tacrolimus complex inhibits the action of calcineurin. This means that 
NFAT is not dephosphorylated and the pro-inﬂammatory cytokines that induce T-
cell activation such as TNF-α, IL-2, IL-3 and IL-5 are not produced preventing the 
development of memory effector T-lymphocytes. 
1.5.2 Novel Systemic Treatments
Novel immuno-therapies are being developed with the help of protein engineering. 
These therapies selectively modulate immunological events in psoriasis.  Knowledge 
Chapter 1 - General Introduction
39
about the pathogenesis of psoriasis is important to understand the mode of action of 
these treatments.
 The immuno-pathogenesis of psoriasis has already been described in 
paragraph 1.2. To sum up, psoriasis is a chronic inﬂammatory skin disorder associated 
with persistent T-cell activation. 52;78 An epidermal dendritic cell captures an antigen, 
matures, and travels to a skin draining lymph node, where naive T-cells are activated 
in a 3-step process. The primary signal consists of stimulation of the TCR by 
peptides presented in the cleft of MHC I or II molecules. This is followed by co-
stimulation, resulting in proliferation and differentiation of T-lymphocytes towards 
type-1 differentiated T-helper cells and cytotoxic T-cells. After migrating to the skin 
the effector memory T-cells secrete cytokines including IL2, IFNγ and TNF-α. These 
factors induce epidermal hyper-proliferation and disturbed differentiation together 
with vascular changes. As a consequence keratinocytes, monocytes and dendritic cells 
start producing cytokines, including IL8, a chemoattractant for neutrophils (formation 
of micropustules of Kogoj and microabcesses of Munro)
 There are several ways to classify biologicals. One possibility is classiﬁcation 
on the basis of protein structure. Three kinds of molecules are now available: monoclonal 
antibodies, recombinant cytokines, and fusion proteins. The nomenclature of these 
proteins is rather straightforward: names of fully human monoclonal antibodies end 
in –umab, humanized monoclonals end in –zumab, and those of chimaeric antibodies 
end in –ximab. The names of fusion proteins end in –cept. Another way of classifying 
biologicals is according to the phase of the psoriatic process they target. Biologicals 
MHC I or II
T-cell receptor
+ CalcineurinCa2+
Calcineurin
NF-ATcP
NF-ATc
NF-ATAP-1
IL-2-promotor
IL-2-mRNA
+
PLCPKC
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Calcium
activated
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Calcineurin
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induced
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-
Figure 8. The phospholipase C pathway is shown. The T-cell receptor recognizes the antigen 
MHC complex and activates phospholipase C. This leads to an inﬂux of calcium2+ in the 
cytoplasm of the T-cell. As a result, a calmodulin calcineurin complex dephosphorylates nFAT, 
a nuclear factor. nFAT is then able to migrate to the nucleus. The complex of AP and nFAT is 
important for the transcription of pro-inﬂammatory cytokines, such as IL-2.(A) The Tacrolimus 
FKBP12 complex binds the calcineurin-calmodulin complex. In this way tacrolimus is able to 
inhibit the dephosphorilation of  nFAT by the calcineurin-calmodulin complex. NFAT is not able 
to migrate to the nucleus, and the production of pro-inﬂammatory cytokines is decreased.(B)
 A  B
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can be divided into groups that inhibit dendritic cell maturation, another group 
that blocks T-cell activation, a third group that blocks the accessory signals or co-
stimulation, a fourth group that manipulates T-cell differentiation by recombinant 
cytokines (immune deviation), a ﬁfth group that inhibits T-cell proliferative signals, a 
sixth group that inhibits effector cytokines and a last group that targets T-cell adhesion 
and migration. There is considerable overlap in effects induced by biologicals. (table 
1) The following paragraphs will discuss some of the biologicals already mentioned 
in table 1. Mode of action, clinical efﬁcacy and safety of alefacept (amevive®), 
etanercept (enbrel®), inﬂiximab (remicade®), adalimumab (humira®) and efalizumab 
(raptiva®) are discussed in the following paragraphs.  
1.5.2.1 Blocking accessory signals or co-stimulation: alefacept (LFA3-TIP, 
Amevive®)
Alefacept is a fusion protein consisting of the ﬁrst LFA-3 extracellular domain fused 
to the hinge regions of a human IgG1. The LFA3-CD2 interaction between an APC 
and T-lymphocyte is disrupted in this way.259
 The efﬁcacy of alefacept has been shown in several studies. For example 
a placebo-controlled phase II study with 229 patients with chronic plaque psoriasis, 
demonstated that after 12 weeks of IV alefacept treatment, 63% of patients receiving 
0.075 mg/kg of alefacept respectively reached a reduction in PASI score of at least 
50% from baseline, compared to 32% of patients in the placebo group.225  A PASI 
reduction of at least 75% was reached in 31% compared with 11% in the placebo 
group. Remarkably, the effects of treatment were long-lasting, because patients who 
cleared or almost cleared from their lesions, did not require any treatment for 10 
months.260No systemic toxicities or drug related events were reported during this 
phase II trial. 
 A phase III study by Krueger studied the clinical efﬁcacy and safety of two 
courses of 7,5 mg per week IV for 12 weeks with placebo. After the ﬁrst course 28% 
of patients treated with alefacept reached a PASI reduction of at least 75%, compared 
to 8% in the placebo group (P<0.001), whereas 40% of patients receiving a second 
course, achieved a PASI reduction of at least 75%. Patients with a PASI reduction of 
at least 75%, that received one course of alefacept, maintained a PASI reduction of 
at least 50%, for 7 months.  No serious adverse events were noted after one or two 
courses of alefacept.261
 Another phase III study, by Ortonne investigated the efﬁcacy and safety of 10 
and 15 mg of alefacept IM once weekly for 12 weeks compared to a placebo treatment. 
Two weeks after the last dose 21 % of patients receiving 15 mg of alefacept reached 
a PASI reduction of at least 75%, as compared to 5% in the placebo group (P<0.001). 
Only 10% of patients receiving 10 mg IM reached this level of improvement, which 
was not signiﬁcantly different from the placebo group. Adverse events in both alefacept 
groups were similar to those in the placebo group.262
 Alefacept has a dual function at the molecular level. The co-stimulatory 
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signal between an APC, expressing LFA-3, and a memory effector T-cell, abundantly 
expressing CD2, is inhibited by alefacept. In psoriatic lesions the expression of CD2 
is upregulated on activated, proliferating memory effector CD45RO+ T-cells. This 
subpopulation of T-cells, playing an important role in the pathogenesis of psoriasis 
is targeted by alefacept, in contrast to the naive CD45RA T-cells.71 Treatment with 
alefacept leads to a depletion of circulating and lesional memory effector T-cells.225;263 
A possible explanation for the signiﬁcant reduction of this T-cell subset, is selective 
apoptosis of these T-cells mediated by NK-cells, that bind alefacept by their Fc-
receptors, resulting in release of cytotoxic granules.264;265
 Goedkoop et al. found a signiﬁcant reduction of dermal CD4+ and epidermal 
CD8+ T-cells in lesional psoriatic skin after 92 days of treatment with 7,5 mg alefacept 
IV. Furthermore they found a signiﬁcant reduction of the epidermal memory effector 
T-cell population in patients with a PASI reduction of at least 50%, in contrast to 
patients with less clinical response.263
 The phase II study of Ellis and Krueger did show, reduced efﬁcacy of alefacept 
in patients receiving 0.150 mg/kg alefacept, as opposed to the higher efﬁcacy with 
concentrations of 0.025 and 0.075 mg/kg alefacept. This is a remarkable observation 
since one would expect higher efﬁcacy with climbing concentrations of alefacept. We 
suggest, that not only memory effector T-cells are depleted by alefacept, but also cells 
expressing NK receptors and possibly regulatory T-cells. Indeed, the CD2-receptor is 
also expressed on these T-cell subsets. High concentrations of alefacept, might down-
regulate cells expressing NK-receptors but also regulatory T-cells, which are believed 
to have an important role in controlling auto-immune diseases, such as psoriasis. 
Therefore future research, focussing on the control mechanisms of the immune system 
may also unravel the precise mode of action of alefacept. 
 Although alefacept is able to affect memory effector T-cells, no serious 
adverse events, including opportunistic infections, have been reported. This may be 
due to the fact that alefacept has a marginal effect on naive T-cells. Furthermore, 
alefacept does not reduce the response against novel antigens and recall antigens.224 
During treatment blood samples are taken, and CD4+ T-cells are quantiﬁed at regular 
intervals. When the concentration of CD4+ T-cells is less than 400 cells/mm3, the 
alefacept treatment must be interrupted or stopped. Only when the CD4+ T-cell count 
exceeds 400 cells/mm3 therapy may be started again.266 
1.5.2.2 Blocking an effector cytokine: therapy with anti-TNF-α fusion protein 
etanercept (Enbrel®)
Etanercept is composed of the TNF-α type II receptor and the Fc part of an IgG antibody, 
and is fully human in origin. It is administered subcutaneously by self- injection. 
Etanercept binds to soluble TNF-α, forming a complex.267 Etanercept is registered in 
the Netherlands for active rheumatoid arthritis and juvenile chronic arthritis and very 
recently also for psoriasis vulgaris. Furthermore, in the USA etanercept is approved 
by the FDA for psoriatic arthritis.268
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 In a study by Mease et al. it was found that twice weekly 25 mg etanercept 
proved to be effective in reducing the median PASI score with 46% in 60 patients 
with psoriatic arthritis. No serious adverse events were reported.269 Etanercept was 
found to be effective in the treatment of chronic plaque psoriasis as well. Leonardi 
et al. demonstrated that 49 % of patients receiving a high dose of etanercept (50 mg 
twice weekly), 34% of patients receiving a medium dose (25 mg twice weekly), 14% 
of patients receiving a low dose of etanercept (25 mg once weekly) and 4% of patients 
receiving a placebo showed a reduction in PASI scores of at least 75% after 12 weeks 
of treatment. (P<0.001) After 24 weeks there was a reduction in PASI score of at least 
75% in 25%, 44% and 59% of the patients in the low dose, medium dose and high 
dose groups respectively. Side effects were generally mild, and similar as compared 
to the placebo group.233 In a randomized trial, studying etanercept monotherapy 25 mg 
s.c twice a week, Gottlieb et al. found after 12 weeks a PASI reduction of at least 75% 
in 30% of the etanercept-treated patients as opposed to 2 % of the placebo-treated 
patients. After 24 weeks these ﬁgures were 56% and 5% respectively. Still 23% of 
patients treated with etanercept did not reach a PASI reduction of 50%.270
 Additional information is needed, concerning side effects and clinical 
efﬁcacy of etanercept.271 The most frequent side effects of etanercept are injection site 
reactions, which, however, subside within a few weeks in most cases.272 Furthermore, 
cutaneous side effects after treatment with etanercept have also been reported. The 
development of cutaneous squamous cell carcinoma, vasculitis and subacute lupus 
erythematosus has been described.273-277 Although no serious side effects were reported 
in the studies just discussed, several case-reports mention neurological complications 
278, re-activation of Mycobacterium tuberculosis 279 or other opportunistic infections, 
when using anti-TNF-α therapy.280-283 Furthermore recently there is some concern 
with respect to the possible association of etanercept use and the development of 
lymphomas. Data on adverse events with an incidence of less than 1% can only be 
obtained, when at least 10 000 people have been treated. Moreover, research is needed 
to determine the relapse rate after withdrawal from etanercept therapy. Comparative 
studies with etanercept are also needed. In addition, characteristics of patients failing 
to respond to treatment with etanercept, should be described’ allowing the prediction 
of treatment failure.271
1.5.2.3 Blocking an effector cytokine: therapy with anti-TNF-α monoclonal antibody 
Inﬂiximab (Remicade®)
Inﬂiximab is a monoclonal IgG antibody that targets TNF-α and mediates lysis of 
TNF-α expressing cells. This chimeric protein has been approved as a treatment for 
Crohn’s disease but also rheumatoid arthritis by the FDA. Its efﬁcacy for the treatment 
of psoriasis has been shown in several studies.235;284-287 In a study by Gottlieb et al. 
29 patients received 3 doses of either 5 or 10 mg/kg of inﬂiximab. After a period of 
10 weeks receiving 3 doses, 81,8% and 72,7% of the patients in the groups of 5 and 
10 mg/kg of inﬂiximab respectively, reached a PASI reduction of at least 75%. The 
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effects induced by the placebo were signiﬁcantly lower with only 18,2% of patients 
reaching a PASI reduction of at least 75% (P<0.05). Some adverse events occurred 
during this study. In 3 patients mild infusion reactions were observed.286 
 Beside infections and neurological complications, it has been noticed that 
patients receiving inﬂiximab, as earlier described for etanercept, may suffer from 
cutaneous side effects.288-290The rashes that appear after inﬂiximab treatment (or anti- 
TNF-α treatment in general) are not yet well described, and less is known about their 
etiology. Furthermore, anaphylaxis may develop after infusion of inﬂiximab, probably 
as a type-1 reaction of the immune system against this chimaeric protein.291 In addition 
the use of inﬂiximab may lead to the development of anti-inﬂiximab antibodies, which 
in turn may decrease the clinical efﬁcacy of anti TNF-α treatment.
1.5.2.4 Blocking an effector cytokine: therapy with anti-TNF-α monoclonal antibody 
Adalimumab (Humira®)
Adalimumab is a fully human monoclonal antibody that targets TNF-α, and has 
recently been approved as treatment for rheumatoid arthritis. Patients with rheumatoid 
arthritis beneﬁt from treatment with adalimumab, and signiﬁcant, rapid and sustained 
improvement of disease activity has been observed together with improved physical 
function.292 Currently clinical studies are being conducted to investigate the antipsoriatic 
potential of Adalimumab.293 Cutaneous side effects following treatment with 
adalimumab have also been described. Beuthien et al describe a patient who develops 
an erythema multiforme like skin eruption after the sixth injection of adalimumab. 
After a short period of discontinuation this skin anomaly disappeared.294  
1.5.2.5 Inhibition of leucocyte adhesion and migration: therapy with anti-CD11a 
monoclonal antibody Efalizumab (Raptiva®)
Efalizumab is a humanized monoclonal antibody that targets CD11a, the alfa subunit 
of LFA-1.  LFA-1 is expressed on T-cells and binds to ICAM-1 expressed by an APC.232 
In a phase II study by Papp et al. the clinical efﬁcacy of efalizumab was proven 
in the treatment of psoriasis.295 Furthermore, it was shown that efalizumab blocks 
extravasation of memory effector T-cells into the skin. Moreover, Gottlieb et al. found 
that efalizumab reduced the expression of CD11a on cutaneous and peripheral blood 
T-cells.296 In a phase III study by Gordon et al. 27% of patients treated with efalizumab 
showed a PASI reduction of at least 75% compared to 4 % of the patients treated with 
placebo. In addition, treatment was well tolerated and safe, with primarily mild to 
moderate adverse events.297 Menter et al. found in a phase III trial that after 24 weeks 
of treatment a PASI reduction of at least 75% was reached by 43,8% of patients and a 
50% PASI reduction by 66,6% of patients.298 
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1.6 OUTLINE AND OBJECTIVES OF THIS THESIS
The central issue of this thesis concerns the dynamics of several types of T-cell subsets 
in the context of epidermal proliferation and keratinisation both during pathogenesis 
and treatment of psoriasis. These phenomena in epidermis as well as dermis were 
studied by use of immunohistochemistry. 
1.6.1 Pathogenesis
I) First, in order to gain further insight into the pathogenesis of psoriasis we addressed 
the following questions:
1. Is the aggravation of psoriasis by infections a permissive factor or a constitutional 
trait? 
2. What are the dynamics of various T-cell subsets in the context of epidermal 
proliferation and keratinisation in the margin of spreading psoriatic plaques?
These questions will be addressed in chapter 2.
II) Second, in order to ﬁnd out more about the role of T-cell subsets, epidermal hyper-
proliferation and keratinisation in psoriasis, two disorders that are assumed to be 
related to psoriasis were investigated. The following questions were addressed in 
chapter 3:
1. To what extent is ﬂexural psoriasis different from plaque psoriasis with respect 
to T-cell subsets, epidermal proliferation and keratinisation.
2. To what extent is Inﬂammatory Linear Verrucous Epidermal Naevus different 
from plaque psoriasis with respect to T-cell subsets, epidermal proliferation and 
keratinisation.
1.6.2 Therapies
I) First, dithranol, calcipotriol and corticosteroids are classical anti-psoriatic 
treatments, which are evaluated. The aim of our studies, described in chapter 4, is 
to ﬁnd out whether these treatments have a preferential effect on some T-cell subsets 
versus proliferation and keratinisation in the context of clinical improvement. The 
following question was addressed: What are the preferred anti-psoriatic targets for the 
following treatments?
1. Dithranol cream: short contact principle.
2. Calcipotriol versus betamethasonedipropionate versus the combination of both.
II) Second, new vitamin D
3
 derivatives and calcineurin inhibitors show great promise 
in the topical treatment of psoriasis. Chapter 5 deals with the effects of these treatments 
addressing the following questions: what are the preferred anti-psoriatic targets for:
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1. Topical tacrolimus gel and cream versus calcipotriol ointment.
2. A new vitamin D
3
 derivative versus calcipotriol ointment.
III) Third, biologicals are promising developments in the treatment of patients with 
moderate to severe psoriasis. During the project of this thesis biological and clinical 
effects of these innovative agents were studied. In chapter 6 of this thesis we restricted 
to the following questions: 
1. To what extent does alefacept as monotherapy and in combination with 
calcipotriol modify the composition of T-cell subsets, cells expressing NK 
receptors, epidermal proliferation and differentiation?
2. Are cutaneous side effects a signiﬁcant problem within a group of RA patients 
using anti-TNF-α treatment and what is the spectrum of cutaneous side effects 
within this group?
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1 .7 INVESTIGATIONAL APPROACH
In order to study the efﬁcacy of novel anti-psoriatic treatments and compare these with 
established therapies we performed clinical and immunohistochemical investigations. 
Speciﬁc immunohistochemical targets were chosen (table 2). Since psoriasis is a 
disease of epidermal hyperproliferation and disturbed differentiation in which the T-
cell plays a crucial role, markers were chosen that represent these important steps in 
the pathogenesis of psoriasis.  
1.7.1 Characterizing epidermal proliferation and differentiation.
In table 2 the proliferation and differentiation markers are shown. As marker of 
epidermal proliferation the number of Ki-67 positive keratinocytes per mm. basement 
membrane were assessed. As marker of epidermal differentiation the percentage 
keratin-10 positve epidermal surface was measured.    
1.7.2 T-cell subsets, cells expressing NK receptors and HLA-DR 
expression.
T-cell subsets play an important role in the pathogenesis of psoriasis, as already 
mentioned. Investigated T-cell subsets are summarized in table 2. The development 
of a psoriatic lesion, comprises several phases, as described in chapter 1.2.4. The 
markers, which were chosen in this thesis, represent important steps in the psoriatic 
process. For instance, CD25, the α-subunit of the IL-2 receptor, represents a state 
of early activation of T-cells, whereas HLA-DR, the MHC-II molecule, is expressed 
on T-cells in a later phase. Furthermore, dendritic cells and keratinocytes may also 
express HLA-DR. CD2 is a receptor on T-cells interacting with LFA-3, and playing 
an important role in co-stimulation. Memory effector T-cells express CD45RO. This 
subset of T-cells shows a type 1 differentiation in psoriasis and is believed to initiate 
the psoriatic process. Alefacept is able to selectively target memory effector T-cells, 
without affecting naive T-cells (CD45RA+ T-cells).225 Furthermore, the reduction of 
memory effector T-cell subset correlates with clinical improvement. Naive T-cells 
were also chosen as a research target. Ideally, this T-cell subset is not targeted by novel 
topical or systemic treatments, because from this pool of naive T-cells, a T-cell with a 
particular TCR is selected and clonally expanded to target pathogens or tumour cells. 
Helper T-cells (CD4) and cytotoxic T-cells (CD8) have been characterized extensively 
in the psoriatic lesion.38 Cells expressing NK-receptors were also characterized. 
CD94+ cells but also CD161+ cells were immunophenotyped in this thesis. The 
CD161 receptor has an activatory function in general 299, whereas the CD94 receptor 
is able to show both activatory 300 and inhibitory functions.301 
 Immunophenotyping of the aforementioned receptors in the margin model 
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but also during treatment with traditional and innovative treatments may increase the 
knowledge concerning the role of these markers in the pathogenesis of psoriasis 
1.7.3 Margin zone model
In order to study cellular and subcellular processes in a sequential way, we used the 
margin zone model.302 Because the psoriatic plaque enlarges by centrifugal expansion, 
investigating phenomena across the margin will reveal information concerning the 
pathogenesis of psoriasis.303-305 In this thesis, the margin zone of actively spreading 
psoriatic lesions was analysed.
1.7.3 Clinical assessments 
To assess the clinical severity of the psoriatic plaques, we used the Psoriasis Area and 
Severity Index (PASI).306 The PASI is a score, taking into account the severity of the 
psoriatic lesion on the head, trunk, upper limbs and lower limbs. To assess the average 
degree of severity of each symptom (i.e. erythema, induration, desquamation) a score 
of 0-4 was assigned. Furthermore, the area covered by lesions on each body part is 
estimated as a percentage of the total area of that particular body part, assigning a 
score of 0 to 6. The PASI is calculated in the following way: First the score of each 
body part is obtained, by multiplying the sum of the severity scores of the three basic 
lesions by the area score and then multiplying the result by the constant weighted 
value assigned to that body part (0.1 for the head, 0.3 for the trunk, 0.2 for the upper 
limbs and 0.4 for the lower limbs) By calculating the sum of the individual body parts 
the PASI is obtained.
 A major drawback of the PASI is the wide variation when attempting to record 
clinical severity by the PASI307;308 Therefore a more objective way to assess clinical 
efﬁcacy of topical and systemic treatments was used. In this respect quantitative 
immunohistochemistry proved to be an objective method.156 Furthermore, to enhance 
reproducibility of the immunohistochemical investigation, image analysis was 
performed. 
1.7.4 Immunohistochemical staining procedure
To evaluate several topical, as well as systemic therapies, biopsies were taken, snap 
frozen in liquid nitrogen and sliced 6 um thick, using a microtome. The biopsies 
were processed for immunohistochemistry. The primary antibodies are mentioned in 
table 2. In the following chapters, the immunohistochemical protocol is described 
in detail. Techniques for enhanced immunohistochemical staining were used. The 
Avidin Biotin Complex (ABC) technique was applied as ampliﬁcation technique. 
Furthermore, a more recent technique for immunohistochemical staining was used: 
the EnVision ampliﬁcation technique (Envision-kit: DAKO Copenhagen Denmark).309 
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This technique provided a more rapid way of immunohistochemical staining together 
with less background staining. Furthermore, it was possible to dilute the primary 
antibodies as compared to the ABC technique.
Primary anti-bodies Cell sources Function
CD4 (clone MT310) T-helper cells (MHC II 
related), Thymocytes, 
monocytes,macrophages, 
dendritic cells
MHC class II-restricted 
antigen induced T-cell 
activation38
CD8 (clone DK25) Cytotoxic T-cells (MHC I 
related), thymocytes
MHC class I-restricted 
antigen induced T-cell 
activation38
CD45RO (clone 
UCHL1)
Memory-effector T-cells, 
B-cells, monocytes, 
macrophages
Tyrosine phosphatase 
important in TCR 
sgnalling78;310
CD45RA (clone 4KB5) Naive T-cel, B-cells, 
monocytes
Tyrosine phosphatase 
important in TCR 
sgnalling78;310
CD2 (clone MT910) T-cells, thymocytes, NK-
cells
Receptor for LFA-3 on 
APC78
CD25 (clone ACT-1) Activated T-cells, B-cells, 
monocytes, NK-cells, 
langerhans cells
Alfa  subunit of the IL-
2 receptor, marker of 
activation(early)56
CD94 (clone HP-3D9) Expressed on T-cells and 
NK-cells
Activatory/Inhibitory NK 
marker, binds HLA-E311
CD161 (clone 191B8) Mostly expressed by NK-T 
cells
Activatory marker, binds 
CD1d on keratinocytes311
HLA-DR (clone 
TAL.1B5)
MHC-II complex on 
APC, dendritic cells, 
keratinocytes, B-cells, 
macrophages and 
monocytes
Antigen presentation of 
bacterial origin, marker 
of activation (late)56
Ki-67 (clone MIB-1) Expressed in G1, S, G2 
and M phase of cells
Marker for( epidermal) 
proliferation312
keratine-10 (clone 
RKSE60)
Normal differentiating 
keratinocytes express 
keratin-10
Marker for 
keratinization313
Table 2. Overview of primary antibodies used to perform the immunohistochemical staining.
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1.7.5 Immunohistochemical scoring.
The number of cells positive for CD2, CD4, CD8, CD25, CD45RO, CD45RA, CD94 
and CD161 were quantiﬁed by microscopy. At 200X magniﬁcation positive cells in 
the epidermis were counted from the basement membrane up to the stratum corneum 
across the whole section. Cells in the dermis were counted from the basement 
membrane down to 100 um under the basement membrane also across the whole 
section. Quantiﬁcation was done in the unit: Positive cells per mm length.
1.7.6 Quantitative image analysis 
For K10 digital images were collected at 50X magniﬁcation and for Ki67 at 100X 
magniﬁcation. Each image was analyzed using IP-lab software (IP-lab software 
version 3.0 Scientiﬁc Imaging Scanalytics Inc, Fairfax VA USA). For quantiﬁcation of 
the number of cells positive for K10, we used the following procedure: After choosing 
a representative “region of interest” the positive stained area was marked with a color 
as a speciﬁc segment (or segments). Furthermore the dermal area was marked using 
a different color, and subtracted in the ROI, leaving the positive epidermal area as 
a percentage of the total epidermis. The ROI is chosen in the center of the section. 
Quantiﬁcation was measured as a % of ROI as unit. 
 For Ki67 a line following the stratum basale was drawn after again choosing 
a ROI and all positive cells above this line were counted. Quantiﬁcation was done in 
the unit:  Positive cells per mm length of basement membrane. 
Chapter 1 - General Introduction
50
REFERENCE LIST
1. Christophers E. Genotyping psoriasis. J.Invest Dermatol. 2003; 120: xvii.
2. Christophers E. Psoriasis--epidemiology and clinical spectrum. Clin.Exp.Dermatol. 
2001; 26: 314-20.
3. Penneys NS, Ziboh V, Simon P et al. Pathogenesis of Woronoff ring in psoriasis. Arch.
Dermatol 1976; 112: 955-7.
4. Bernhard JD. Clinical pearl: Auspitz sign in psoriasis scale. J.Am.Acad.Dermatol. 
1997; 36: 621.
5. Holubar K, Fatovic-Ferencic S. Papillary tip bleeding or the Auspitz phenomenon: a 
hero wrongly credited and a misnomer resolved. J.Am.Acad.Dermatol. 2003; 48: 263-
4.
6. Bernhard JD. Auspitz sign is not sensitive or speciﬁc for psoriasis. J.Am.Acad.Dermatol. 
1990; 22: 1079-81.
7. Valdimarsson H, Baker BS, Jonsdottir I et al. Psoriasis: a T-cell-mediated autoimmune 
disease induced by streptococcal superantigens? Immunol.Today 1995; 16: 145-9.
8. Leung DY, Travers JB, Giorno R et al. Evidence for a streptococcal superantigen-driven 
process in acute guttate psoriasis. J.Clin.Invest 1995; 96: 2106-12.
9. Takedai T, Yamamoto I, Tokeshi J. Acute generalized pustular psoriasis presenting with 
erythroderma associated with shock and acute renal failure. Hawaii Med.J. 2003; 62: 
278-81.
10. Pearson LH, Allen BS, Smith JG, Jr. Acrodermatitis continua of Hallopeau: treatment 
with etretinate and review of relapsing pustular eruptions of the hands and feet. J.Am.
Acad.Dermatol. 1984; 11: 755-62.
11. Iizuka H, Takahashi H, Ishida-Yamamoto A. Pathophysiology of generalized pustular 
psoriasis. Arch.Dermatol.Res. 2003; 295 Suppl 1: S55-S59.
12. Van De Kerkhof PC, De Hoop D, de Korte J et al. Scalp psoriasis, clinical presentations 
and therapeutic management. Dermatology 1998; 197: 326-34.
13. Fullerton SH, Orenberg EK. Facial involvement as a marker of severe psoriasis. Cutis 
1987; 40: 309-10.
14. Young PJ, Hyun RJ, Beom CY et al. Facial psoriasis: Comparison of patients with and 
without facial involvement. J.Am.Acad.Dermatol. 2004; 50: 582-4.
15. Clayton TH, Harrison PV, Nicholls R et al. Topical tacrolimus for facial psoriasis. 
Br.J.Dermatol. 2003; 149: 419-20.
16. Freeman AK, Linowski GJ, Brady C et al. Tacrolimus ointment for the treatment of 
psoriasis on the face and intertriginous areas. J.Am.Acad.Dermatol. 2003; 48: 564-8.
17. Yamamoto T, Nishioka K. Topical tacrolimus: an effective therapy for facial psoriasis. 
Eur.J.Dermatol. 2003; 13: 471-3.
18. Mrowietz U, Wustlich S, Hoexter G et al. An experimental ointment formulation of 
pimecrolimus is effective in psoriasis without occlusion. Acta Derm.Venereol. 2003; 
83: 351-3.
19. Calvert HT, Smith MA, Wells RS. Psoriasis and the nails. Br.J.Dermatol. 1963; 75: 
415-8.
20. De Jong EM, Seegers BA, Gulinck MK et al. Psoriasis of the nails associated with 
disability in a large number of patients: results of a recent interview with 1,728 patients. 
Dermatology 1996; 193: 300-3.
21. de Berker D. Management of nail psoriasis. Clin.Exp.Dermatol. 2000; 25: 357-62.
Chapter 1 - General Introduction
51
22. Kaur I, Saraswat A, Kumar B. Nail changes in psoriasis: a study of 167 patients. Int.
J.Dermatol. 2001; 40: 601-3.
23. Geyer AS, Onumah N, Uyttendaele H et al. Modulation of linear nail growth to treat 
diseases of the nail. J.Am.Acad.Dermatol. 2004; 50: 229-34.
24. Cannavo SP, Guarneri F, Vaccaro M et al. Treatment of psoriatic nails with topical 
cyclosporin: a prospective, randomized placebo-controlled study. Dermatology 2003; 
206: 153-6.
25. Blumberg BS, Bunim JJ, Calkins E et al. ARA nomenclature and classiﬁcation of 
arthritis and rheumatism (tentative). Arthritis Rheum. 1964; 26: 93-7.
26. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn's disease. J.Am.
Acad.Dermatol. 2003; 48: 805-21.
27. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J.Am.
Acad.Dermatol. 2001; 44: 755-61.
28. Kuijpers AL, Van De Kerkhof PC. Risk-beneﬁt assessment of methotrexate in the 
treatment of severe psoriasis. Am.J.Clin.Dermatol. 2000; 1: 27-39.
29. Markham T, Watson A, Rogers S. Adverse effects with long-term cyclosporin for severe 
psoriasis. Clin.Exp.Dermatol. 2002; 27: 111-4.
30. van de Kerkhof PCM. The differential diagnosis of poriasis. Acta Derm.Venereol. 8, 
50-58. 1999. 
31. Cheesbrough MJ, Kilby PE. The inﬂammatory linear verrucous epidermal naevus--a 
case report. Clin.Exp.Dermatol. 1978; 3: 293-8.
32. Altman J, Mehregan AH. Inﬂammatory linear verrucose epidermal nevus. Arch.
Dermatol. 1971; 104: 385-9.
33. van Steensel MA, Steijlen PM. Genetics of psoriasis. Clin.Dermatol. 1997; 15: 669-
75.
34. Barker JN. Genetic aspects of psoriasis. Clin.Exp.Dermatol. 2001; 26: 321-5.
35. Higgins E. Alcohol, smoking and psoriasis. Clin.Exp.Dermatol 2000; 25: 107-10.
36. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and 
management. Am.J.Clin.Dermatol 2000; 1: 159-65.
37. Bos JD, Hagenaars C, Das PK et al. Predominance of "memory" T cells (CD4+, 
CDw29+) over "naive" T cells (CD4+, CD45R+) in both normal and diseased human 
skin. Arch.Dermatol.Res. 1989; 281: 24-30.
38. Bos JD, Hulsebosch HJ, Krieg SR et al. Immunocompetent cells in psoriasis. In situ 
immunophenotyping by monoclonal antibodies. Arch.Dermatol.Res. 1983; 275: 181-
9.
39. Steffen C. William John Munro and Munro's abscess, and Franz Kogoj and Kogoj's 
spongiform pustule. Am.J.Dermatopathol. 2002; 24: 364-8.
40. Van De Kerkhof PC, Chang A. Migration of polymorphonuclear leukocytes in psoriasis. 
Skin Pharmacol. 1989; 2: 138-54.
41. Biasi D, Carletto A, Caramaschi P et al. Neutrophil functions and IL-8 in psoriatic 
arthritis and in cutaneous psoriasis. Inﬂammation 1998; 22: 533-43.
42. Duan H, Koga T, Kohda F et al. Interleukin-8-positive neutrophils in psoriasis. 
J.Dermatol.Sci. 2001; 26: 119-24.
43. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N.Engl.J.Med. 1979; 301: 555.
44. Ellis CN, Fradin MS, Messana JM et al. Cyclosporine for plaque-type psoriasis. Results 
of a multidose, double-blind trial. N.Engl.J.Med. 1991; 324: 277-84.
Chapter 1 - General Introduction
52
45. Ellis CN, Gorsulowsky DC, Hamilton TA et al. Cyclosporine improves psoriasis in a 
double-blind study. JAMA 1986; 256: 3110-6.
46. Pol A, Bergers M, Schalkwijk J. Comparison of antiproliferative effects of experimental 
and established antipsoriatic drugs on human keratinocytes, using a simple 96-well-
plate assay. In Vitro Cell Dev.Biol.Anim 2003; 39: 36-42.
47. Baker BS, Grifﬁths CE, Lambert S et al. The effects of cyclosporine A on T lymphocyte 
and dendritic cell subpopulations in psoriasis. Transplant.Proc. 1988; 20: 72-7.
48. Baker BS, Swain AF, Grifﬁths CE et al. Epidermal T lymphocytes and dendritic cells 
in chronic plaque psoriasis: the effects of PUVA treatment. Clin.Exp.Immunol 1985; 
61: 526-34.
49. Erber WN. Human leucocyte differentiation antigens: review of the CD nomenclature. 
Pathology 1990; 22: 61-9.
50. Bernard A, Boumsell L. The clusters of differentiation (CD) deﬁned by the First 
International Workshop on Human Leucocyte Differentiation Antigens. Hum.Immunol. 
1984; 11: 1-10.
51. Baker BS, Swain AF, Fry L et al. Epidermal T lymphocytes and HLA-DR expression in 
psoriasis. Br.J.Dermatol. 1984; 110: 555-64.
52. Bos JD, de Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. 
Immunol.Today 1999; 20: 40-6.
53. Gupta AK, Baadsgaard O, Ellis CN et al. Lymphocytes and macrophages of the 
epidermis and dermis in lesional psoriatic skin, but not epidermal Langerhans cells, are 
depleted by treatment with cyclosporin A. Arch.Dermatol.Res. 1989; 281: 219-26.
54. Gottlieb SL, Gilleaudeau P, Johnson R et al. Response of psoriasis to a lymphocyte-
selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, 
pathogenic basis. Nat.Med. 1995; 1: 442-7.
55. Chang JC, Smith LR, Froning KJ et al. CD8+ T cells in psoriatic lesions preferentially 
use T-cell receptor V beta 3 and/or V beta 13.1 genes. Proc.Natl.Acad.Sci.U.S.A 1994; 
91: 9282-6.
56. Ferenczi K, Burack L, Pope M et al. CD69, HLA-DR and the IL-2R identify persistently 
activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by ﬂow 
cytometry. J.Autoimmun. 2000; 14: 63-78.
57. Austin LM, Ozawa M, Kikuchi T et al. The majority of epidermal T cells in Psoriasis 
vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and 
tumor necrosis factor-alpha, deﬁning TC1 (cytotoxic T lymphocyte) and TH1 effector 
populations: a type 1 differentiation bias is also measured in circulating blood T cells in 
psoriatic patients. J.Invest Dermatol. 1999; 113: 752-9.
58. Berridge MJ. Lymphocyte activation in health and disease. Crit Rev.Immunol. 1997; 
17: 155-78.
59. Ovigne JM, Baker BS, Brown DW et al. Epidermal CD8+ T cells in chronic plaque 
psoriasis are Tc1 cells producing heterogeneous levels of interferon-gamma. Exp.
Dermatol. 2001; 10: 168-74.
60. Cella M, Scheidegger D, Palmer-Lehmann K et al. Ligation of CD40 on dendritic cells 
triggers production of high levels of interleukin-12 and enhances T cell stimulatory 
capacity: T-T help via APC activation. J.Exp.Med. 1996; 184: 747-52.
61. Schlaak JF, Buslau M, Jochum W et al. T cells involved in psoriasis vulgaris belong to 
the Th1 subset. J.Invest Dermatol. 1994; 102: 145-9.
Chapter 1 - General Introduction
53
62. Trepicchio WL, Ozawa M, Walters IB et al. Interleukin-11 therapy selectively 
downregulates type I cytokine proinﬂammatory pathways in psoriasis lesions. J.Clin.
Invest 1999; 104: 1527-37.
63. Kemeny DM, NOble A, Holmes BJ et al. The role of CD8+ T cells in immunoglobulin 
E regulation. Allergy 1995; 50: 9-14.
64. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and 
disease. Altern.Med.Rev. 2003; 8: 223-46.
65. Pichler WJ. [Regulation of the immune response: the TH1/TH2 concept]. Schweiz.Med.
Wochenschr. 1997; 127: 341-8.
66. Ishikawa N, Goyal PK, Mahida YR et al. Early cytokine responses during intestinal 
parasitic infections. Immunology 1998; 93: 257-63.
67. Menssen A, Trommler P, Vollmer S et al. Evidence for an antigen-speciﬁc cellular 
immune response in skin lesions of patients with psoriasis vulgaris. J.Immunol. 1995; 
155: 4078-83.
68. Schon MP, Zollner TM, Boehncke WH. The molecular basis of lymphocyte recruitment 
to the skin: clues for pathogenesis and selective therapies of inﬂammatory disorders. 
J.Invest Dermatol. 2003; 121: 951-62.
69. Fuhlbrigge RC, Kieffer JD, Armerding D et al. Cutaneous lymphocyte antigen is a 
specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997; 389: 978-
81.
70. Groves RW, Ross E, Barker JN et al. Effect of in vivo interleukin-1 on adhesion 
molecule expression in normal human skin. J.Invest Dermatol. 1992; 98: 384-7.
71. Robert C, Kupper TS. Inﬂammatory skin diseases, T cells, and immune surveillance. 
N.Engl.J.Med. 1999; 341: 1817-28.
72. Homey B, Dieu-Nosjean MC, Wiesenborn A et al. Up-regulation of macrophage 
inﬂammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. 
J.Immunol. 2000; 164: 6621-32.
73. Fukuoka M, Ogino Y, Sato H et al. Regulation of RANTES and IL-8 production in 
normal human dermal ﬁbroblasts by active vitamin D3 (tacalcitol). Br.J.Pharmacol. 
1998; 124: 1433-8.
74. Fukuoka M, Ogino Y, Sato H et al. RANTES expression in psoriatic skin, and regulation 
of RANTES and IL-8 production in cultured epidermal keratinocytes by active vitamin 
D3 (tacalcitol). Br.J.Dermatol. 1998; 138: 63-70.
75. Rottman JB, Smith TL, Ganley KG et al. Potential role of the chemokine receptors 
CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. 
Lab Invest 2001; 81: 335-47.
76. Gottlieb AB, Lifshitz B, Fu SM et al. Expression of HLA-DR molecules by keratinocytes, 
and presence of Langerhans cells in the dermal inﬁltrate of active psoriatic plaques. 
J.Exp.Med. 1986; 164: 1013-28.
77. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. 
J.Clin.Invest 1996; 98: 1878-87.
78. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic 
agents. J.Am.Acad.Dermatol. 2002; 46: 1-23.
79. Boehncke WH, Wortmann S, Kaufmann R et al. A subset of macrophages located along 
the basement membrane ("lining cells") is a characteristic histopathological feature of 
psoriasis. Am.J.Dermatopathol. 1995; 17: 139-44.
80. van den Oord JJ, Wolf-Peeters C. Epithelium-lining macrophages in psoriasis. 
Br.J.Dermatol. 1994; 130: 589-94.
Chapter 1 - General Introduction
54
81. Grossman RM, Krueger J, Yourish D et al. Interleukin 6 is expressed in high levels in 
psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc.Natl.
Acad.Sci.U.S.A 1989; 86: 6367-71.
82. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by 
CD4+CD25+ immunoregulatory cells. J.Immunol. 2001; 167: 1137-40.
83. Piccirillo CA, Shevach EM. Naturally-occurring CD4(+)CD25(+) immunoregulatory 
T cells: central players in the arena of peripheral tolerance. Semin.Immunol. 2004; 16: 
81-8.
84. Vasu C, Prabhakar BS, Holterman MJ. Targeted CTLA-4 engagement induces 
CD4+CD25+CTLA-4high T regulatory cells with target (allo)antigen speciﬁcity. 
J.Immunol. 2004; 173: 2866-76.
85. Kohm AP, Williams JS, Miller SD. Cutting edge: ligation of the glucocorticoid-
induced TNF receptor enhances autoreactive CD4+ T cell activation and experimental 
autoimmune encephalomyelitis. J.Immunol. 2004; 172: 4686-90.
86. Sugiyama H, Gyulai R, Toichi E et al. Dysfunctional blood and target tissue 
CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained 
pathogenic effector T cell proliferation. J.Immunol. 2005; 174: 164-73.
87. Kursar M, Bonhagen K, Fensterle J et al. Regulatory CD4+CD25+ T cells restrict 
memory CD8+ T cell responses. J.Exp.Med. 2002; 196: 1585-92.
88. Sutmuller RP, Offringa R, Melief CJ. Revival of the regulatory Tcell: new targets for 
drug development. Drug Discov.Today 2004; 9: 310-6.
89. Trinchieri G. Biology of natural killer cells. Adv.Immunol. 1989; 47: 187-376.
90. Lanier LL. The origin and functions of natural killer cells. Clin.Immunol. 2000; 95: 
S14-S18.
91. Lopez-Botet M, Bellon T, Llano M et al. Paired inhibitory and triggering NK cell 
receptors for HLA class I molecules. Hum.Immunol. 2000; 61: 7-17.
92. Wang KS, Frank DA, Ritz J. Interleukin-2 enhances the response of natural killer cells 
to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. 
Blood 2000; 95: 3183-90.
93. Ortaldo JR, Winkler-Pickett RT, Yagita H et al. Comparative studies of CD3- and CD3+ 
CD56+ cells: examination of morphology, functions, T cell receptor rearrangement, and 
pore-forming protein expression. Cell Immunol. 1991; 136: 486-95.
94. Ferrini S, Cambiaggi A, Meazza R et al. T cell clones expressing the natural killer cell-
related p58 receptor molecule display heterogeneity in phenotypic properties and p58 
function. Eur.J.Immunol. 1994; 24: 2294-8.
95. Mingari MC, Vitale C, Cambiaggi A et al. Cytolytic T lymphocytes displaying natural 
killer (NK)-like activity: expression of NK-related functional receptors for HLA class I 
molecules (p58 and CD94) and inhibitory effect on the TCR-mediated target cell lysis 
or lymphokine production. Int.Immunol. 1995; 7: 697-703.
96. Karpuj MV, Steinman L, Oksenberg JR. Multiple sclerosis: a polygenic disease 
involving epistatic interactions, germline rearrangements and environmental effects. 
Neurogenetics. 1997; 1: 21-8.
97. Kukreja A, Maclaren NK. Autoimmunity and diabetes. J.Clin.Endocrinol.Metab 1999; 
84: 4371-8.
98. Kukreja A, Maclaren NK. NKT cells and type-1 diabetes and the "hygiene hypothesis" 
to explain the rising incidence rates. Diabetes Technol.Ther. 2002; 4: 323-33.
Chapter 1 - General Introduction
55
99. Ortonne JP. Recent developments in the understanding of the pathogenesis of psoriasis. 
Br.J.Dermatol. 1999; 140 Suppl 54: 1-7.
100. Nair RP, Stuart P, Henseler T et al. Localization of psoriasis-susceptibility locus PSORS1 
to a 60-kb interval telomeric to HLA-C. Am.J.Hum.Genet. 2000; 66: 1833-44.
101. Balendran N, Clough RL, Arguello JR et al. Characterization of the major susceptibility 
region for psoriasis at chromosome 6p21.3. J.Invest Dermatol. 1999; 113: 322-8.
102. Allen MH, Veal C, Faassen A et al. A non-HLA gene within the MHC in psoriasis. 
Lancet 1999; 353: 1589-90.
103. Cheng L, Zhang SZ, Xiao CY et al. The A5.1 allele of the major histocompatibility 
complex class I chain-related gene A is associated with psoriasis vulgaris in Chinese. 
Br.J.Dermatol. 2000; 143: 324-9.
104. Nickoloff BJ, Wrone-Smith T, Bonish B et al. Response of murine and normal human 
skin to injection of allogeneic blood-derived psoriatic immunocytes: detection of T cells 
expressing receptors typically present on natural killer cells, including CD94, CD158, 
and CD161. Arch.Dermatol. 1999; 135: 546-52.
105. Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces 
psoriasis. Am.J.Pathol. 1999; 155: 145-58.
106. Nickoloff BJ, Bonish B, Huang BB et al. Characterization of a T cell line bearing 
natural killer receptors and capable of creating psoriasis in a SCID mouse model system. 
J.Dermatol.Sci. 2000; 24: 212-25.
107. Koreck A, Suranyi A, Szony BJ et al. CD3+CD56+ NK T cells are signiﬁcantly 
decreased in the peripheral blood of patients with psoriasis. Clin.Exp.Immunol. 2002; 
127: 176-82.
108. Yanagihara Y, Shiozawa K, Takai M et al. Natural killer (NK) T cells are signiﬁcantly 
decreased in the peripheral blood of patients with rheumatoid arthritis (RA). Clin.Exp.
Immunol. 1999; 118: 131-6.
109. Aractingi S, Briand N, Le Danff C et al. HLA-G and NK receptor are expressed in 
psoriatic skin: a possible pathway for regulating inﬁltrating T cells? Am.J.Pathol. 2001; 
159: 71-7.
110. Cameron AL, Kirby B, Fei W et al. Natural killer and natural killer-T cells in psoriasis. 
Arch.Dermatol.Res. 2002; 294: 363-9.
111. Cameron AL, Kirby B, Grifﬁths CE. Circulating natural killer cells in psoriasis. 
Br.J.Dermatol. 2003; 149: 160-4.
112. Kastrukoff LF, Morgan NG, Zecchini D et al. A role for natural killer cells in the 
immunopathogenesis of multiple sclerosis. J.Neuroimmunol. 1998; 86: 123-33.
113. Negishi K, Waldeck N, Chandy G et al. Natural killer cell and islet killer cell activities 
in human type 1 diabetes. Exp.Clin.Endocrinol. 1987; 89: 345-53.
114. Sibbitt WL, Jr., Bankhurst AD. Natural killer cells in connective tissue disorders. Clin.
Rheum.Dis. 1985; 11: 507-21.
115. Akahoshi M, Nakashima H, Tanaka Y et al. Th1/Th2 balance of peripheral T helper 
cells in systemic lupus erythematosus. Arthritis Rheum. 1999; 42: 1644-8.
116. Seaman WE. Natural killer cells and natural killer T cells. Arthritis Rheum. 2000; 43: 
1204-17.
117. Zhang B, Yamamura T, Kondo T et al. Regulation of experimental autoimmune 
encephalomyelitis by natural killer (NK) cells. J.Exp.Med. 1997; 186: 1677-87.
118. Fort MM, Leach MW, Rennick DM. A role for NK cells as regulators of CD4+ T cells 
in a transfer model of colitis. J.Immunol. 1998; 161: 3256-61.
Chapter 1 - General Introduction
56
119. Hussain MJ, Alviggi L, Millward BA et al. Evidence that the reduced number of natural 
killer cells in type 1 (insulin-dependent) diabetes may be genetically determined. 
Diabetologia 1987; 30: 907-11.
120. Greaves MW, Weinstein GD. Treatment of psoriasis. N.Engl.J.Med. 1995; 332: 581-8.
121. Lebwohl M. The role of salicylic acid in the treatment of psoriasis. Int.J.Dermatol 
1999; 38: 16-24.
122. Kemeny L, Ruzicka T, Braun-Falco O. Dithranol: a review of the mechanism of action 
in the treatment of psoriasis vulgaris. Skin Pharmacol. 1990; 3: 1-20.
123. Morliere P, Dubertret L, Sa e Melo et al. The effect of anthralin (dithranol) on 
mitochondria. Br.J.Dermatol. 1985; 112: 509-15.
124. Cavey D, Dickinson RG, Shroot B et al. The in vivo fate of topically applied dithranol 
in the skin of the hairless rat. A comparison of continuous and short contact application. 
Arzneimittelforschung. 1985; 35: 605-9.
125. Bohlen P, Grove J, Beya MF et al. Skin polyamine levels in psoriasis: the effect of 
dithranol therapy. Eur.J.Clin.Invest 1978; 8: 215-8.
126. Tucker WF, MacNeil S, Dawson RA et al. An investigation of the ability of antipsoriatic 
drugs to inhibit calmodulin activity: a possible mode of action of dithranol (anthralin). 
J.Invest Dermatol. 1986; 87: 232-5.
127. Shroot B. Mode of action of dithranol, pharmacokinetics/dynamics. Acta Derm.
Venereol.Suppl (Stockh) 1992; 172: 10-2.
128. Saihan EM, Albano J, Burton JL. The effect of steroid and dithranol therapy on cyclic 
nucleotides in psoriatic epidermis. Br.J.Dermatol. 1980; 102: 565-9.
129. Barr RM, Wong E, Cunningham FM et al. Effect of dithranol treatment on arachidonic 
acid and its lipoxygenase products in psoriasis. Arch.Dermatol.Res. 1989; 280: 474-6.
130. Anderson R, Lukey PT, Dippenaar U et al. Dithranol mediates pro-oxidative inhibition of 
polymorphonuclear leukocyte migration and lymphocyte proliferation. Br.J.Dermatol. 
1987; 117: 405-18.
131. Mrowietz U, Jessat H, Schwarz A et al. Anthralin (dithranol) in vitro inhibits human 
monocytes to secrete IL-6, IL-8 and TNF-alpha, but not IL-1. Br.J.Dermatol. 1997; 
136: 542-7.
132. Lange RW, Hayden PJ, Chignell CF et al. Anthralin stimulates keratinocyte-derived 
proinﬂammatory cytokines via generation of reactive oxygen species. Inﬂamm.Res. 
1998; 47: 174-81.
133. Farkas A, Kemeny L, Szony BJ et al. Dithranol upregulates IL-10 receptors on the 
cultured human keratinocyte cell line HaCaT. Inﬂamm.Res. 2001; 50: 44-9.
134. Bonnekoh B, Bockelmann R, Ambach A et al. Dithranol and dimethylfumarate suppress 
the interferon-gamma-induced up- regulation of cytokeratin 17 as a putative psoriasis 
autoantigen in vitro. Skin Pharmacol.Appl.Skin Physiol 2001; 14: 217-25.
135. Swinkels OQ, Prins M, Gerritsen MJ et al. An immunohistochemical assessment of 
the response of the psoriatic lesion to single and repeated applications of high-dose 
dithranol cream. Skin Pharmacol.Appl.Skin Physiol 2002; 15: 393-400.
136. van der Vleuten CJ, De Jong EM, Van De Kerkhof PC. Epidermal differentiation 
characteristics of the psoriatic plaque during short contact treatment with dithranol 
cream. Clin.Exp.Dermatol. 1996; 21: 409-14.
137. Schaefer H, Farber EM, Goldberg L et al. Limited application period for dithranol in 
psoriasis. Preliminary report on penetration and clinical efﬁcacy. Br.J.Dermatol. 1980; 
102: 571-3.
Chapter 1 - General Introduction
57
138. Gay MW, Moore WJ, Morgan JM et al. Anthralin toxicity. Arch.Dermatol. 1972; 105: 
213-5.
139. Swinkels OQ, Kucharekova M, Prins M et al. The effects of topical corticosteroids and 
a coal tar preparation on dithranol-induced irritation in patients with psoriasis. Skin 
Pharmacol.Appl.Skin Physiol 2003; 16: 12-7.
140. Smith EL, Walworth NC, Holick MF. Effect of 1 alpha,25-dihydroxyvitamin D3 on the 
morphologic and biochemical differentiation of cultured human epidermal keratinocytes 
grown in serum-free conditions. J.Invest Dermatol. 1986; 86: 709-14.
141. Kragballe K, Wildfang IL. Calcipotriol (MC 903), a novel vitamin D3 analogue 
stimulates terminal differentiation and inhibits proliferation of cultured human 
keratinocytes. Arch.Dermatol.Res. 1990; 282: 164-7.
142. Bhalla AK, Amento EP, Clemens TL et al. Speciﬁc high-afﬁnity receptors for 1,25-
dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in 
monocytes and induction in T lymphocytes following activation. J.Clin.Endocrinol.
Metab 1983; 57: 1308-10.
143. Morimoto S, Yoshikawa K, Kozuka T et al. An open study of vitamin D3 treatment in 
psoriasis vulgaris. Br.J.Dermatol. 1986; 115: 421-9.
144. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240: 
889-95.
145. Sone T, Ozono K, Pike JW. A 55-kilodalton accessory factor facilitates vitamin D 
receptor DNA binding. Mol.Endocrinol. 1991; 5: 1578-86.
146. Feldman D, Chen T, Hirst M et al. Demonstration of 1,25-dihydroxyvitamin D3 
receptors in human skin biopsies. J.Clin.Endocrinol.Metab 1980; 51: 1463-5.
147. Dam TN, Moller B, Hindkjaer J et al. The vitamin D3 analog calcipotriol suppresses 
the number and antigen-presenting function of Langerhans cells in normal human skin. 
J.Investig.Dermatol.Symp.Proc. 1996; 1: 72-7.
148. Ranson M, Posen S, Mason RS. Human melanocytes as a target tissue for hormones: 
in vitro studies with 1 alpha-25, dihydroxyvitamin D3, alpha-melanocyte stimulating 
hormone, and beta-estradiol. J.Invest Dermatol. 1988; 91: 593-8.
149. Eil C, Marx SJ. Nuclear uptake of 1,25-dihydroxy[3H]cholecalciferol in dispersed 
ﬁbroblasts cultured from normal human skin. Proc.Natl.Acad.Sci.U.S.A 1981; 78: 
2562-6.
150. Merke J, Milde P, Lewicka S et al. Identiﬁcation and regulation of 1,25-dihydroxyvitamin 
D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured 
bovine aortic endothelial cells and human dermal capillaries. J.Clin.Invest 1989; 83: 
1903-15.
151. Muller K, Bendtzen K. 1,25-Dihydroxyvitamin D3 as a natural regulator of human 
immune functions. J.Investig.Dermatol.Symp.Proc. 1996; 1: 68-71.
152. Binderup L, Bramm E. Effects of a novel vitamin D analogue MC903 on cell 
proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem.
Pharmacol. 1988; 37: 889-95.
153. van der Vleuten CJ, De Jong EM, Van De Kerkhof PC. Epidermal differentiation 
characteristics of the psoriatic plaque during treatment with calcipotriol. Arch.Dermatol.
Res. 1996; 288: 366-72.
154. Castelijns FA, Gerritsen MJ, van Erp PE et al. Efﬁcacy of calcipotriol ointment applied 
under hydrocolloid occlusion in psoriasis. Dermatology 2000; 200: 25-30.
Chapter 1 - General Introduction
58
155. Mozzanica N, Cattaneo A, Schmitt E et al. Topical calcipotriol for psoriasis--an 
immunohistologic study. Acta Derm.Venereol.Suppl (Stockh) 1994; 186: 171-2.
156. De Jong EM, Van De Kerkhof PC. Simultaneous assessment of inﬂammation and 
epidermal proliferation in psoriatic plaques during long-term treatment with the vitamin 
D3 analogue MC903: modulations and interrelations. Br.J.Dermatol. 1991; 124: 221-
9.
157. Ashcroft DM, Po AL, Williams HC et al. Systematic review of comparative efﬁcacy 
and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000; 320: 
963-7.
158. Berth-Jones J, Hutchinson PE. Vitamin D analogues and psoriasis. Br.J.Dermatol. 
1992; 127: 71-8.
159. Berth-Jones J, Chu AC, Dodd WA et al. A multicentre, parallel-group comparison of 
calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. 
Br.J.Dermatol. 1992; 127: 266-71.
160. Cunliffe WJ, Berth-Jones J, Claudy A et al. Comparative study of calcipotriol (MC 903) 
ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. 
J.Am.Acad.Dermatol. 1992; 26: 736-43.
161. Thaci D, Daiber W, Boehncke WH et al. Calcipotriol solution for the treatment of scalp 
psoriasis: evaluation of efﬁcacy, safety and acceptance in 3,396 patients. Dermatology 
2001; 203: 153-6.
162. Kienbaum S, Lehmann P, Ruzicka T. Topical calcipotriol in the treatment of intertriginous 
psoriasis. Br.J.Dermatol. 1996; 135: 647-50.
163. Lu I, Gilleaudeau P, McLane JA et al. Modulation of epidermal differentiation, tissue 
inﬂammation, and T- lymphocyte inﬁlitration in psoriatic plaques by topical calcitriol. 
J.Cutan.Pathol. 1996; 23: 419-30.
164. Reichrath J, Horf R, Chen TC et al. Expression of integrin subunits and CD44 isoforms 
in psoriatic skin and effects of topical calcitriol application. J.Cutan.Pathol. 1997; 24: 
499-506.
165. Bourke JF, Iqbal SJ, Hutchinson PE. A randomized double-blind comparison of the 
effects on systemic calcium homeostasis of topical calcitriol (3 micrograms/g) and 
calcipotriol (50 micrograms/g) in the treatment of chronic plaque psoriasis vulgaris. 
Acta Derm.Venereol. 1997; 77: 228-30.
166. Hutchinson PE, Marks R, White J. The efﬁcacy, safety and tolerance of calcitriol 3 
microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact 
dithranol. Dermatology 2000; 201: 139-45.
167. Ortonne JP, Humbert P, Nicolas JF et al. Intra-individual comparison of the cutaneous 
safety and efﬁcacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-
1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or 
ﬂexural areas. Br.J.Dermatol. 2003; 148: 326-33.
168. Gerritsen MJ, Boezeman JB, Vlijmen-Willems IM et al. The effect of tacalcitol 
(1,24(OH)2D3) on cutaneous inﬂammation, epidermal proliferation and keratinization 
in psoriasis: a placebo-controlled, double-blind study. Br.J.Dermatol. 1994; 131: 57-
63.
169. Veien NK, Bjerke JR, Rossmann-Ringdahl I et al. Once daily treatment of psoriasis 
with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind 
trial. Br.J.Dermatol. 1997; 137: 581-6.
Chapter 1 - General Introduction
59
170. Van De Kerkhof PC, Werfel T, Haustein UF et al. Tacalcitol ointment in the treatment 
of psoriasis vulgaris: a multicentre, placebo-controlled, double-blind study on efﬁcacy 
and safety. Br.J.Dermatol. 1996; 135: 758-65.
171. Van De Kerkhof PC. Therapeutic strategies: rotational therapy and combinations. Clin.
Exp.Dermatol. 2001; 26: 356-61.
172. Glade CP, van Erp PE, Van De Kerkhof PC. Epidermal cell DNA content and intermediate 
ﬁlaments keratin 10 and vimentin after treatment of psoriasis with calcipotriol cream 
once daily, twice daily and in combination with clobetasone 17-butyrate cream or 
betamethasone 17-valerate cream: a comparative ﬂow cytometric study. Br.J.Dermatol. 
1996; 135: 379-84.
173. van Rossum MM, van Erp PE, Van De Kerkhof PC. Treatment of psoriasis with a new 
combination of calcipotriol and betamethasone dipropionate: a ﬂow cytometric study. 
Dermatology 2001; 203: 148-52.
174. Nielsen PG. Calcipotriol or clobetasol propionate occluded with a hydrocolloid dressing 
for treatment of nummular psoriasis. Acta Derm.Venereol. 1993; 73: 394.
175. Bourke JF, Berth-Jones J, Hutchinson PE. Occlusion enhances the efﬁcacy of topical 
calcipotriol in the treatment of psoriasis vulgaris. Clin.Exp.Dermatol. 1993; 18: 504-6.
176. Lebwohl M, Siskin SB, Epinette W et al. A multicenter trial of calcipotriene ointment 
and halobetasol ointment compared with either agent alone for the treatment of psoriasis. 
J.Am.Acad.Dermatol. 1996; 35: 268-9.
177. Ruzicka T, Lorenz B. Comparison of calcipotriol monotherapy and a combination of 
calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the 
topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. 
Br.J.Dermatol. 1998; 138: 254-8.
178. Kaufmann R, Bibby AJ, Bissonnette R et al. A new calcipotriol/betamethasone 
dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis 
vulgaris. Dermatology 2002; 205: 389-93.
179. Ring J, Kowalzick L, Christophers E et al. Calcitriol 3 microg g-1 ointment in 
combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: 
results of a comparative study. Br.J.Dermatol. 2001; 144: 495-9.
180. Trozak DJ. Topical corticosteroid therapy in psoriasis vulgaris. Cutis 1990; 46: 341-
50.
181. Kragballe K. Topical corticosteroids: mechanisms of action. Acta Derm.Venereol.Suppl 
(Stockh) 1989; 151: 7-10.
182. Ponec M, Hasper I, Vianden GD et al. Effects of glucocorticosteroids on primary human 
skin ﬁbroblasts. II. Effects on total protein and collagen biosynthesis by conﬂuent cell 
cultures. Arch.Dermatol.Res. 1977; 259: 125-34.
183. De Jong EM, Ferrier CM, de Zwart A et al. Effects of topical treatment with budesonide 
on parameters for epidermal proliferation, keratinization and inﬂammation in psoriasis. 
J.Dermatol Sci. 1995; 9: 185-94.
184. Berth-Jones J, Fletcher A, Hutchinson PE. Epidermal cytokeratin and immunocyte 
responses during treatment of psoriasis with calcipotriol and betamethasone valerate. 
Br.J.Dermatol. 1992; 126: 356-61.
185. Goette DK, Odom RB. Adverse effects of corticosteroids. Cutis 1979; 23: 477-87.
186. Wilkinson DS, Kirton V, Wilkinson JD. Perioral dermatitis: a 12-year review. 
Br.J.Dermatol. 1979; 101: 245-57.
Chapter 1 - General Introduction
60
187. Frost P, Weinstein GD. Topical administration of Vitamin A acid for ichthyosiform 
dermatoses and psoriasis. JAMA 1969; 207: 1863-8.
188. Krueger GG, Drake LA, Elias PM et al. The safety and efﬁcacy of tazarotene gel, a 
topical acetylenic retinoid, in the treatment of psoriasis. Arch.Dermatol. 1998; 134: 
57-60.
189. Marks R. Clinical safety of tazarotene in the treatment of plaque psoriasis. J.Am.Acad.
Dermatol. 1997; 37: S25-S32.
190. Zanolli M. Phototherapy arsenal in the treatment of psoriasis. Dermatol.Clin. 2004; 22: 
397-406, viii.
191. Gollnick H, Bauer R, Brindley C et al. Acitretin versus etretinate in psoriasis. Clinical 
and pharmacokinetic results of a German multicenter study. J.Am.Acad.Dermatol. 
1988; 19: 458-68.
192. Goldfarb MT, Ellis CN, Gupta AK et al. Acitretin improves psoriasis in a dose-dependent 
fashion. J.Am.Acad.Dermatol. 1988; 18: 655-62.
193. Berbis P. [Acitretine]. Ann.Dermatol.Venereol. 2001; 128: 737-45.
194. Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. 
J.Am.Acad.Dermatol. 1999; 41: S7-S12.
195. Gollnick H, Bonnekoh B. Textbook of psoriasis. Blackwell Science, 1999: 233-56.
196. Orfanos CE, Bauer R. Evidence for anti-inﬂammatory activities of oral synthetic 
retinoids: experimental ﬁndings and clinical experience. Br.J.Dermatol. 1983; 109 
Suppl 25: 55-60.
197. Lowe NJ, Kaplan R, Breeding J. Etretinate treatment for psoriasis inhibits epidermal 
ornithine decarboxylase. J.Am.Acad.Dermatol. 1982; 6: 697-8.
198. Rentenaar RJ, Heydendael VM, van Diepen FN et al. Systemic treatment with either 
cyclosporin A or methotrexate does not inﬂuence the T helper 1/T helper 2 balance in 
psoriatic patients. J.Clin.Immunol. 2004; 24: 361-9.
199. Nyfors A. Beneﬁts and adverse drug experiences during long-term methotrexate 
treatment of 248 psoriatics. Dan.Med.Bull. 1978; 25: 208-11.
200. Van De Kerkhof PC, Mali JW. Methotrexate maintenance following Ingram therapy in 
'difﬁcult' psoriasis. Br.J.Dermatol. 1982; 106: 623-7.
201. Said S, Jeffes EW, Weinstein GD. Methotrexate. Clin.Dermatol. 1997; 15: 781-97.
202. Zachariae H, Sogaard H, Heickendorff L. Methotrexate-induced liver cirrhosis. Clinical, 
histological and serological studies--a further 10-year follow-up. Dermatology 1996; 
192: 343-6.
203. Nguyen C, Duhl AJ, Escallon CS et al. Multiple anomalies in a fetus exposed to low-
dose methotrexate in the ﬁrst trimester. Obstet.Gynecol. 2002; 99: 599-602.
204. Kozlowski RD, Steinbrunner JV, MacKenzie AH et al. Outcome of ﬁrst-trimester 
exposure to low-dose methotrexate in eight patients with rheumatic disease. Am.J.Med. 
1990; 88: 589-92.
205. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. 
Immunol.Today 1992; 13: 136-42.
206. Wong RL, Winslow CM, Cooper KD. The mechanisms of action of cyclosporin A in the 
treatment of psoriasis. Immunol.Today 1993; 14: 69-74.
207. Mozzanica N, Pigatto PD, Finzi AF. Cyclosporin in psoriasis: pathophysiology and 
experimental data. Dermatology 1993; 187 Suppl 1: 3-7.
Chapter 1 - General Introduction
61
208. Demidem A, Taylor JR, Grammer SF et al. T-lymphocyte-activating properties of 
epidermal antigen-presenting cells from normal and psoriatic skin: evidence that 
psoriatic epidermal antigen-presenting cells resemble cultured normal Langerhans 
cells. J.Invest Dermatol. 1991; 97: 454-60.
209. Kalman VK, Klimpel GR. Cyclosporin A inhibits the production of gamma interferon 
(IFN gamma), but does not inhibit production of virus-induced IFN alpha/beta. Cell 
Immunol. 1983; 78: 122-9.
210. Timonen P, Friend D, Abeywickrama K et al. Efﬁcacy of low-dose cyclosporin A in 
psoriasis: results of dose-ﬁnding studies. Br.J.Dermatol. 1990; 122 Suppl 36: 33-9.
211. Litjens NH, Nibbering PH, Barrois AJ et al. Beneﬁcial effects of fumarate therapy 
in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. 
Br.J.Dermatol. 2003; 148: 444-51.
212. Litjens NH, Rademaker M, Ravensbergen B et al. Monomethylfumarate affects 
polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 
lymphocyte responses. Eur.J.Immunol. 2004; 34: 565-75.
213. Hoxtermann S, Nuchel C, Altmeyer P. Fumaric acid esters suppress peripheral CD4- 
and CD8-positive lymphocytes in psoriasis. Dermatology 1998; 196: 223-30.
214. Skaria AM, Schmid U. Antipsoriatic effect of fumaric acid derivates. J.Am.Acad.
Dermatol. 1996; 34: 323-4.
215. Nugteren-Huying WM, van der Schroeff JG, Hermans J et al. [Fumaric acid therapy 
in psoriasis; a double-blind, placebo-controlled study]. Ned.Tijdschr.Geneeskd. 1990; 
134: 2387-91.
216. Kolbach DN, Nieboer C. Fumaric acid therapy in psoriasis: results and side effects of 2 
years of treatment. J.Am.Acad.Dermatol. 1992; 27: 769-71.
217. Altmeyer PJ, Matthes U, Pawlak F et al. Antipsoriatic effect of fumaric acid derivatives. 
Results of a multicenter double-blind study in 100 patients. J.Am.Acad.Dermatol. 1994; 
30: 977-81.
218. Altmeyer P, Hartwig R, Matthes U. [Efﬁcacy and safety proﬁle of fumaric acid esters in 
oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 
patients]. Hautarzt 1996; 47: 190-6.
219. Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric 
acid esters: scientiﬁc background and guidelines for therapeutic use. The German 
Fumaric Acid Ester Consensus Conference. Br.J.Dermatol. 1999; 141: 424-9.
220. Mrowietz U. [Psoriasis therapy with biologicals]. Hautarzt 2003; 54: 224-9.
221. Branco L, Barren P, Mao SY et al. Selective deletion of antigen-speciﬁc, activated T cells 
by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells. Transplantation 
1999; 68: 1588-96.
222. Trajkovic V. Nuvion. Protein Design Labs. Curr.Opin.Investig.Drugs 2002; 3: 411-4.
223. Weinshenker BG, Bass BH, Ebers GC et al. Remission of psoriatic lesions with 
muromonab-CD3 (orthoclone OKT3) treatment. J.Am.Acad.Dermatol 1989; 20: 1132-
3.
224. Gottlieb AB, Lebwohl M, Shirin S et al. Anti-CD4 monoclonal antibody treatment of 
moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, 
placebo-controlled study. J.Am.Acad.Dermatol. 2000; 43: 595-604.
225. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of 
memory effector T lymphocytes. N.Engl.J.Med. 2001; 345: 248-55.
Chapter 1 - General Introduction
62
226. Abrams JR, Lebwohl MG, Guzzo CA et al. CTLA4Ig-mediated blockade of T-cell 
costimulation in patients with psoriasis vulgaris. J.Clin.Invest 1999; 103: 1243-52.
227. Gottlieb, A., Abdulghani, A., Totoritis M, Lizambri R, Shuey S, Romano, P., and et 
al. Results of a single-dose, dose-escalating trial of an anti-B7.1 monoclonal antibody 
(IDEC114) in patients with psoriasis. J.Invest Dermatol 114, 840. 2000. 
228. Ghoreschi K, Thomas P, Breit S et al. Interleukin-4 therapy of psoriasis induces Th2 
responses and improves human autoimmune disease. Nat.Med. 2003; 9: 40-6.
229. Asadullah K, Friedrich M, Hanneken S et al. Effects of systemic interleukin-10 therapy 
on psoriatic skin lesions: histologic, immunohistologic, and molecular biology ﬁndings. 
J.Invest Dermatol. 2001; 116: 721-7.
230. Krueger JG, Walters IB, Miyazawa M et al. Successful in vivo blockade of CD25 
(high-afﬁnity interleukin 2 receptor) on T cells by administration of humanized anti-Tac 
antibody to patients with psoriasis. J.Am.Acad.Dermatol 2000; 43: 448-58.
231. Owen CM, Harrison PV. Successful treatment of severe psoriasis with basiliximab, an 
interleukin-2 receptor monoclonal antibody. Clin.Exp.Dermatol. 2000; 25: 195-7.
232. Gottlieb A, Krueger JG, Bright R et al. Effects of administration of a single dose of a 
humanized monoclonal antibody to CD11a on the immunobiology and clinical activity 
of psoriasis. J.Am.Acad.Dermatol. 2000; 42: 428-35.
233. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients 
with psoriasis. N.Engl.J.Med. 2003; 349: 2014-22.
234. Nikas SN, Drosos AA. Onercept. Serono. Curr.Opin.Investig.Drugs 2003; 4: 1369-76.
235. Chaudhari U, Romano P, Mulcahy LD et al. Efﬁcacy and safety of inﬂiximab 
monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-7.
236. Scheinfeld N. Adalimumab (HUMIRA): a review. J.Drugs Dermatol 2003; 2: 375-7.
237. Remitz A, Reitamo S, Erkko P et al. Tacrolimus ointment improves psoriasis in a 
microplaque assay. Br.J.Dermatol. 1999; 141: 103-7.
238. Mrowietz U, Graeber M, Brautigam M et al. The novel ascomycin derivative SDZ 
ASM 981 is effective for psoriasis when used topically under occlusion. Br.J.Dermatol. 
1998; 139: 992-6.
239. Prasad R, Gladman D. Current and investigational treatment of psoriatic arthritis. 
Expert.Opin.Investig.Drugs 2004; 13: 139-50.
240. Franssen ME, Smit JV, van Erp PE et al. A multiparameter ﬂow cytometric analysis of 
the effect of bexarotene on the epidermis of the psoriatic lesion. Br.J.Dermatol 2003; 
149: 506-12.
241. Pershadsingh HA. Peroxisome proliferator-activated receptor-gamma: therapeutic 
target for diseases beyond diabetes: quo vadis? Expert.Opin.Investig.Drugs 2004; 13: 
215-28.
242. Reitamo S, Spuls P, Sassolas B et al. Efﬁcacy of sirolimus (rapamycin) administered 
concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe 
psoriasis: a randomized controlled trial. Br.J.Dermatol 2001; 145: 438-45.
243. Reynolds NJ, Al Daraji WI. Calcineurin inhibitors and sirolimus: mechanisms of action 
and applications in dermatology. Clin.Exp.Dermatol. 2002; 27: 555-61.
244. Halloran PF. Sirolimus and cyclosporin for renal transplantation. Lancet 2000; 356: 
179-80.
245. Javier AF, Bata-Csorgo Z, Ellis CN et al. Rapamycin (sirolimus) inhibits proliferating 
cell nuclear antigen expression and blocks cell cycle in the G1 phase in human 
keratinocyte stem cells. J.Clin.Invest 1997; 99: 2094-9.
Chapter 1 - General Introduction
63
246. Fisher GJ, Duell EA, Nickoloff BJ et al. Levels of cyclosporin in epidermis of treated 
psoriasis patients differentially inhibit growth of keratinocytes cultured in serum free 
versus serum containing media. J.Invest Dermatol. 1988; 91: 142-6.
247. Abu-Elmagd K, van Thiel D, Jegasothy BV et al. FK 506: a new therapeutic agent for 
severe recalcitrant psoriasis. Transplant.Proc. 1991; 23: 3322-4.
248. Thomson AW, Nalesnik M, Abu-Elmagd K et al. Inﬂuence of FK 506 on T lymphocytes, 
Langerhans' cells and the expression of cytokine receptors and adhesion molecules in 
psoriatic skin lesions: a preliminary study. Transplant.Proc. 1991; 23: 3330-1.
249. Van De Kerkhof PC, Vissers WH. The topical treatment of psoriasis. Skin Pharmacol.
Appl.Skin Physiol 2003; 16: 69-83.
250. Reitamo S, Rissanen J, Remitz A et al. Tacrolimus ointment does not affect collagen 
synthesis: results of a single-center randomized trial. J.Invest Dermatol. 1998; 111: 
396-8.
251. Zonneveld IM, Rubins A, Jablonska S et al. Topical tacrolimus is not effective in 
chronic plaque psoriasis. A pilot study. Arch.Dermatol. 1998; 134: 1101-2.
252. Carroll CL, Clarke J, Camacho F et al. Topical tacrolimus ointment combined with 6% 
salicylic Acid gel for plaque psoriasis treatment. Arch.Dermatol. 2005; 141: 43-6.
253. Allen A, Siegfried E, Silverman R et al. Signiﬁcant absorption of topical tacrolimus in 
3 patients with Netherton syndrome. Arch.Dermatol. 2001; 137: 747-50.
254. Reitamo S, Wollenberg A, Schopf E et al. Safety and efﬁcacy of 1 year of tacrolimus 
ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus 
Ointment Study Group. Arch.Dermatol. 2000; 136: 999-1006.
255. Kang S, Lucky AW, Pariser D et al. Long-term safety and efﬁcacy of tacrolimus 
ointment for the treatment of atopic dermatitis in children. J.Am.Acad.Dermatol. 2001; 
44: S58-S64.
256. Bornhovd E, Burgdorf WH, Wollenberg A. Macrolactam immunomodulators for topical 
treatment of inﬂammatory skin diseases. J.Am.Acad.Dermatol. 2001; 45: 736-43.
257. Bornhovd EC, Schuller E, Bieber T et al. [Immunosuppressive macrolides and their use 
in dermatology]. Hautarzt 2000; 51: 646-54.
258. Bornhovd EC, Burgdorf WH, Wollenberg A. Immunomodulatory macrolactams for 
topical treatment of inﬂammatory skin diseases. Curr.Opin.Investig.Drugs 2002; 3: 
708-12.
259. Majeau GR, Meier W, Jimmo B et al. Mechanism of lymphocyte function-associated 
molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis 
in vitro and in human CD2 transgenic mice. J.Immunol. 1994; 152: 2753-67.
260. Krueger GG, Ellis CN. Alefacept therapy produces remission for patients with chronic 
plaque psoriasis. Br.J.Dermatol. 2003; 148: 784-8.
261. Krueger GG. Clinical response to alefacept: results of a phase 3 study of intravenous 
administration of alefacept in patients with chronic plaque psoriasis. J.Eur.Acad.
Dermatol.Venereol. 2003; 17 Suppl 2: 17-24.
262. Ortonne JP. Clinical response to alefacept: results of a phase 3 study of intramuscular 
administration of alefacept in patients with chronic plaque psoriasis. J.Eur.Acad.
Dermatol.Venereol. 2003; 17 Suppl 2: 12-6.
263. Goedkoop AY, de Rie MA, Picavet DI et al. Alefacept therapy reduces the effector T-
cell population in lesional psoriatic epidermis. Arch.Dermatol.Res. 2004; 295: 465-73.
264. da Silva AJ, Brickelmaier M, Majeau GR et al. Alefacept, an immunomodulatory 
recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-
dependent apoptosis of CD2(+) cells. J.Immunol. 2002; 168: 4462-71.
Chapter 1 - General Introduction
64
265. Cooper JC, Morgan G, Harding S et al. Alefacept selectively promotes NK cell-mediated 
deletion of CD45R0+ human T cells. Eur.J.Immunol. 2003; 33: 666-75.
266. Lowe NJ, Gonzalez J, Bagel J et al. Repeat courses of intravenous alefacept in patients 
with chronic plaque psoriasis provide consistent safety and efﬁcacy. Int.J.Dermatol. 
2003; 42: 224-30.
267. Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of 
tumor necrosis factor antagonists. J.Pharmacol.Exp.Ther. 2002; 301: 418-26.
268. Goffe B, Cather JC. Etanercept: An overview. J.Am.Acad.Dermatol. 2003; 49: S105-
S111.
269. Mease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and 
psoriasis: a randomised trial. Lancet 2000; 356: 385-90.
270. Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as 
monotherapy for psoriasis. Arch.Dermatol. 2003; 139: 1627-32.
271. Schottelius AJ, Moldawer LL, Dinarello CA et al. Biology of tumor necrosis factor-
alpha- implications for psoriasis. Exp.Dermatol. 2004; 13: 193-222.
272. Zeltser R, Valle L, Tanck C et al. Clinical, histological, and immunophenotypic 
characteristics of injection site reactions associated with etanercept: a recombinant 
tumor necrosis factor alpha receptor: Fc fusion protein. Arch.Dermatol. 2001; 137: 
893-9.
273. Fryrear RS, Wiggins AK, Sangueza O et al. Rapid onset of cutaneous squamous cell 
carcinoma of the penis in a patient with psoriasis on etanercept therapy. J.Am.Acad.
Dermatol. 2004; 51: 1026.
274. McCain ME, Quinet RJ, Davis WE. Etanercept and inﬂiximab associated with cutaneous 
vasculitis. Rheumatology.(Oxford) 2002; 41: 116-7.
275. Bleumink GS, ter Borg EJ, Ramselaar CG et al. Etanercept-induced subacute cutaneous 
lupus erythematosus. Rheumatology.(Oxford) 2001; 40: 1317-9.
276. Adams AE, Zwicker J, Curiel C et al. Aggressive cutaneous T-cell lymphomas after 
TNFalpha blockade. J.Am.Acad.Dermatol. 2004; 51: 660-2.
277. Roux CH, Brocq O, Albert CB, V et al. Cutaneous vasculitis and glomerulonephritis in 
a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis. Joint Bone 
Spine 2004; 71: 444-5.
278. Mohan N, Edwards ET, Cupps TR et al. Demyelination occurring during anti-tumor 
necrosis factor alpha therapy for inﬂammatory arthritides. Arthritis Rheum. 2001; 44: 
2862-9.
279. Fennelly K, Iseman MD. Etanercept or mycobacterium lung injury? Chest 2003; 124: 
1174-5.
280. Yim K, Nazeer SH, Kiska D et al. Recurrent Mycobacterium xenopi infection in a 
patient with rheumatoid arthritis receiving etanercept. Scand.J.Infect.Dis. 2004; 36: 
150-4.
281. Kroesen S, Widmer AF, Tyndall A et al. Serious bacterial infections in patients with 
rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology.(Oxford) 2003; 42: 
617-21.
282. Slifman NR, Gershon SK, Lee JH et al. Listeria monocytogenes infection as a 
complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis 
Rheum. 2003; 48: 319-24.
283. Lee JH, Slifman NR, Gershon SK et al. Life-threatening histoplasmosis complicating 
immunotherapy with tumor necrosis factor alpha antagonists inﬂiximab and etanercept. 
Arthritis Rheum. 2002; 46: 2565-70.
Chapter 1 - General Introduction
65
284. O'Quinn RP, Miller JL. The effectiveness of tumor necrosis factor alpha antibody 
(inﬂiximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch.Dermatol. 2002; 
138: 644-8.
285. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal 
antibody against tumor necrosis factor alpha, inﬂiximab. J.Am.Acad.Dermatol. 2002; 
46: 886-91.
286. Gottlieb AB, Chaudhari U, Mulcahy LD et al. Inﬂiximab monotherapy provides rapid 
and sustained beneﬁt for plaque-type psoriasis. J.Am.Acad.Dermatol. 2003; 48: 829-
35.
287. Gottlieb AB. Inﬂiximab for psoriasis. J.Am.Acad.Dermatol. 2003; 49: S112-S117.
288. Soliotis F, Glover M, Jawad AS. Severe skin reaction after leﬂunomide and etanercept 
in a patient with rheumatoid arthritis. Ann.Rheum.Dis. 2002; 61: 850-1.
289. Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with 
etanercept for rheumatoid arthritis. Ann.Intern.Med. 1999; 131: 634.
290. Devos SA, Van Den BN, De Vos M et al. Adverse skin reactions to anti-TNF-alpha 
monoclonal antibody therapy. Dermatology 2003; 206: 388-90.
291. Soykan I, Ertan C, Ozden A. Severe anaphylactic reaction to inﬂiximab: report of a 
case. Am.J.Gastroenterol. 2000; 95: 2395-6.
292. Van De Putte LB, Rau R, Breedveld FC et al. Efﬁcacy and safety of the fully human 
anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD 
refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann.Rheum.Dis. 
2003; 62: 1168-77.
293. Scheinfeld N. Adalimumab (HUMIRA): a review. J.Drugs Dermatol. 2003; 2: 375-7.
294. Beuthien W, Mellinghoff HU, von Kempis J. Skin reaction to adalimumab. Arthritis 
Rheum. 2004; 50: 1690-2.
295. Papp K, Bissonnette R, Krueger JG et al. The treatment of moderate to severe psoriasis 
with a new anti-CD11a monoclonal antibody. J.Am.Acad.Dermatol. 2001; 45: 665-74.
296. Gottlieb AB, Krueger JG, Wittkowski K et al. Psoriasis as a model for T-cell-mediated 
disease: immunobiologic and clinical effects of treatment with multiple doses of 
efalizumab, an anti-CD11a antibody. Arch.Dermatol. 2002; 138: 591-600.
297. Gordon KB, Papp KA, Hamilton TK et al. Efalizumab for patients with moderate to 
severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290: 3073-80.
298. Menter A, Gordon K, Carey W et al. Efﬁcacy and safety observed during 24 weeks of 
efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch.Dermatol. 
2005; 141: 31-8.
299. Bonish B, Jullien D, Dutronc Y et al. Overexpression of CD1d by keratinocytes in 
psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J.Immunol. 
2000; 165: 4076-85.
300. Aramburu J, Balboa MA, Rodriguez A et al. Stimulation of IL-2-activated natural killer 
cells through the Kp43 surface antigen up-regulates TNF-alpha production involving 
the LFA-1 integrin. J.Immunol. 1993; 151: 3420-9.
301. Perez-Villar JJ, Melero I, Rodriguez A et al. Functional ambivalence of the Kp43 
(CD94) NK cell-associated surface antigen. J.Immunol. 1995; 154: 5779-88.
302. Van De Kerkhof PC, Gerritsen MJ, De Jong EM. Transition from symptomless to 
lesional psoriatic skin. Clin.Exp.Dermatol. 1996; 21: 325-9.
Chapter 1 - General Introduction
66
303. Gerritsen MJ, Elbers ME, De Jong EM et al. Recruitment of cycling epidermal cells 
and expression of ﬁlaggrin, involucrin and tenascin in the margin of the active psoriatic 
plaque, in the uninvolved skin of psoriatic patients and in the normal healthy skin. 
J.Dermatol.Sci. 1997; 14: 179-88.
304. Chowaniec O, Jablonska S, Beutner EH et al. Earliest clinical and histological changes 
in psoriasis. Dermatologica 1981; 163: 42-51.
305. Ragaz A, Ackerman AB. Evolution, maturation, and regression of lesions of 
psoriasis. New observations and correlation of clinical and histologic ﬁndings. 
Am.J.Dermatopathol. 1979; 1: 199-214.
306. Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. 
Dermatologica 1978; 157: 238-44.
307. Van De Kerkhof PC. On the limitations of the psoriasis area and severity index (PASI). 
Br.J.Dermatol. 1992; 126: 205.
308. Ramsay B, Lawrence CM. Measurement of involved surface area in patients with 
psoriasis. Br.J.Dermatol. 1991; 124: 565-70.
309. Kammerer U, Kapp M, Gassel AM et al. A new rapid immunohistochemical staining 
technique using the EnVision antibody complex. J.Histochem.Cytochem. 2001; 49: 
623-30.
310. A.B.Gottlieb. Psoriasis:emerging therapeutic strategies. Nature reviews 2005; 4: 19-
34.
311. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch.Dermatol. 1999; 
135: 1104-10.
312. Gerdes J, Lemke H, Baisch H et al. Cell cycle analysis of a cell proliferation-associated 
human nuclear antigen deﬁned by the monoclonal antibody Ki-67. J.Immunol. 1984; 
133: 1710-5.
313. Mommers JM, van Rossum MM, van Erp PE et al. Changes in keratin 6 and keratin 10 
(co-)expression in lesional and symptomless skin of spreading psoriasis. Dermatology 
2000; 201: 15-20.
C
hapter
Pathogenesis of 
psoriasis
This chapter was based on the following publications: 
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2.1 AGGRAVATION OF PSORIASIS BY INFECTIONS: A 
CONSTITUTIONAL TRAIT OR A VARIABLE EXPRESSION?
Summary
Introduction Focal infections are a well-known triggering factor in patients with 
psoriasis. A question, which remains to be answered, is whether relapsing of psoriasis 
after infections is a constitutional trait of a restricted population or whether it is a 
feature of all patients in some phase of their disease.
Methods A questionnaire was mailed to patients with psoriasis comprising general 
questions, psoriasis related questions and questions on the relationship between focal 
infections and aggravation of psoriasis. The questionnaire was mailed to 126 patients 
and 45 questionnaires, which were returned, were evaluable. 
Results From the 45 questionnaires the following preliminary conclusion can be 
drawn. Aggravation of psoriasis following infections appeared to be a consistent 
trait throughout the duration of psoriasis in 18% of patients as opposed to 71% of 
the patients who did not experience this association at all and 11% who experienced 
the association sometimes. Patients who experienced aggravation of psoriasis by 
infections as a consistent feature have an age of onset 9 years earlier as opposed to 
patients without this association and express guttate psoriasis in the vast majority 
as ﬁrst manifestation at initiation of psoriasis. These patients had an average of 4.6 
relapses per year in contrast to 1.1 per year in the patients without an association 
between infection and aggravation of psoriasis. In these patients infections proved to 
be responsible for 67% of the exacerbations. Stress was indicated in this subpopulation 
as a triggering factor as well in 88% of the patients.
Conclusion Although this conclusion only can be very preliminary based on the small 
group of patients, we may conclude that patients with a strong association between 
aggravation of psoriasis and infections belong to a restricted population of patients 
tending to an unstable course of the disease.
Introduction
Psoriasis is a polygenic disease and several triggering factors may elicit or aggravate 
the expression of this disease.1
 Focal infections are a well-established triggering factor.2-5 Provoking 
infections could be traced in 44% of a mixed series of psoriatic patients.6 In particular 
infections of the upper respiratory tract may trigger psoriasis.
 The mechanism of aggravation of psoriasis by focal infections has been 
suggested to be mediated by bacterial superantigens.7 In particular, toxins from β-
haemolytic streptococci comprise superantigens which may activate T-cells after 
presentation by Langerhanscells to the Vβ region of the T-cell receptor.8 
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The question arises to what extent “relapsing after infections” is a constitutional trait 
restricted to a subpopulation of genetically predisposed patients within the population 
of patients with psoriasis? If such a subpopulation exists, what are the major clinical 
characteristics of these patients?
 A questionnaire was developed to ﬁnd out to what extent patients with 
psoriasis experienced aggravation of psoriasis as a consistent feature and whether 
those patients with frequent relapse have other clinical characteristics, different from 
patients who never relapse following infections.
Materials and methods
A questionnaire was designed which comprised: (I) general questions, (II) psoriasis 
related questions, (III) questions on the relationship between focal infections and 
aggravation of psoriasis.
(I) General questions comprised birthdate, sex and use of medication
(II) Psoriasis related questions comprised age of onset and clinical presentations 
at start, in particular whether psoriasis followed an infection, whether aggravations 
of psoriasis following infections were a consistent feature during the course of the 
disease, family history of psoriasis, koebner phenomenon (the appearance of new 
lesions following an injury of the skin), pustulation and response to treatments. The 
infections were not conﬁrmed by a physician in all patients.
(III) Questions on details of the relationship between focal infections, and 
aggravation of psoriasis were speciﬁed in greater detail. The patients were asked (i) 
how often during last year and during the years before the patient had an infection in 
general. In particular the patients were asked to report tonsillitis, pharyngitis, sinusitis, 
urocystitis, remaining infections. Further we asked the patients (ii), how frequent he/
she had relapsed during last year and the years before, (iii) whether a relapse always, 
mostly (at least 5 out of 10 times), sometimes (1-5 out of 10 times) and never followed 
an infection, (iv) whether exacerbations were experienced as stressful and whether 
stress did aggravate psoriasis.
 The questionnaire was mailed to a group of 126 patients. These patients had 
responded previously to an advertisement in the newspaper that they were willing to 
ﬁll in questionnaires, provide blood and skin for research projects.
 The questionnaire was mailed in the month of January 2003 and answers were 
collected in the months of February and March. Out of 126 patients, 18 questionnaires 
were returned for reason of unknown address and 45 questionnaires were answered 
and returned, which corresponds to a response rate of 42%.
Statistical analysis comprised student T-test, chi square test and multiple regression 
analysis.
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Results
The average age of responders was 55 ± 13 (mean ±SD) years. In total 28 males and 
17 females responded. The average age of onset of psoriasis was 29.7 ± 12.8 (mean 
±SD) years for males and 20.1 ±15.4 (mean ± SD) years for females. The age of onset 
for females was earlier as compared to males (P= 0.04).
 During the last year, 11 out of 45 patients (24%) reported an exacerbation of 
psoriasis following an infection, whereas 30 out of 45 patients (67%) indicated that 
a relapse never followed an infection. Four patients out of 45 indicated that they had 
sometimes a relapse following an infection. Whilst 18 out of 45 (40%) of the patients 
did not remember whether initiation of psoriasis followed an infection, 5 out of 45 
(10%) indicated that such had been the case and 22 out of 45 (44%) indicated that 
such had not occurred at the initiation of psoriasis. A positive correlation was shown 
between failure of initiation of psoriasis following an infection during the ﬁrst year 
and failure of exacerbation on infection of psoriasis during last year (X2 =7.0, P=0.01). 
The relationship between psoriasis and infections at initiation of psoriasis during the 
last year can be seen in table I. Patients who indicated that recently their psoriasis was 
exacerbated by infections consistently indicated that this held true during the course 
of psoriasis.
Initiation of psoriasis following infection 
 Last year 
exacerbation 
after infection
? Yes No Total 
? 4 0 0 4 
Yes 6 3 2 11 
No 8 2 20 30 
Total 18 5 22 45 
Table 1 Patients with initiation of psoriasis following infections versus exacerbations of 
psoriasis following infection during last year.
The patients indicated whether a relapse “never”, “sometimes” (1-5 out of 10 relapses) 
or “mostly (5-10 out of 10 relapses) followed an infection.The majority of patients 
(n=32) indicated that they never had a relapse following an infection and 8 patients 
indicated that they mostly experienced infection induced aggravation of psoriasis, 
whereas 5 patients indicated that they sometimes experienced this association. The 
clinical characteristics of the patients indicating mostly infection induced aggravations 
were compared with those who never experienced this association.
 The age of onset in patients who mostly had infections induced aggravations 
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of psoriasis was 17.6 ± 11.6 vs. 26.6 ± 14.2 in patients who never had this association 
(P=0.09). Six out of 7 patients who mostly experienced psoriasis exacerbations 
following infections had guttate psoriasis as ﬁrst manifestations.
Patients who experienced mostly aggravation of psoriasis following an infection 
had 4.6 ± 4.3 relapses per year versus 1.1 ± 0.9 in patients who never experienced 
this association. Multiple regression analysis between the number of relapses of 
psoriasis during last year and the number of infections during that year in patients who 
have mostly aggravation of psoriasis following an infection revealed a correlation 
coefﬁcient r=0.82.In this group of patients the correlation of the number of relapses 
with pharyngitis was 0.61, with sinusitis 0.43, with cystitis 0.057 and with remaining 
infections -0.33.
 Comparing patients who mostly experienced infection induced aggravation 
of psoriasis with those who never experienced such revealed that the occurrence of 
the Koebner phenomenon, the appearance of new lesions following a trauma,  was 
virtually identical in both groups (table 2) and that pustulation occurred in 22% and 
13% resp. of the patients (no statistically signiﬁcant difference). Table 3 indicates 
that no statistically signiﬁcant differences exist between both groups with 
respect to experience of stress or relevance of stress to induce a relapse. 
However 7 out of 8 patients (88%) who experienced that aggravation mostly 
resulted from an infection also experienced aggravations induced by stress. 
Aggravation 
following an 
infection 
Exacerbation causes stress Stress causes exacerbation 
Yes No Yes No 
Never (0/10) 17 (53%) 15 (47%) 19 (59%) 13 (41%) 
Mostly (5-10/10) 5 (62%) 3 (38%) 7 (88%) 1 (12%) 
X2=0.23 p=0.63  X2 =2.23 p=0.13 
Table 3. Role of stress in patients who mostly experienced exacerbation after infection vs. 
patients without this association
Aggravation 
following an 
infection 
Last year Koebner positive
Yes  No ?
Never (0/10) 8 (25%) 23 (72%) 1 (3%) 
Mostly (5-10/10) 2 (25%) 6 (75%) 0 (0%) 
Table 2. Koebner phenomenon in patients who mostly experienced exarcerbation after infection 
vs. patients without this association (X2= 0.25, P=0.88)
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Discussion
The present questionnaire comprises a small group of patients. Therefore, conclusions 
from this report only can be preliminary and needs to be conﬁrmed by a study of a 
large patients populations. However, the report suggests that aggravation of psoriasis 
by infections is a consistent feature in a preselection of the patients and not a general 
characteristic of the entire population of patients with psoriasis.
Patients who show often aggravations of psoriasis following infections differ in 
several respect from patients who consistently do not show this association At the 
initiation of psoriasis the majority of patients showing the association with infections 
had guttate psoriasis (6 out of 8) and patients in this group were 9 years younger as 
compared to patients who did not experience this association. It is a well established 
fact that guttate psoriasis is a frequent manifestation of childhood psoriasis. 
 Patients who show exacerbations following infections usually have guttate 
psoriasis at start, however guttate psoriasis also may occur in 50% of the patients who 
have psoriasis not dependent from infections.
 Relapses are 4 times as frequent in patients who experience mostly infection 
induced aggravations. The correlation coefﬁcient of r= 0.82 between aggravation 
of psoriasis and infections in this group implies that infections are responsible for 
the aggravation of psoriasis in 67% of the cases. A remarkable observation is that a 
positive Koebner phenomenon occurred in 25% of the patients irrespective whether 
they showed infection induced aggravations or not. A positive Koebner phenomenon 
has been reported in 25% of a large population of psoriatics.9
 Pharyngitis shows the highest correlation with relapses, indicating that throat 
infections are most relevant to the aggravation of psoriasis.
Although below the level of statistical signiﬁcance, 7 out of 8 patients who indicated 
to have mostly exacerbations following infections also indicated that stress induces 
aggravation of the disease.
 The present study indicates that aggravation of psoriasis by infection is 
restricted to a subpopulation of 18% of psoriatics. This subgroup is also characterized 
by guttate psoriasis at initiation and an age of onset which is 9 years earlier as 
compared to patients without this association. The course in the ﬁrst group is more 
severe with about 4 times as much exacerbations and a tendency to be more prone to 
exacerbations by other triggering factors such as stress.
 Previously, a subtype of patients with psoriasis has been deﬁned as Type 
I: early onset (< 40 years), a positive family history and type II: absence of HLA 
Cw6, B13 and B57.10 Furthermore, it was shown that HLA-B13 may predispose to 
severe streptococcal infections.11 Recently microbial infection was investigated by 
nasopharyngeal swabbing and standard methods of bacterial isolation and assessment 
of titers of antibacterial antibodies in patients with type I vs. type II psoriasis.12 Patients 
with type I psoriasis had a signiﬁcantly higher incidence of laboratory indicators for 
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streptococcal  infections as opposed to type II psoriasis, although healthy subjects 
expressing HLA-Cw6, B13 and B57 had no indication for an increase of indicators 
for streptococcal infections.12 
 In conclusion, it is highly likely that a subgroup of psoriatics exists who 
are prone to exacerbate following infections as a genetic trait rather than a variable 
expression in the entire population of psoriatics.
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2.2 MEMORY EFFECTOR (CD45RO+) AND CYTOTOXIC 
(CD8+) T-CELLS APPEAR EARLY IN THE MARGIN ZONE OF 
SPREADING PSORIATIC LESIONS IN CONTRAST TO CELLS 
EXPRESSING NK-RECEPTORS, WHICH APPEAR LATE. 
Summary
Background Inﬂux of immunocytes, increased epidermal proliferation and abnormal 
keratinization are hallmarks of the psoriatic lesion. T-lymphocyte subsets in particular 
activated effector memory T-cells and natural killer T-cells (NK-T cells) have been 
suggested to play an important role in the pathogenesis of psoriasis.
Objectives In the present study we investigated the number of T-cell subsets (CD4, 
CD8, CD45RO, CD45RA, CD2, CD25, CD94 and CD161), the proliferation marker 
Ki-67 and the keratinization marker Keratin 10 across the margin of the spreading 
psoriatic plaque: distant uninvolved skin, the outer margin (immediately outside the 
clinical edge), the inner margin (immediately inside the clinical edge), and the central 
area.
Patients and Methods Eight patients with active psoriasis vulgaris participated in 
this study. Biopsies were taken from the spreading psoriatic lesion from the distant 
uninvolved skin, the outer margin, the inner margin and the central area. Biopsies 
were processed for immunohistochemical staining.
Results In the outer margin CD8+ (cytotoxic T-cells) and CD45RO+ (memory effector 
T-cells) T-lymphocytes invade the epidermis and in this early stage the activation 
markers CD2 and CD25 also show a substantial increase. The next phase, from the 
outer to the inner margin shows a statistically signiﬁcant increase of these markers, 
especially the cells expressing NK-receptors (CD94 and CD161) show a massive 
increase together with a signiﬁcant increase of epidermal proliferation (Ki-67) and a 
decrease of the K10 positive epidermal surface. 
Conclusions CD8+, CD45RO+, CD2+ and CD25+ T-cells have a role in the early 
phase of the psoriatic process, whereas CD94 and CD161 expressing cells together 
with epidermal proliferation and keratinization are involved in a later phase.
Key words: memory effector T-cells, cytotoxic T-cells, NK-T cells, spreading 
psoriasis
Introduction
Within the context of epidermal proliferation, abnormal keratinization and 
inﬂammation, the T-lymphocyte plays a pivotal role in the pathogenesis of psoriasis. The 
epidermis is characterised by a 8 fold increased recruitment of cycling epidermal cells 
(Ki-67 positive nuclei) and a major increase of proliferation associated keratinization 
which is reﬂected in keratin-16 expression at the expense of keratin-10 expression 
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in the suprabasal compartment.1;2 Increased expression of adhesion molecules on 
endothelial cells such as ICAM1-3 and selectins, angiogenesis and abnormalities in 
the extracellular matrix together with an inﬂux of several immunocytes such as T-
lymphocytes, monocytes, macrophages, polymorphonuclear leukocytes and dendritic 
cells all contribute to the complex pathogenesis of psoriasis.3-5 The keratinocyte has 
been suggested to be the primary cell in the pathogenesis of psoriasis. Although 
keratinocyte cultures never have revealed a primary abnormality which is conserved 
in vitro, it is possible that keratinocytes either release mediators of inﬂammation which 
contribute to the psoriatic phenotype 6 or respond abnormally to cytokines released 
from immunocytes.7-9 In early psoriatic lesions however, before overt epidermal 
hyperproliferation, inﬂammatory changes have been observed, including expression 
of extracellular matrix molecules, endothelial changes and accumulation of T-cells, 
which proved to be the earliest inﬂammatory cells invading the psoriatic epidermis.10 
Placek et al. also found a redistribution of immunocompetent cells before altered 
expression of keratinocyte differentiation markers in the psoriatic lesion.11
 The last decade the T-lymphocyte is considered to be of major importance 
in the pathogenesis of psoriasis. The well-established efﬁcacy of cyclosporin in 
the treatment of psoriasis has focussed research on the T-lymphocyte as a relevant 
denominator of psoriasis. More recently treatments which speciﬁcally are targeted 
on T-lymphocytes such as anti-CD3, anti-CD4 and anti-CD25 have reconﬁrmed the 
relevance of the T-lymphocyte in the pathogenesis of psoriasis.3;12;13 Furthermore, 
interference with antigen presenting cells and T-lymphocytes proved to be an effective 
antipsoriatic principle. Efﬁcacy in psoriasis has been shown for alefacept, interfering 
with CD2-LFA3 interaction and anti-CD80 and CLA4 Ig interfering with B7-B8, 
CD28 interaction.14 Activated T-lymphocytes expressing CD2 and the IL-2 receptor 
(CD25) have been observed in large numbers in the psoriatic lesion. The majority 
of these activated T-lymphocytes are memory effector cells (CD45RO+).3 In the 
psoriatic lesion mature antigen presenting cells, producing IL12, induce a Th-1 or Tc-
1 response, characterised by increased production of TNF-α, IL-2 and IFN-γ, amongst 
other cytokines.15;16 
 More recently, innate immunity has been suggested to be of relevance in the 
pathogenesis of psoriasis. CD94 recognises MHC class I on autologous cells whilst 
CD161 is a general activatory receptor, both are involved in innate immunity, as 
neither requires previous sensitization to act. CD94 receptors are expressed on most 
NK-cells and some T-cells, whereas CD161 is an obligate NK-T cell receptor.17-19T-
lymphocytes may contribute to innate immunity via the NK-T cell receptor. NK-T cells 
interact with antigen presenting cells (CD94+ T-cell: MHC bound) and keratinocytes 
(CD161+ T-cell: not MHC bound) via principles of adaptive and innate immunity 
.It has been shown that NK-T cells are present in the psoriatic lesion in signiﬁcantly 
higher numbers compared to the uninvolved or normal skin.17 These cells may either 
initiate or may stabilise (inhibit) the psoriatic process.20 
 The aim of the present study was to ﬁnd out which T-lymphocyte 
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subpopulations and CD94 and CD161 positive cells are present in early psoriasis in 
anticipation of increased epidermal proliferation and to what extent T-lymphocyte 
subpopulations change during maturation of the lesion from early to chronic. 
 In the present study the changes across the margin zone of spreading psoriatic 
lesions were investigated. In earlier studies it was shown that epidermal proliferation 
and keratinization in the symptomless skin just adjacent to the psoriatic plaque (outer 
margin) were comparable to the situation in distant uninvolved skin2, whereas a major 
increase in these epidermal changes was observed in the outerhalf zone of the psoriatic 
lesion (inner margin). Furthermore it was shown that these parameters were more 
expressed in the inner margin as compared to the central zone of the clinical lesion 
(central area).21 The inner margin also showed more active and intense inﬂammatory 
changes as compared to the central area.21
 Skin biopsies were taken from distant uninvolved skin, outer margin, 
inner margin and central area in the present study. Biopsies were processed for 
immunohistochemical staining to quantify in various stages of the psoriatic lesion 
relevant T-lymphocyte subsets in the context of epidermal proliferation (Ki-67+ nuclei 
per mm basement membrane) and keratinization (percentage Keratin 10+ epidermal 
surface). T-lymphocyte subsets, which were analysed comprised: CD4+ and CD8+ 
T-cells, memory effector (CD45RO+) and naive T-cells (CD45RA), activated T-
lymphocytes (CD2 and CD25) and cells expressing NK receptors (CD94+ and 
CD161+ cells)  
Patients and Methods   
Patients
Eight patients with spreading plaque psoriasis were included in this study. All the 
patients had given informed consent prior to the study. They had psoriatic plaques 
with a diameter of at least 2 cm. For 2 weeks they did not use any local therapy and 
for 4 weeks had not received any systemic treatment. They did not use medication that 
could interfere with the psoriasis e.g. systemic corticosteroids, α-blockers, lithium 
carbonate, anti-malaria medication and immunosuppressants.
Biopsies
Four 3-mm punch biopsies were taken from every psoriatic patient after local 
anaesthesia with xylocaine/adrenaline 1:100.000. One biopsy was taken from the 
centre of the lesion, one from the involved margin, one from the uninvolved margin 
of the lesion directly adjacent to the plaque and one from the distant uninvolved skin. 
Distant uninvolved skin was deﬁned as clinically normal looking skin at a distance of 
at least 2 cm from the spreading lesion. 
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Immunohistochemistry
Sections were sliced 6 um thick and were air-dried for 30 minutes. Then the sections 
were ﬁxated in cold acetone for 10 minutes. After blocking for endogenous peroxidase 
(1% H2O2/Na-azide in 1% BSA/PBS), they were washed in PBS for 10 minutes 
and incubated  with 20% normal horse serum (Vector laboratories, Burlingame, 
USA). Subsequently sections were incubated with the primary antibodies for 1 
hour. The following primary antibodies (mouse anti-human) were used, diluted in 
1% bovine serum albumin (Organon, Technika, Boxtel, Netherlands)/PBS, anti-
CD2 (1:50) (clone MT910), anti-CD4 (clone MT310) (1:25), anti-CD8 (clone 
DK25) (1:25), anti-CD45RO (clone UCHL1) (1:25), anti-CD45RA (clone 4KB5) 
(1:25), anti-CD94 (clone HP-3D9) (1:25), anti-CD25 (clone ACT-1) (1:25), Ki-67 
(clone MIB-1)  (1:100), anti-HLA-DR (clone TAL.1B5) (1:50) (all obtained from 
DAKO, Copenhagen Denmark), anti-keratine-10 (clone RKSE60) (1:200) (Monosan 
laboratories Uden The Netherlands), anti-CD161 (clone IM3450) (1:25) (Immunotech 
Marseille France). Sections were washed in PBS for 15 minutes. Secondary IgG horse 
anti-mouse biotinylated antibody (ABC- kit-mouse, Vector laboratories Burlingame 
USA)(dilution 1:200 in 1% BSA/PBS) was added for 30 minutes. The sections were 
washed for 15 minutes in PBS and this step was followed by incubation with avidin-
biotin complex (ABC kit-mouse, Vector Laboratories Burlingame USA) (avidin/biotin 
diluted 1:50 in 1 % BSA/PBS) To visualise the staining we used enhanced DAB as 
chromogen (DAB+ kit from DAKO). Counterstaining was performed with Mayer’s 
Haematoxylin (Sigma St Louis USA). Furthermore from each patient we performed 
a hematoxiline-eosine staining. After dehydration in alcohol and histosafe, sections 
were mounted in Permount. 
Immuno-histochemical scoring
Quantiﬁcation of the number of cells positive for CD2, CD4, CD8, CD25, CD45RO, 
CD45RA, CD94 and CD161 was performed. At 200X magniﬁcation positive cells in 
the epidermis were counted from the basement membrane up to the stratum corneum 
across the whole section. Cells in the dermis were counted from the basement 
membrane down to 100 um under the basement membrane across the whole section 
as well. Quantiﬁcation was done in the unit: Positive cells per mm length.
Quantitative image analysis
For K10 digital photographs were made at 50X magniﬁcation and for Ki67 digital 
photographs were made at 100X magniﬁcation. Each photograph was analysed using 
IP-lab software. For quantiﬁcation of the number of cells positive for K10, we used the 
following procedure: Using IP-lab software a deﬁned window is set for the analysis 
of the markers from an area which is representative for the section. This window 
is designated as Region of Interest (ROI). After choosing a representative ROI, all 
positive segments in the ROI were marked with a colour and counted. We subtracted 
the present dermal surface in the ROI. The ROI is chosen in the centre of the section. 
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Quantiﬁcation was measured as a % of ROI as unit. For Ki67 a line following the 
stratum basale was drawn after again choosing a ROI and all positive cells above this 
line were counted. Quantiﬁcation was done in the unit: Positive cells per mm length 
of basement membrane.
Statistical analysis
To compare the signiﬁcance between the centre, the inner margin, the outer margin 
and the distant uninvolved skin, we performed an analysis of variance. If this appeared 
to be signiﬁcant, a posthoc comparison was made using the Duncan multiple-range 
test. 
Results
In Figure 1 and 2 respectively the percentage keratin-10 positive epidermal surface 
and the number of Ki-67 positive keratinocytes per mm basement membrane 
are shown. Between the distant uninvolved skin and the outer margin there is no 
statistical signiﬁcant decrease (table 1) for the % K10 positive epidermal surface, 
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Figure 1 Percentage Keratin-10 
positive epidermal surface in the 
centre, inner margin, outer margin 
and distant uninvolved skin of the 
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Figure 2 Ki67 positive keratinocytes 
per mm basement membrane in the 
centre, inner margin, outer margin 
and distant uninvolved skin of the 
spreading psoriatic lesion.(Mean ± 
SEM) 
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Figure 3 Epidermal Th-cells (CD4), 
Tc-cells (CD8), effector memory T-
cells (CD45RO) and naive T-cells 
(CD45RA) in the centre, inner 
margin, outer margin and distant 
uninvolved skin of the spreading 
psoriatic lesion.(Mean ± SEM) 
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and no signiﬁcant increase of Ki-67 positive cells per mm. basement membrane. 
With respect to the inﬁltrate (ﬁgure 3-6), there is no statistical signiﬁcant increase of 
the inﬂammatory inﬁltrate when comparing the distant uninvolved skin to the outer 
margin in epidermis as well as dermis, although a borderline signiﬁcant increase is 
observed for dermal CD45RO+ and CD25+ cells in the outer margin. There was a 
markedly increased ratio for the outer margin/distant uninvolved skin of 3.5-8.3 or 
higher in the epidermis for the following markers: CD8, CD45RO, CD2 and CD25 
(table 1). In ﬁgure 7 representative immunostained sections for the aforementioned 
markers in the outer margin and distant uninvolved skin are shown.
 In the inner margin there is a highly signiﬁcant (p<0.01)  increase of Ki-
67 positive epidermal cells per mm basement membrane when compared to the 
outer margin, and only a borderline reduction was observed for the percentage K10 
positive epidermal surface. For all inﬂammatory markers in the epidermis (ﬁgure 
3 and 4) there is a highly signiﬁcant increase when comparing the inner and outer 
margin. For the dermis the same is true with exception of CD45RO, CD2 and CD25, 
which parameters were only slightly increased in the inner margin as compared to the 
epidermis
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Figure 4 Epidermal CD2 and 
CD25 positive lymphocytes, both 
activationmarkers and NK-T cells 
CD94 (MHC-I bound) and CD161 
(not MHC-I bound) in the centre, 
inner margin, outer margin and 
distant uninvolved skin of the 
spreading psoriatic lesion. (Mean 
± SEM)  
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Figure 5 Dermal Th-cells (CD4), 
Tc-cells (CD8), effector memory 
T-cells (CD45RO) and naive T-
cells (CD45RA) in the centre, inner 
margin, outer margin and distant 
uninvolved skin of the spreading 
psoriatic lesion. (Mean ± SEM)  
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Figure 6 Dermal CD2 and CD25 
positive lymphocytes, both 
activationmarkers, and NK-T 
cells CD94 (MHC-I bound) and 
CD161 (not MHC-I bound) in the 
centre, inner margin, outer margin 
and distant uninvolved skin of the 
spreading psoriatic lesion. (Mean ± 
SEM)
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Centre/ Inner margin Inner margin/ Outer 
margin 
Outer margin/ Distant 
uninvolved 
p-value 
(epi/derm) 
ratios (epi/
derm) 
p-value 
(epi/derm) 
ratios 
(epi/
derm) 
p-value 
(epi/derm) 
ratios 
(epi/
derm) 
K10 0.24 1.12 0.054 0.75 0.72 1.03 
Ki67 0.011 0.75 0.00018 3.53 0.20 1.72 
CD4 0.47/0.43 0.90/1.12 0.063/0.0006 2.21/1.45 0.21/0.43 1.30/1.45 
CD8 0.71/0.93 1.060/0.96 0.0091/0.021 3.34/2.08 0.39/0.53 3.48/1.51 
CD45RO 0.46/0.41 1.18/1.16 0.011/0.29 2.96/1.26 0.18/0.065 4.33/1.86 
CD45RA 0.47/0.98 0.83/0.99 0.017/0.013 2.67/2.58 0.53/0.66 1.65/1.33 
CD2 0.68/0.22 1.08/1.27 0.0084/0.18 2.36/1.42 0.10/0.24 4.87/1.58 
CD25 0.88/0.0017 0.93/1.48 0.00018/0.42 2.95/1.29 0.66/0.067 8.33/1.85 
CD94 0.53/0.90 0.80/1.030 0.012/0.014 8.42/3.23 0.70/0.456  */2.75 
CD161 0.59/0.45 1.11/1.119 0.0049/0.031 9.55/2.43 0.98/0.66 2.00/2.01 
Table 1 p-Values and ratios for the centre versus the inner margin, the inner versus the outer 
margin and the outer margin versus the distant uninvolved skin (the signiﬁcant p-values are 
shown in bold, * = no data, NS = not signiﬁcant).   
Figure 7 T-cell markers in the outer 
margin and distant uninvolved skin of 
spreading psoriatic lesions; CD45RO+ T-
cells in the outer margin (A) and distant 
uninvolved skin (B), CD8+ T-cells in the 
outer margin (C) and distant uninvolved 
skin (D), CD2+ T-cells in the outer 
margin (E) and distant uninvolved skin 
(F) and ﬁnally CD25+ T-cells in the outer 
margin (G) and distant uninvolved skin 
(H). (Magniﬁcation 50X)
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outer margin. In ﬁgure 8 representative immunostained sections for Ki67 positive 
epidermal cells, CD94+ cells and CD161+ cells in the inner margin and outer margin 
are shown.
 The centre versus the inner margin did not show a signiﬁcant change for the 
percentage K10 positive epidermal surface. However the number of Ki-67 positive 
keratinocytes was signiﬁcantly decreased in the centre as compared to the inner 
margin (p<0.05). For the inﬂammatory markers there was no statistically signiﬁcant 
change when comparing the number of positive cells in the centre and inner margin, 
with the exception of a decrease of dermal CD25+ T-cells in the centre (p<0.01).
Discussion   
In the outer margin (early lesion) there was a substantial increase when compared to 
the distant uninvolved skin of the number of epidermal CD8+ (ratio: 3.48), CD45RO+ 
(ratio: 4.33), CD2+ (ratio: 4.87) and CD25+ (ratio: 8.33) T-cells (table 1). It is 
attractive to speculate that especially those T-cell subsets play an important role in 
the early pathogenesis of psoriasis. Chang et al. found that mainly CD8+ T-cells, and 
not CD4+ T-cells are clonally expanded in the psoriatic lesion, and therefore might 
have a role as effector.22 This is in agreement with our ﬁnding of markedly increased 
numbers of CD8+ positive T-cells in the outer margin (early lesion) as opposed to the 
distant uninvolved skin. The blocking by alefacept of the LFA3-CD2 interaction has a 
substantial effect on the memory effector (CD45RO) T-cell population. The subsequent 
decrease of CD45RO+ T-cells is correlated with the amelioration of psoriasis. In the 
present study we found increased levels of both CD25+, CD2+ and CD45RO+ T-cells 
in the outer margin of the spreading psoriatic lesion, suggesting that these T-cells have 
Figure 8 Ki-67 positive epidermal cells 
and cells expressing NK-receptors in 
the inner and outer margin of spreading 
psoriatic lesions; Ki67 positive epidermal 
cells in the inner margin (A) and outer 
margin (B), CD94+ cells in the inner 
margin (C) and outer margin (D) and 
ﬁnally CD161+ cells in the inner (E) and 
outer margin (F). (Magniﬁcation 50 X) 
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an important role in an early phase of psoriasis, which might explain the therapeutic 
effects of for instance Alefacept and Basiliximab in plaque psoriasis (anti-CD25).12;14 
Regarding proliferation (Ki-67 positive keratinocytes) and differentiation (percentage 
K10 positive epidermal surface) there was no statistical signiﬁcance found between 
the outer margin and the distant uninvolved skin. This is in agreement with earlier 
ﬁndings by Mommers et al.2
 The inner margin, when compared to the outer margin, did show a statistically 
signiﬁcant increase of Ki-67 positive keratinocytes per mm. basement membrane. The 
percentage K10 positive epidermal surface did show a borderline signiﬁcant decrease. 
Mommers et al. also found a statistically signiﬁcant reduction of cells expressing K10, 
and increased levels of proliferating cells in the involved inner margin as compared to 
the uninvolved outer margin.2 The number of all T-cell subsets showed a signiﬁcant 
increase, with the exception of dermal CD45RO+, CD2+ and CD25+ T-cells. All T-
cell subsets did show high ratios of inner margin versus outer margin in the epidermis 
(between 2.21 and 9.55), especially cells expressing NK-receptors with a ratio as high 
as 8.42 for CD94 and 9.55 for CD161.(table 1)
 The signiﬁcant increase of CD94 and CD161 in the inner margin as 
compared to the outer margin extends the observations by Cameron et al.17 They found 
signiﬁcantly increased numbers of T-cells bearing NK-T cell receptors as opposed to 
uninvolved or normal skin. Several hypotheses have been postulated regarding the 
role of NK-T cell receptors in psoriasis. Nickoloff et al. stated that NK-T cells might 
play a role in the initiation of a psoriatic lesion. NK-T cells can be upregulated when 
the barrier function of the skin is disturbed and interact with bacterial superantigens. 
When NK-T cells enter the epidermis they interact with CD1d-bearing keratinocytes. 
After this interaction keratinocytes start to produce IFN-γ, in turn IFN-γ triggers 
an aberrant differentiation process in the epidermis.20;23  NK-T cells may on the 
other hand have an inhibitory or down regulatory effect.19 This is supported by the 
observation that reduced NK-T cell activity is a risk factor for auto-immune disease in 
a mouse model.24 Furthermore there is evidence that psoriatic patients have reduced 
levels of NK-T cells in peripheral blood.25 NK-T cells presumably migrate from 
the peripheral blood to the skin, to exhibit their inhibitory capacity in the psoriatic 
lesion. Aractingi et al. showed that the inhibitory ligand HLA-G for NK-receptors 
is exclusively expressed in psoriasis and has a downregulatory role in psoriasis.26 In 
addition, the aforementioned hypothesis is also supported by data from the present 
study. Whereas activated memory effector T-cells are abundantly present in the outer 
margin, cells expressing NK-receptors appeared with increased amounts in the inner 
margin, accompanying epidermal proliferation and abnormal keratinization.
When comparing the centre with the inner margin of the psoriatic lesion we observed 
a signiﬁcant decrease of the number Ki-67 positive keratinocytes per mm. basement 
membrane. There was no signiﬁcant decrease observed in the centre as compared to 
the outer margin for the various T-cell subsets.
 It can be concluded that especially CD8+, CD45RO+, CD2+ and CD25+ 
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T-cells are already markedly increased in the outer margin, whereas the proliferation 
and differentiation markers and the cells expressing the NK receptors CD94 and 
CD161 are still essentially normal when compared to the distant uninvolved skin. The 
statistically signiﬁcant increase of these markers in the inner margin as compared to 
the outer margin indicates that cells with NK-receptors are relevant in a later phase of 
the psoriatic process.    
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3.1 IMMUNOHISTOCHEMICAL DIFFERENTIATION 
BETWEEN INFLAMMATORY LINEAR VERRUCOUS 
EPIDERMAL NEVUS (ILVEN) AND PSORIASIS; A CASE 
REPORT. 
Summary
Background  Inﬂammatory linear verrucous epidermal nevus (ILVEN) is a rare skin 
disorder with a clinical and histological resemblance to psoriasis. In the past clinical 
and histological criteria have been deﬁned. However, there remains to be a discussion 
whether ILVEN is a disease entity distinct from linear psoriasis.
Objectives To compare by quantitative immunohistochemistry the subsets of T-
lymphocytes and markers for epidermal growth and keratinisation in biopsies taken 
from skin lesions of 4 patients with psoriasis and 3 patients with ILVEN: 1. patients 
with psoriasis (case 1-4) 2. patient with ILVEN cum psoriasis (case 5) 3. patients 
with ILVEN sine psoriasis (case 6 and 7). Our aim was to delineate ILVEN from 
psoriasis.
Methods Four patients with active psoriasis and three patients with signs and symptoms 
of ILVEN are described in this case report. Two patients of the ILVEN group had only 
linear verrucous lesions (ILVEN sine psoriasis), and one patient had linear lesions 
combined with widespread psoriasis outside the linear verrucous lesion (ILVEN cum 
psoriasis). The following markers were investigated in skin biopsies taken from the 
aforementioned patients by quantitative immunohistochemistry: CD2, CD4, CD8, 
CD25, CD161, CD94, CD45RO, CD45RA, HLA-DR, Keratine-10, Ki-67. 
Results In patients with ILVEN (cum and sine psoriasis) the number of Ki-67 positive 
nuclei, tended to be lower, the percentage of keratin-10 positive cells and HLA-DR 
expression higher as compared to psoriasis. In ILVEN sine psoriasis all T-cell subsets 
and cells expressing NK receptors were reduced as compared to psoriasis, except for 
CD45RA+ cells, whereas in the patient with ILVEN cum psoriasis the number of 
these T cell subsets had an intermediary position. In particular the density of CD8+, 
CD45RO+ and CD2+, CD94+ and CD161+ showed a marked difference between 
ILVEN sine psoriasis and psoriasis.  
Conclusions In addition to the increased keratin 10 expression in ILVEN sine psoriasis, 
T cells relevant in the pathogenesis of psoriasis are markedly reduced in ILVEN sine 
psoriasis as compared to psoriasis. T-cells subsets in ILVEN cum psoriasis had an 
intermediary position.
Introduction
Inﬂammatory linear verrucous epidermal nevus (ILVEN) is a rare skin disease 
characterized by  unilateral lichenoid, verrucous or psoriasiform lesions. The lesions 
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coalesce to form plaques and linear bands and may have a clinical resemblance to 
psoriasis.1;2 
 In 1971 Altman and Mehregan deﬁned clinical criteria for the diagnosis 
ILVEN 3: early age onset; 4:1 predominance in females; frequent involvement of 
the left lower extremity; pruritus; distinctive inﬂammatory and linear appearance, 
following the lines of Blaschko; persistent lesions showing marked refractoriness to 
treatment.
 ILVEN and linear psoriasis have been compared and contrasted in literature. 
A difﬁculty has resulted from the fact that linear psoriasiform lesions may appear in 
patients with psoriasis; the linear lesions may resemble closely to ILVEN. In fact these 
linear lesions in psoriasis may be regarded as psoriasiform Blaschkitis, Koebnerized 
by a linear genetic defect. In patients with psoriasis who also have linear psoriasiform 
lesions the situation is complicated. Therefore, we deﬁned for comparative studies 
three groups of patients:
(i) Chronic plaque psoriasis
(ii) ILVEN cum psoriasis; ILVEN in psoriatic patients
(iii) ILVEN sine psoriasis; ILVEN in patients without signs of psoriasis
 Histopathological criteria for the diagnosis ILVEN were deﬁned by Dupré 
and Cristol in 1977.4 In addition to the psoriasiform features, including epidermal 
acanthosis with elongated rete ridges, focal parakeratosis, elongation of dermal 
papillae and a mixed, predominantly lymphocytic inﬁltrate, they described distinct 
areas of hypergranulosis with overlying orthokeratosis to alternate with areas of 
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1 35  7  No  Yes  M Widespread Moderate Active
2 5  35  No  Yes  F Widespread Moderate  Active 
3 11  32  No  Yes  F
Psoriasis 
Inversa  
Moderate  Active 
4 40  26  No  Yes  M Widespread  ?  Active 
5 5  83  Yes  No  F
Right arm 
+  leg
 Intense  Stable 
6 At birth  16  Yes  No  M
right leg and 
buttocks 
Moderate  None 
7 25  23  Yes  No  M  right am  Intense  None 
Table 1 Clinical characteristics of patients with ILVEN and psoriasis.
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agranulosis with overlying parakeratotic hyperkeratosis in ILVEN. However others 
stated that this is not a pathognomonic feature of ILVEN.5 
 Because of the lack of generally accepted pathognomonic features of ILVEN 
it remains to be difﬁcult to distinguish ILVEN from linear psoriasis both clinically 
and histopathologically.5 Previously de Jong et al. concluded that the absence of 
neutrophils and a normal expression of keratin 10 are in favour for the diagnosis 
ILVEN.6 Welch et al. stated that ILVEN shows another pattern of clonal dysregulation 
than other linear epidermal naevi.7 
 As psoriasis can be regarded as a T-lymphocyte driven disorder, it is 
attractive to speculate that analysis of T-lymphocyte subsets may help to unravel the 
ever-remaining question whether ILVEN can be regarded as a disease entity distinct 
from psoriasis. 8;9
 The aim of the present case-report is to compare by quantitative 
immunohistochemistry the number and composition of the T-lymphocyte inﬁltrate 
of patients with clinical and histological hallmarks of ILVEN with patients bearing 
clinically and histologically the characteristics of psoriasis. Furthermore, we compared 
the degree of proliferation and differentiation in these conditions. 
Case-reports
Clinical characteristics of the studied cases are summarized in table 1. Furthermore 
the general histological observations are mentioned in table 2.
Cases 1-4: Patients with psoriasis.
Patients with classical plaque psoriasis, covering at least 15 % of the body, participated 
in this study. Two male and two female patients, aged between 42 and 56 years old 
had active psoriasis with a fairly symmetrical distribution, not arranged according to 
Patiënt Papillo-
matosis
Acant-
hosis
Epidermal 
PMN
Hyper-
keratosis 
Inﬂamm. 
Inﬁltrate
Histological 
diagnosis
1 ++ ++ + + Epi./derm. Psoriasis 
2 ++ + - - Epi./derm. Psoriasis 
3 + + + - Epi./derm. Psoriasis 
4 + + + + Epi./derm. Psoriasis 
5 ++ ++ - - Epi./derm ILVEN + 
Psoriasis 
6 + ++ - - Derm. ILVEN 
7 + + - - Derm. ILVEN
Table 2 Histological characteristics of patients with ILVEN and psoriasis. 
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linear patterns. Case 1 and case 4 had lesions over the head, trunk and extremities. 
One of them (case 1) suffered in addition from lesions over the axillae and groins, had 
swellings of the distal interphalangeal joints, onycholysis of the nail plate and nail 
pitting. Furthermore case 1, case 3 and case 4 experienced substantial itch. Case 2 had 
widespread nummular lesions over her body and case 3 had also lesions over her body 
except for her back and extremities. Biopsies from all four patients had histopathologic 
features that could be designated to psoriasis. They all showed papillomatosis and 
acanthosis, and a dermal as well as pronounced epidermal inﬁltrate. Case 1, 3 and 4 
had epidermal polymorphonuclear leukocytes. Case 1 and 4 showed also extensive 
hyperkeratosis. The four patients had responded well to topical or systemic treatment 
in the past. Case 3 and case 4 had received UVB-therapy. Case 1 had received 
methotrexate in the past. At the time of biopsies patients were in a stable phase of 
their disease. During the last two weeks they had applied no topical treatments and 
had not taken any systemic treatments for at least 4 weeks.
 
Case 5: Patient with ILVEN cum Psoriasis
Case 5 was an 89 year-old female who had extensive erythematosquamous verrucous 
lesions over her body, according to linear patterns following the lines of Blaschko since 
she was 5 years old (Figure 1). The lesions were linearly arranged on her right arm, 
right leg and right half of the thorax. She suffered from severe pruritis at these sites. 
The biopsy material from the linearly arranged lesions was compatible with ILVEN. 
Extensive hyperkeratosis papillomatosis and acanthosis were seen. Parakeratosis with 
underlying agranulosis was also seen. Furthermore this patient had also developed 
Figure 1  89 year old female (case 5) 
who had extensive erythemato-
squamous verrucous lesions over 
her body and right leg, according to 
linear patterns following the lines of 
Blaschko.
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over her body erythematosquamous lesions, not arranged according to linear patterns 
clinically compatible with psoriasis.
 Because topical treatment and UVB therapy were failing, it was decided to 
perform multiple excisions of the linear lesions. The psoriatic lesions, not arranged 
according to a non-linear pattern, did respond well to dithranol and PUVA therapy in 
the past.  
Case 6 and 7: Patients with ILVEN sine psoriasis.
These cases exclusively had linear lesions without any sign of psoriasis on other 
parts of the body. Case 6 (ﬁgure 2) was a 16 year-old boy with a sharply demarcated 
erythematosquamous and verrucous skin lesion on the right leg and right buttocks, 
following the lines of Blaschko. This skin lesion was present at birth and progressed 
over the years . Histopathologically the lesion was compatible with ILVEN. Acanthosis 
and papillomatosis could be observed however no pronounced epidermal inﬁltrate was 
noticed. There was alternation of parakeratosis with agranulosis and orthokeratosis 
with hypergranulosis. Therapy with topical corticosteroids, cryotherapy, vitamin D 
derivatives and dithranol were not successful.
 Case 7 was a 49 year-old male with linear erythematosquamous lesions, 
which appeared at the age of 25. The lesions were localised on the left arm and axilla 
and followed the lines of Blaschko. They caused severe itch. Because cryotherapy and 
several topical therapies were not successful, the lesions were excised. Histopathology 
was compatible with ILVEN. Acanthosis and papillomatosis with sparse inﬁltrate and 
without a pronounced epidermal inﬁltrate were present. Parakeratosis with agranulosis 
Figure 2 16 year old boy (case 6) with 
linearly arranged sharply demarcated 
skin lesions following the lines of 
Blaschko over the right leg.
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could also be seen. Biopsies were taken from both patients, when the lesions were in 
a stable phase. 
Material and Methods
Biopsies were taken from lesional skin of four patients with active psoriasis and three 
patients with ILVEN. Biopsies were prepared for immunohistochemical staining 
of the following markers: cytokeratine 10 (marker for epidermal differentiation), 
Ki-67 (a marker for proliferation), CD2 (predominantly expressed on activated T-
lymphocytes), CD4 (T-helper lymphocytes) CD8 (cytotoxic T-lymphocytes), CD25 
(Il-2 receptor, expressed on activated T-lymphocytes), CD161 (NK-receptor, not 
bound to MHC), CD94 (NK-receptor bound to MHC), CD45RO (effector memory 
T-lymphocyte) CD45RA (naive T-lymphocyte).
 Sections were sliced 6 um thick and were air-dried for 30 minutes. Then the 
sections were ﬁxated in cold acetone for 10 minutes. After blocking for endogenous 
peroxidase (1% H2O2/Na-azide in 1% BSA/PBS), they were washed in PBS for 
10 minutes and incubated  with 20% normal horse serum (Vector laboratories, 
Burlingame, USA). Subsequently sections were incubated with the primary antibodies 
for 1 hour. The following primary antibodies (mouse anti-human) were used, diluted 
in 1% bovine serum albumin (Organon, Technika, Boxtel, Netherlands)/PBS, anti-
CD2 (1:50) (clone MT910), anti-CD4 (clone MT310) (1:25), anti-CD8 (clone DK25) 
(1:25), anti-CD45RO (clone UCHL1) (1:25), anti-CD45RA (clone 4KB5) (1:25), 
anti-CD94 (clone HP-3D9) (1:25), anti-CD25 (clone ACT-1) (1:25), Ki-67 (clone 
MIB-1)  (1:100), anti-HLA-DR (clone TAL.1B5) (1:50) (all obtained from DAKO, 
Copenhagen Denmark), keratine-10 (clone RKSE60) (1:200) (Monosan laboratories 
Uden Netherlands), anti-CD161 (clone IM3450) (1:25) (Immunotech Marseille 
France). Sections were washed in PBS for 15 minutes. Secondary IgG horse anti-
mouse biotinylated antibody (ABC- kit-mouse, Vector laboratories Burlingame 
USA)(dilution 1:200 in 1% BSA/PBS) was added for 30 minutes. The sections were 
washed for 15 minutes in PBS and this step was followed by incubation with avidin-
biotin complex (ABC kit-mouse, Vector Laboratories Burlingame USA) (avidin/biotin 
diluted 1:50 in 1 % BSA/PBS) To visualize the staining we used enhanced DAB as 
chromogen (DAB+ kit from DAKO). Counterstaining was performed with Mayer’s 
Haematoxylin (Sigma St Louis USA). Furthermore from each patient we performed 
a hematoxiline-eosine staining. After dehydration in alcohol and histosafe, sections 
were mounted in Permount. 
 
Image analysis
Of each section digital photographs were made at 50X magniﬁcation, except for Ki67 
staining we used 100X magniﬁcation. We made three representative photographs 
of the sections per marker. Each photograph was analysed using IP-lab software. 
For quantiﬁcation of the number of cells positive for CD2, CD4, CD8, CD45RO, 
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CD45RA, CD25, CD161 and CD94 we used the following procedure: After choosing 
a representative “region of interest”(ROI), all positive segments in the ROI are marked 
with a colour and counted. The ROI is chosen in the centre of the section. Epidermis 
and a zone of dermis up to 100 um under the basement membrane were taken within 
the ROI. Dermal and epidermal inﬁltrate was counted separately. Quantiﬁcation was 
measured as unit: Positive cells per mm2.
 For quantiﬁcation of Ki67-antigen positive nuclei we used the following 
procedure: A line following the stratum basale was drawn and all positive cells above 
this line were counted. Quantiﬁcation was done in the unit: Positive cells per mm 
length of basement membrane.
 For quantiﬁcation of keratine-10 positive cells and HLA-DR positive cells 
we used the following procedure: Counting keratine-10 surface we only took the 
epidermal compartment as ROI. We subtracted dermal surface if it was present in 
the epidermal compartment. For HLA-DR we took the same ROI as for the other 
inﬂammatory markers. Quantiﬁcation was measured as a % of ROI as unit. 
Immunohistochemical results
The psoriatic lesions as compared to the lesions in ILVEN showed the well-established 
immunohistochemical features characterized by elevated numbers of Ki-67 positive 
nuclei, a reduced expression of K10 positive cells, HLA-DR expression and a marked 
expression of T-lymphocyte subsets (table 3, ﬁgure 3).
 Comparison of psoriasis vulgaris (cases 1-4) with ILVEN cum psoriasis 
(case 5) and ILVEN sine psoriasis (cases 6-7) revealed that the number of Ki-67 
positive nuclei tended to be lower in ILVEN sine psoriasis and ILVEN cum psoriasis, 
as compared to psoriasis; The percentage of keratin-10 positive epidermal surface 
was markedly lower in psoriasis as compared to both ILVEN phenotypes; HLA-DR 
expression tended to be more prominent in ILVEN sine psoriasis and ILVEN cum 
psoriasis as compared to psoriasis. 
The number of T-cell subsets and cells expressing NK receptors has been summarized 
Psoriasis ILVEN cum 
psoriasis
ILVEN sine
psoriasis
Mean % of  keratine-10 positive 
surface in epidermis. 
41,6 ± 10 (SD) 61,5 63,3 ± 8,03 (SD)
Mean number of Ki-67 positive 
nuclei per mm.
198,4 ± 39 (SD) 105,56 165,86 ± 36,22 
(SD)
Mean % of HLA-DR positive 
surface in dermis and epidermis. 
19,01 ± 4,13 
(SD)
47,20 22,70 ± 9,29 
(SD)
Table 3 The percentage keratin-10 positive surface, the number of Ki-67 positive cells per mm. 
basement membrane and the percentage HLA-DR positive surface in psoriasis, versus ILVEN 
cum psoriasis, versus ILVEN sine psoriasis.
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in ﬁgure 3. It can be seen that in epidermis and dermis CD4+, CD8+, CD45RO+, CD2+, 
CD25+, CD94+ and CD161+ cells were lower in ILVEN sine psoriasis as compared to 
psoriasis. Reconciling exclusively the epidermis grosso modo a similar picture is seen. 
A remarkable reduction of CD8+, CD45RO+, CD2+, CD25+, CD94+ and CD161+ 
cells were lower in ILVEN sine psoriasis as compared to psoriasis. Comparing ILVEN 
cum psoriasis with psoriasis on one hand and ILVEN sine psoriasis on the other hand 
the T-cell counts were intermediary. Considering dermis and epidermis the number of 
all T-cell subsets in ILVEN cum psoriasis approached the density in ILVEN without 
psoriasis, with the exception of CD2+ cells, which approached the counts found in 
psoriasis. Considering the epidermis only, ILVEN cum psoriasis had an intermediary 
density of T-cells between psoriasis and ILVEN sine psoriasis, with the exception of 
CD45RO+ cells and CD25+ cells which where higher in ILVEN cum psoriasis, as 
compared to psoriasis.
Discussion
The present study reconﬁrms the validity of clinical and histopathological hallmarks 
for ILVEN, as deﬁned previously. Indeed 2 out of 3 patients had an early onset and 
all had longstanding disease, which proved to be refractory to antipsoriatic treatments 
without any indication of spontaneous improvement and all patients suffered from 
severe itch. The alternating pattern with ortho- and parakeratosis was observed 
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exclusively in case 6 and was not seen in case 5 and 7.
 In an earlier report the normal expression of keratin 10 was an important 
feature of ILVEN 6 and such was reconﬁrmed in the present study. (Table 3) Indeed a 
marked difference between psoriasis and ILVEN (cum and sine psoriasis) is evident. 
The proliferation marker Ki-67 tended to be lower in ILVEN (cum and sine psoriasis) 
but showed a considerable overlap. HLA-DR expression did not provide a clear 
differentiation between psoriasis and both presentations of ILVEN.
 In dermis and epidermis, CD4+, CD8+, CD45RO+, CD2+, CD25+, CD94+ 
and CD161+ cells were lower in patients with ILVEN sine psoriasis as compared to 
psoriasis. Reconciling the epidermis only, patients with ILVEN sine psoriasis had 
major reductions of CD8+, CD45RO+, CD2+, CD94+ and CD161+ cells as compared 
to psoriasis. It is intriguing that, as compared to psoriasis patients with ILVEN sine 
psoriasis have a major reduction of these immunocytes which have been supposed 
to play a crucial role in the pathogenesis of psoriasis as well as a primary target for 
antipsoriatic treatments.10; 11 Indeed recently it was shown that a selective reduction of 
CD45RO+ T-cells could be induced by inhibition of the LFA3-CD2 interaction, which 
at same time ameliorated the psoriatic lesions.12
 Case 5 is a presentation of ILVEN in a psoriatic patient. The linear lesions 
in this patient may well represent a Koebner phenomenon to a pre-existing genetic 
mosaicism. Although  the present report describes only one single case, a preliminary 
conclusion might be that the ILVEN lesion in this patient is characterized grosso modo 
by densities of T-cell populations in between psoriasis and ILVEN.
 In conclusion, the previously reported increased expression of Keratin 10 
in ILVEN as compared to psoriasis was conﬁrmed. In ILVEN sine psoriasis, T-cell 
subsets relevant in the pathogenesis of psoriasis are markedly reduced as compared to 
psoriasis. In ILVEN cum psoriasis T-cell subsets and cells expressing NK-receptors 
had an intermediary position. Therefore, T-cell targeted treatments are unlikely to be 
of beneﬁt in patients with ILVEN.
Chapter 3 - Special expressions of psoriasis
100
Reference List
1. Cheesbrough MJ, Kilby PE. The inﬂammatory linear verrucous epidermal naevus--a case 
report. Clin.Exp.Dermatol. 1978; 3: 293-8.
2. Altman J, Mehregan AH. Inﬂammatory linear verrucose epidermal nevus. Arch.Dermatol. 
1971; 104: 385-9.
3. Rogers M, McCrossin I, Commens C. Epidermal nevi and the epidermal nevus syndrome. 
A review of 131 cases. J.Am.Acad.Dermatol. 1989; 20: 476-88.
4. Dupre A, Christol B. [Bilateral inﬂammatory linear verrucous epidermal nevus localized 
on the lip and with minimal histological lesions]. Ann.Dermatol.Venereol. 1977; 104: 
163-4.
5. Menni S, Restano L, Gianotti R et al. Inﬂammatory linear verrucous epidermal nevus 
(ILVEN) and psoriasis in a child? Int.J.Dermatol. 2000; 39: 30-2.
6. de Jong E, Rulo HF, van de Kerkhof PC. Inﬂammatory linear verrucous epidermal naevus 
(ILVEN) versus linear psoriasis. A clinical, histological and immunohistochemical study. 
Acta Derm.Venereol. 1991; 71: 343-6.
7. Welch ML, Smith KJ, Skelton HG et al. Immunohistochemical features in inﬂammatory 
linear verrucous epidermal nevi suggest a distinctive pattern of clonal dysregulation of 
growth. Military Medical Consortium for the Advancement of Retroviral Research. J.Am.
Acad.Dermatol. 1993; 29: 242-8.
8. Gatti S, Carrozzo AM, Orlandi A et al. Treatment of inﬂammatory linear verrucous 
epidermal naevus with calcipotriol. Br.J.Dermatol. 1995; 132: 837-9.
9. de Mare S, van de Kerkhof PC, Happle R. Dithranol in the treatment of inﬂammatory 
linear verrucous epidermal nevus. Acta Derm.Venereol. 1989; 69: 77-80.
10. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch.Dermatol. 1999; 135: 
1104-10.
11. Gottlieb AB. Immunologic mechanisms in psoriasis. J.Invest Dermatol. 1990; 95: 18S-
9S.
12. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic 
agents. J.Am.Acad.Dermatol. 2002; 46: 1-23.
Chapter 3 - Special expressions of psoriasis
101
3.2 FLEXURAL VERSUS PLAQUE LESIONS IN PSORIASIS: 
AN IMMUNOHISTOCHEMICAL DIFFERENTIATION.
Summary
Background Clinical presentation, therapeutic options, micro-environment and 
HLA-typing have been reported to be different in ﬂexural psoriasis as compared to 
plaque psoriasis. We were interested in any difference concerning the pathogenesis 
of both conditions. By analysing T-cell subsets, NK-T cells and proliferation and 
differentiation markers insight in the pathogenesis of both subtypes was obtained.
Objectives Quantitative study of T-cell subsets, cells expressing NK-receptors and 
markers of proliferation and differentiation in ﬂexural and plaque psoriasis. 
Methods Biopsies from 6 patients with both ﬂexural and plaque lesions were obtained 
and processed for immunohistochemistry. Several T-cell subsets were stained: 
CD4+, CD8+, CD2+, CD25+, CD45RO+ and CD45RA+ T-cells. In addition cells 
expressing NK receptors were stained: CD94+ cells and CD161+ cells. T-cell subsets 
and cells expressing NK-receptors were analysed by immunohistochemical scoring. 
The proliferation marker Ki-67 and differentiationmarker keratin-10 were revealed 
immunohistochemically by respectively MIB-1 and RKSE60. Both markers were 
analysed using quantitative image analyses.
Results The number of Ki-67 positive nuclei and the percentage of keratin-10 positive 
epidermal cells in ﬂexural an plaque psoriasis were comparable. There is no difference 
between ﬂexural and plaque psoriasis concerning other T-cell subsets. However a 
highly signiﬁcant reduction is seen in ﬂexural psoriasis with respect to CD161+ cells 
in the dermis.
Conclusions The similarity of chronic plaque psoriasis compared to ﬂexural psoriasis 
with respect to T-cell subsets, epidermal proliferation and keratinization suggests that 
both conditions are pathogenetically identical. We propose the decreased ammount 
of lesional CD161+ cells in the dermis of ﬂexural psoriatic lesions may result from 
chronic microbial challenge in ﬂexural psoriasis.
Introduction
Chronic plaque psoriasis is the most frequent manifestation of psoriasis. The well-
known predilection sites are the extensor surfaces of the elbows and knees, the scalp 
and the regio sacralis. Flexural psoriasis is another manifestation of psoriasis. Its 
prevalence is about 2-6% of the patients with psoriasis and this condition is more 
common in adults than in children. 1-3 Areas involved are the axillae, groins, gluteal 
clefts and submammary folds. Scaling, a typical sign of plaque psoriasis, is mostly 
absent in ﬂexural psoriasis. Lesions of inverse psoriasis tend to be more erythematous 
as compared to chronique plaque psoriasis. Patients with ﬂexural psoriasis have a 
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higher frequency of palmar involvement as compared to patients with chronic plaque 
psoriasis.4 
 Karvonen et al. postulated that ﬂexural psoriasis is genetically distinct from 
plaque psoriasis. They found different HLA types in the group of patients with ﬂexural 
psoriasis as compared to plaque psoriasis.5
 In the pathogenesis of psoriasis, bacterial overgrowth and mycotic infections 
have been indicated as triggering factors.6 It has been shown by Kanda et al. that 
several fungi inﬂuence cytokine production by peripheral blood mononuclear cells in 
psoriatic patients. They also showed that Malassezia furfur was able to induce a Th1 
skewed response in psoriatic patients.7 Several studies showed the immunomodulatory 
effects of fungi. 8-10 Bacterial overgrowth is a well established feature of ﬂexural 
psoriasis, however the association between mycotic infections and ﬂexural psoriasis is 
less convincing.11-13 Furthermore it is hypothesized by some investigators that patients 
with psoriasis are protected against microbial super-infection by overexpression of 
human β-defensins.14-16
 In addition to the clinical, genetic and pathogenetic differences therapeutic 
responsiveness of ﬂexural and chronic plaque psoriasis is also different. Topical 
corticosteroids, and especially the more potent ones, are less well tolerated in ﬂexural 
psoriasis as compared to chronic plaque psoriasis. Local side effects such as athrophy, 
teleangiectasia and striae formation are often more pronounced in intertriginous 
areas because these areas are more sensitive to corticosteroid penetration.17;18 If 
a corticosteroid is prescribed in ﬂexural psoriasis, a mild corticosteroid should be 
selected only for a short period and preferably this treatment is combined with another 
therapy, for example a vitamin D3 analogue.19 Several studies have demonstrated 
that the natural occuring, hormonally active form of vitamin D3, calcitriol, is better 
tolerated in ﬂexural psoriasis than the vitamin D3 derivative calcipotriol.20 The recently 
introduced calcineurin inhibitors tacrolimus and pimecrolimus have been shown to be 
efffective in the treatment of ﬂexural psoriasis.21;22 Freeman et al. demonstrated that 
topical tacrolimus ointment is a safe and effective nonsteroidal treatment of psoriasis 
in the facial and intertriginous areas.22 Treatment with imidazoles and antibacterial 
treatments are suggested to be effective in ﬂexural psoriasis. However solid evidence 
that antimycotic and antibacterial treatments are effective in ﬂexural psoriasis has not 
been provided so far. 
 Because of differences between ﬂexural psoriasis and chronic plaque 
psoriasis with respect to clinical presentation, microbial colonization and therapeutic 
responsiveness we posed the question whether ﬂexural psoriasis is pathogenetically 
different from chronic plaque psoriasis? In order to answer this question we carried 
out an inventory of T-cell subsets, cells expressing NK receptors and markers for 
epidermal growth and differentiation in ﬂexural and chronic plaque psoriasis. 
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Material and methods
Patients
Six patients with a combination of plaque psoriasis and inverse psoriasis participated 
in this study. Demographic data are shown in table 1. Furthermore, patients had 
stopped topical treatment 2 weeks before the investigation. Systemic treatment or UV-
radiation had been stopped at least one month before. They did not use any medication 
that could interfere with the severity of psoraisis. They did not use any “biological” 
in the past.
Clinical score and biopsy procedure
After receiving informed consent, the SUM-scores of two target lesions, one plaque 
lesion and one ﬂexural lesion, were assessed. Three millimetre punch biopsies were 
taken from the plaque lesion and from the inverse lesion. The SUM-score is a clinical 
score indicating the severity of a psoriatic plaque. He SUM-score comprises of three 
clinical parameters for erythema (0-4), scaling (0-4) and induration(0-4). Punch 
biopsies 4 mm in diameter were taken from the chronic plaque lesion and ﬂexural 
lesion after local anaesthesia. Biopsy specimens were stored at -80°C before use. 
Immunohistochemistry
The following markers were investigated;
(i) T-cell subsets: CD4, CD8, CD45RO, CD45RA, CD2 and CD25. 
(ii) Cells expressing NK receptors: CD94, CD161.  
(iii) Epidermal proliferation: Ki-67 positive keratinocytes.
(iiii)Epidermal differentiation: Keratine-10 positive epidermis. 
Biopsies were embedded in Tissue Tek OCT compound (Miles Scientiﬁc, Naperville, 
USA), snap frozen in liquid nitrogen and stored at –80°C until use.
Sections were sliced 6 μm thick and were air-dried for 30 minutes. Then the sections 
Sex Age Duration of 
disease 
PASI Former Treatment 
modalities 
Koebner 
M 45 31 years 13,4 Anthralin/ Vit.D3/
cortico’s
 + 
F 53 34 years 6,9 Cortico’s/ Vit. D3 -
M 60 24 years 12,4 Cortico’s/ Vit. D3 -
M 42 8 years 7,5 Cortico’s/ Vit. D3 -
M 47 uk 5,8 Cortico’s  + 
M 52  20 years 3,8  Vit. D3 -
Table 1 Demographic ﬁndings of patients. Treatments were all stopped before the start of the 
investigations, according to inclusion and exclusion criteria. 
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were ﬁxed in cold acetone for 10 minutes. After blocking 5 minutes for endogenous 
peroxidase, using 0.2% sodium azide, they were washed in PBS for 10 minutes. 
Subsequently sections were incubated with the primary antibodies for 1 hour. The 
following primary antibodies (mouse anti-human) were used, diluted in 1% bovine 
serum albumin (Sigma, St Louis, USA)/PBS: anti-CD2 (1:50) (clone MT910), anti-
CD4 (clone MT310) (1:25), anti-CD8 (clone DK25) (1:25), anti-CD45RO (clone 
UCHL1) (1:25), anti-CD45RA (clone 4KB5) (1:25), anti-CD94 (clone HP-3D9) 
(1:25), anti-CD25 (clone ACT-1) (1:25), Ki67 (clone MIB-1) (1:100),  (all obtained 
from DAKO, Copenhagen Denmark), keratine-10 (clone RKSE60) (1:100) (Monosan 
Laboratories Uden Netherlands), anti-CD161 (clone 191B8) (1:25) (Immunotech 
Marseille France).
 Sections were washed in PBS for 15 minutes. Secondary IgG labeled 
polymer, HRP anti-mouse EnVision+ (DAKO Copenhagen Denmark) was added 
for 30 minutes.23 The sections were washed for 15 minutes in PBS. To visualize the 
staining we used AEC + High Sensitivity Substrate Chromogen for 10 minutes (DAKO 
Copenhagen Denmark). Counterstaining was performed with Mayer’s Haematoxylin 
(Sigma St Louis USA). The sections were washed in tap water and dried. Sections 
were ﬁnally mounted in glycerol gelatin (Sigma St Louis USA). Furthermore, from 
each patient we performed a hematoxiline-eosine staining. After dehydration in 
alcohol and histosafe, these sections were mounted in Permount.
Immunohistochemical scoring
For the quantitative analysis of the T-lymphocyte markers we used the following 
procedure: One section of the slide is chosen and all immunocytes with 200 x 
magniﬁcation in the epidermal compartment are counted. Epidermal immunocytes in 
the stratum corneum are not counted. The immunocytes in the dermal compartment 
are also counted. Positive dermal T-lymphocytes are counted between the basement 
membrane and 100 um under the basement membrane. 
Image Analysis
For analysing Ki-67 positive keratinocytes three representative digital photographs 
are made at 100x magniﬁcation. Each photograph is analysed using IP-lab software. 
A line is drawn, with a known length, following the stratum basale, and all positive 
cells above this line are counted. Quantiﬁcation is done in the unit: positive cells per 
mm length of basement membrane.
 For quantiﬁcation of keratine-10 positive cells, photographs are made 
at 50x magniﬁcation. For counting the keratine-10 positive epidermal surface, 
only the epidermal compartment is used as region of interest (ROI). Using IP-lab 
software a deﬁned window is set for the analysis of the markers from an area which 
is representative for the section. This window is designated as Region of Interest 
(ROI). The dermal surface is substracted if it is present in the epidermal compartment. 
Quantiﬁcation is measured as a % of epidermal surface as unit.
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Statistical analysis
Student’s t-test was employed to determine that two populations (or representative 
measures from it) are equal. If the probability is < 0.05 one may assume that the 
populations are not equal
Results
The SUM scores of the chronic plaque lesions were 7.83 ± 0.31 (mean ± SEM) and 
for the ﬂexural lesions 6.17 ± 0.31 (mean ± SEM). The p-value was 0.011, when 
comparing the clinical scores in plaque and ﬂexural psoriasis. The differences between 
these scores were largely due to the differences in scores for scaling.(table 2)
The number of Ki-67 positive nuclei and the percentage of keratin 10 positive 
keratinocytes in ﬂexural and plaque psoriasis are shown in ﬁgures 1 and 2. The 
differences between ﬂexural and plaque psoriasis with respect to the number of ki-67 
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Figure 2 Percentage Keratin 10 
positive epidermal surface (mean 
± SEM) in plaque psoriasis versus 
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Figure 1 Ki-67 positive nuclei in 
the epidermis per mm. basement 
membrane (mean ± SEM) in plaque 
versus ﬂexural psoriasis.
Plaque lesion Flexural lesion 
SUM-score 7.83 ± 0.31 6.17 ± 0.31 
Erythema 2.83 ± 0.17 3 ± 0 
Induration 2.33 ± 0.21 1.67 ± 0.21 
Scaling 2.67 ± 0.21 1.50 ± 0.22 
Table 2: Clinical scores for ﬂexural and chronic plaque lesions (mean ± SEM). p-value is 0.011 
for the difference in clinical SUM-score between ﬂexural and plaque psoriasis.
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positive nuclei and percentage keratin 10 positive cells were at the level of p=0.487 
and p=0.933 respectively, which implies not a statistical difference.
 T-cell subsets in ﬂexural and chronic plaque psoriasis are shown in ﬁgure 3 
and 4. It can be seen that the number of CD8+ T-cells in ﬂexural and plaque psoriasis 
are higher as compared to the number of CD4+ T-cells in the epidermis, and that the 
reverse is true for the dermis. The number of CD45RO+ T-cells is higher as compared 
to the number of CD45RA+ T-cells in epidermis as well as dermis. The p-values for 
differences between ﬂexural and plaque psoriasis are shown in table 3. It can be seen 
that there is even not a tendency for a difference between ﬂexural and plaque psoriasis 
with respect to the T-cell subsets investigated.
 Cells expressing NK receptors (CD94 and CD161) are shown in ﬁgure 3 
and 4. Epidermal CD94+ cells show a tendency to an increase in ﬂexural psoriasis 
as compared to plaque psoriasis. A highly signiﬁcant difference between ﬂexural and 
plaque psoriasis is observed with respect to CD161+ cells in the dermis. CD161+ 
cells in the dermis of ﬂexural psoriasis are markedly decreased as compared to plaque 
psoriasis.(p<0.001)
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Figure 4 Counts per mm (mean ± 
SEM) of T-cell subsets and cells 
expressing NK receptors  in the 
dermis of plaque and ﬂexural 
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Figure 3 Counts per mm (mean ± 
SEM) of T-cell subsets and cells 
expressing NK receptors in the 
epidermis of plaque and ﬂexural 
psoriasis.
p-waarde CD2 CD4 CD8 CD25 CD45RO CD45RA CD94 CD161 
epidermis 0,6432 0,8965 0,3208 0,6468 0,6563 0,7975 0,0486 0,7762 
dermis 0,6424 0,7621 0,9042 0,4915 0,4909 0,5271 0,3519 0,0098 
Table 3 p-values for differences between plaque psoriasis and ﬂexural psoriasis for T-cell 
subsets and cells expressing NK-receptors in the epidermis and dermis.
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Discussion
The present study shows that markers for epidermal proliferation and keratinization in 
ﬂexural- and plaque psoriasis are comparable in both conditions. Also T-cell subsets 
even did not show a tendency to a difference between ﬂexural and plaque psoriasis. 
The fact that CD45RO+ T-cells outnumber CD45RA+ T-cells and the dominancy of 
CD8+ T-cells in epidermis and CD4+ T-cells in the dermis in both conditions is totally 
in line with other studies on T-cell subpopulations in psoriasis.24-26
 In the light of the similarity between plaque psoriasis and ﬂexural psoriasis 
the differences in therapeutic responsiveness are most likely to be the result of 
differences in pharmaco- dynamics of the ﬂexural skin with respect to transepidermal 
penetration and the semi-occlusive effect of the ﬂexures.
 It is a well-established fact that bacterial overgrowth characterizes ﬂexural 
psoriasis. Microbial infections may act as a triggering factor7, although such a 
triggering effect may be restricted to some episodes of the initiation of ﬂexural lesions 
and may be of limited value as target for anti-psoriatic treatment. Due to up-regulation 
of β-defensins in psoriatic skin, the role of micro-organisms in the initiation and 
persistence of lesions in ﬂexural areas may be of less importance then in case of 
for instance atopic dermatitis, that lacks such up-regulation. This also explains the 
similarity in quantity and quality of the T-cell subsets in plaque and ﬂexural psoriasis, 
because β-defensins may counteract the microbial challenge in ﬂexural areas.
 NK-T-cells are an interphase between innate and adaptive immunity. In the 
present study, the presence of cells expressing NK receptors in the epidermis was 
comparable in plaque versus ﬂexural psoriasis. An unexpected ﬁnding was the highly 
signiﬁcant and substantial decrease of CD 161+ cells in the dermis of ﬂexural versus 
plaque psoriasis. It is attractive to speculate that chronic microbial challenge in 
ﬂexural psoriasis is counteracted by NK-T cells, resulting in a depletion of the dermal 
reservoir of these cells. 
 Additional studies on the regulation of NK-T cells in ﬂexural psoriasis may 
elucidate further the interaction of microbes with the immunopathogenesis of ﬂexural 
psoriasis.
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4.1 DITHRANOL CREAM HAS NO EFFECT ON LESIONAL T-
CELL SUBSETS DURING A 6-WEEK TREATMENT COURSE 
FOR PLAQUE PSORIASIS. 
Abstract
Dithranol is a classical treatment of chronic plaque psoriasis. Data from in vitro and 
some in vivo studies have shown that dithranol interferes with inﬂammatory processes 
in psoriasis. In the present study we investigated the effect of an outpatient dithranol 
scheme on T-cell subsets, epidermal proliferation and differentiation in relation to 
clinical efﬁcacy at day 0, day 7 and week 6.We investigated the following T-cell subsets 
by use of quantitative immunohistochemistry: CD4+, CD8+, CD45RO+, CD45RA+, 
CD2+ and CD25+ T-cells. Furthermore cells expressing NK-receptors were studied: 
CD161+ and CD94+ cells. For studying the number of Ki-67 positive cells per mm 
basement membrane and percentage K10 positive epidermal surface, image analysis 
was performed. We also investigated the HLA-DR expression. In relation to these 
immunohistochemical data, we analysed the SUM-score. Dithranol induced a highly 
signiﬁcant normalisation of K10 expression, which was already signiﬁcant at day 
7 and reduced signiﬁcantly the amount of cycling epidermal cells at week 6. The 
SUM-score also reduced signiﬁcantly between day 0 and week 6. No effect on T-cell 
subsets and cells expressing NK-receptors, was observed during treatment. The HLA-
DR expression was unchanged after 6 weeks of dithranol treatment. The well-known 
effect of dithranol on epidermal hyperproliferation and keratinisation is reconﬁrmed 
by this study. The in vivo effect of dithranol on T-cell subsets, extends previous studies 
showing no effect of dithranol on T-cells.
Introduction
Dithranol is a classical treatment of chronic plaque psoriasis. The precise mode of 
action of dithranol has not been discovered yet. There is evidence that superoxide 
anion radicals and hydroxyl radicals are the biochemical basis for the antipsoriatic 
action of dithranol. 1
 The primary target of dithranol is still unclear. Nevertheless it has been 
shown decades ago that dithranol inhibits DNA synthesis, possibly by interfering with 
cellular respiration.2;3  
 It has been shown that dithranol interferes with epidermal growth by inhibition 
of epidermal cyclic guanosine monophosphate, amongst other cellbiological processes 
wich are important for epidermal proliferation.4;5
 Furthermore, dithranol is believed to interfere with several inﬂammatory 
processes in psoriasis. This compound reduces the concentration of arachidonic acid in 
lesional psoriatic skin.6 Also mitogen induced Lymphocyte proliferation and neutrophil 
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chemotaxis is inhibited by dithranol.7 Moreover, it was shown that cytokine secretion 
from stimulated human monocytes was inhibited by dithranol.8 It was reported that 
dithranol stimulated keratinocyte-derived proinﬂammatory cytokines like GM-CSF, 
IL-6, IL-8 and TNF-α.9 At the receptor level, dithranol upregulates IL-10 receptors 
on the cultured human keratinocyte cell line HaCaT.10 Dithranol signiﬁcantly reduced 
K17 expression in an in vitro model for a presumptive IFN-γ/K17 autoimmune loop 
with human HaCaT keratinocytes.11
 In earlier studies, it was found that dithranol induced no change in epidermal 
pan-T-cells, although dermal pan-T-cells did show a signiﬁcant reduction in 4-8 weeks 
of treatment.12;13 Swinkels et al. showed a signiﬁcant reduction of polymorphonuclear 
leucocytes after 12 days of repeated application of dithranol cream, but no signiﬁcant 
reduction of pan-T-cells. Data on the effect of dithranol on T-cell subsets in psoriatic 
lesions indicate that pan-T-cells in the epidermis are not effected by dithranol, whilst 
the effect of dithranol on dermal pan-T-cells are at variance. Therefore we performed 
a study to elucidate the effect of dithranol on T-cell subsets relevant to psoriasis, using 
a quantitative immunohistochemical scoring. The scores were related to clinical effect 
and effect on markers for epidermal proliferation and differentiation
 In the present study we investigated the effect at day 7 and week 6 of an 
outpatient dithranol treatment on clinical and immunohistochemical data. We took 
biopsies in an early phase of treatment (day 7) and at 6 weeks and processed these for 
immunohistochemical analysis. We investigated the following T-cell subsets: CD4+, 
CD8+, CD45RO+, CD45RA+, CD2+ and CD25+ T-cells. Furthermore cells expressing 
NK-receptors were studied: CD161+ and CD94+ cells. As marker for proliferation the 
number of Ki-67 positive cells per mm basement membrane was counted, and as 
marker for differentiation the percentage increase of Keratin-10 positive epidermal 
surface was calculated using image analysis. In addition we investigated the HLA-DR 
expression at day 7 and week 6.  
Material and methods
Patients
Seven patients with plaque psoriasis participated in the present study. They received 
treatment with dithranol cream at the daycare unit of the University Medical Centre 
St Radboud Nijmegen, the Netherlands. Before inclusion patients gave their written 
consent. Exclusion criteria were: Use of topical treatment other than salicylic acid 
in the 2 weeks before start of the research; use of systemic treatment in the 4 weeks 
before start of the research; use of drugs inﬂuencing the course of psoriasis, like β-
blockers, Lithium, antimalarials and NSAID’s. Eventually 6 patients, divided in 4 
men and 2 women completed the study, because one patient switched to Calcipotriol 
treatment after 5 weeks topical dithranol therapy.
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Study design
Seven patients were treated with dithranol cream on an outpatient basis using a short 
contact scheme. The concentration of dithranol cream varied from 0.05 to 5.0%. The 
cream was applied in climbing concentrations. According to protocol, each cream 
concentration was applied for 3 days, from 15 to 30 to a maximum of 45 minutes. If 
no skin irritation developed after 9 days of dithranol application, the concentration 
was increased. After application the cream was removed with water and detergents. 
At baseline day, after 1 week and after 6 weeks, biopsies were taken from one of the 
two psoriatic target lesions. Before the biopsy procedure was performed, a clinical 
evaluation was done. The clinical assessment was done using the SUM- and PASI-
score. 
Immunohistochemistry
A standard protocol for immunohistochemical staining was used. In brief the 
following inﬂammatory markers were analysed: CD4 (T-helper cells) CD8 (cytotoxic 
T-cells), CD45RO (memory effector T-cells), CD45RA (naive T-cells), CD2 (co-
stimulatory receptor for LFA-3), CD25 (IL-2 receptor), CD161 (NK-T cell receptor), 
CD94 (NK-receptor). As marker for epidermal proliferation the number of Ki-67 
positive keratinocytes were analysed using image analysis. As marker for epidermal 
differentiation the percentage K10 positive epidermal surface was analysed.14 
Immunohistochemical scoring and image analysis
Immunohistochemical scoring was performed for the T-cell subsets and cells expressing 
NK-receptors, whereas markers of proliferation (Ki-67 positive keratinocytes) and 
differentiation (percentage K10 positive epidermal surface) were analysed using 
image analysis (IP-lab software). 14
Statistical analysis
For analysis between day 0, day 7 and week 6 we used the ANOVA test. If signiﬁcance 
was reached, a posthoc comparison of Duncan was used.
Results
In ﬁgure 1 the average reduction in SUM-score is shown. A signiﬁcant reduction of 
the SUM-score can be seen between day 0 and week 6 (p < 0.05). 
 The results for the proliferation marker Ki-67 are depicted in ﬁgure 2. The 
cycling epidermal cells reduced signiﬁcantly (p < 0.05) between day 0 and week 6. At 
day 7 there was no signiﬁcant reduction of Ki-67 positive cells. 
 In ﬁgure 3 the percentage keratin-10 positive epidermal surface in lesional 
psoriatic skin at day 0, 7 and week 6 is depicted. Between day 0 and week 6 there was 
a highly signiﬁcant increase of keratin-10 expression (p<0.01). Remarkably at day 7 
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there was already a signiﬁcant increase (p<0.05) of K10 expression. 
 In ﬁgures 4a/4b and 5a/5b the effect of dithranol cream on T-cell subsets in 
epidermis and dermis is shown. In epidermis as well as dermis there was no signiﬁcant 
reduction at day 7 or week 6 of T-cell subsets, with the exception of dermal CD8+ T-
cells at day 7 as compared to day 0.(p<0.05)
 Finally, the effect of dithranol on HLA-DR expression is depicted in ﬁgure 
6. Dithranol cream did not induce a signiﬁcant reduction of HLA-DR expression in a 
6- week treatment course.
Discussion
The present study reconﬁrms the impressive effect of dithranol on keratinisation and 
epidermal proliferation. In previous in vivo studies the antiproliferative effect and 
normalization of keratinisation by dithranol have been shown consistently. 12;15  It is 
intriguing that short contact dithranol treatment did not reduce HLA-DR expression 
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Figure 1 Average decrease in SUM-score 
(± SEM) at day 7 and week 6. At week 6 
there was a signiﬁcant reduction (p<0.05) 
of SUM-score by dithranol cream.
Figure 2 Signiﬁcant reduction of the 
average number of cycling epidermal 
cells (Ki-67 positive epidermal cells) 
per mm basement membrane (± SEM) at 
week 6 (p<0.05) by dithranol cream.
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Figure 3 Signiﬁcant increase of the 
percentage K10 positive epidermal 
surface (± SEM)  at day 7 (p<0.05) and 
week 6 (p<0.01) by dithranol cream.
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and did not affect the number of T-cell subpopulations, except for a transient fall of 
dermal CD8+ T-cells after 7 days of treatment. The clinical efﬁcacy was limited. At 
day 42 there was still a mean SUM-score of 4,33 (p<0.05). A high dose schedule 
might have had a more substantial effect on the clinical score. However the present 
mild dithranol schedule had a signiﬁcant effect on epidermal proliferation and 
keratinisation without a relevant effect on T-cell subsets. Representative images of the 
immunostained sections for the aforementioned markers are shown in ﬁgure 7. These 
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Figure 4a The effect by Dithranol cream 
on epidermal CD4+, CD8+, CD45RO+ 
and CD45RA+ T-cells. No signiﬁcant 
reduction of the average number of T-cell 
subsets is reached at day 7 or week 6(± 
SEM). 
Figure 4b The effect by Dithranol cream 
on epidermal CD2+and CD25+ T-cells and 
CD161+ and CD94+ cells. No signiﬁcant 
reduction of the average number of T-cell 
subsets (± SEM) and cells expressing NK-
receptors is reached, at day 7 or week 6. 
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Figure 5a The effect by Dithranol cream 
on dermal CD4+, CD8+, CD45RO+ 
and CD45RA+ T-cells. No signiﬁcant 
reduction of the average number of T-
cell subsets (± SEM) is reached, with 
the exception of CD8+ T-cells at day 7 
(p<0.05) as compared to day 0.
Figure 5b The effect by Dithranol cream 
on epidermal CD2+and CD25+ T-cells and 
CD161+ and CD94+ cells. No signiﬁcant 
reduction of the average number of T-cell 
subsets and cells expressing NK-receptors 
(± SEM) is reached at day 7 and week 6. 
Chapter 4 - Effect of established antipsoriatic treatments on T-cell subsets and other markers
118
data are in agreement with earlier ﬁndings by Swinkels et al. and van der Vleuten et 
al.12;15 They found that dithranol does not reduce epidermal T-cells in vivo, after 2 and 
4 weeks of treatment respectively. Data concerning dermal T-cells are at variance. 
Whereas van der Vleuten et al. found a signiﬁcant reduction of dermal T-cells after 
4 weeks, Swinkels et al did not ﬁnd a signiﬁcant reduction of dermal T-cells after 12 
days of treatment.12;15 
 Based on the present study and available literature it can be concluded that 
dithranol at therapeutic concentration has no signiﬁcant effect on pan-T-cells and the 
number of T-cell subsets in a 4 and 6 week treatment course. It is possible that the 
HLA-DR
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Figure 6 Reduction of HLA-DR 
expression (± SEM) by dithranol cream 
on day 7 and week 6. No signiﬁcant 
reduction of HLA-DR expression is 
reached.
Figure 7 Representative images of 
coupes immunostained for memory 
effector T-cells (CD45RO) before 
(A) and after treatment (B), cytotoxic 
T-cells (CD8) before (C) and 
after treatment (D), Ki-67 antigen 
before (E) and after treatment (F), 
and keratin10 before (G) and after 
treatment (H).
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irritancy induced by dithranol may cause the accumulation of T-cell subsets on the 
short term. Such may explain the discrepancy between the in vitro effects of dithranol, 
indicating immunosuppressive properties and the actual in vivo effects of dithranol. 
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4.2 THE EFFECT OF CALCIPOTRIOL OINTMENT TWICE-
DAILY VS BETAMETHASONE DIPROPIONATE OINTMENT 
TWICE-DAILY VS CALCIPOTRIOL AND BETAMETHASONE 
DIPROPIONATE ONCE DAILY ON EPIDERMAL 
PROLIFERATION, KERATINIZATION AND T-CELL SUBSETS 
IN CHRONIC PLAQUE PSORIASIS
Abstract
Several reports have indicated that the combination of calcipotriol ointment and potent 
or ultrapotent corticosteroids are more effective and better tolerated as compared to 
the monotherapies.
The aim of the present study was to ﬁnd out the effect of the combination of calcipotriol 
ointment once daily and betamethasone dipropionate ointment once daily vs the effect 
of twice daily applications of each of the two treatments as monotherapy during a 4-
week-treatment-period.
Seven patients with chronic plaque psoriasis were included for treatment with the 
three treatment schedules. Before treatment and after 4 weeks treatment biopsies 
were taken and markers for epidermal proliferation (Ki-67), epidermal differentiation 
(keratin-10) were studied using a quantitative image analysis and T-cell subsets in 
epidermis and dermis (CD4, CD8, CD25, CD45RO, CD45RA, CD94, CD161, CD2) 
were studied using immuno-histochemical scoring.
The most impressive clinical result was reached with the combination. Calcipotriol 
proved to have a major effect on the proliferation marker Ki-67 and differentiation 
marker keratin-10, whereas the effect on T-cell subsets was more selective with major 
reductions of CD45RO+ and CD8+ T-cells. In contrast, the effect of bethametasone 
dipropionate on the epidermis was restricted to a normalization of differentiation 
with a highly signiﬁcant increase of keratin-10 positive epidermal surface without 
a signiﬁcant effect on Ki-67 nuclei and the effect on T-cell subsets was restricted 
to a reduction of natural killer T-cell receptors designated by CD94  and CD161 in 
the epidermis. The combination of the two treatments did not affect the proliferation 
marker Ki-67 and keratinization marker keratin-10 beyond the effect of calcipotriol 
monotherapy. However, the combination had a profound effect on virtually all T-cell 
subsets beyond the effect of the monotherapies.
It is concluded that the action spectra of calcipotriol and betamethasone on the psoriatic 
plaque are different and that the combination has effects on T-cell subsets beyond the 
addition of the effects of monotherapies.
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Introduction
Topical treatment with calcipotriol as monotherapy or in combination with a potent 
or ultra potent topical corticosteroid has become the ﬁrst line treatment of psoriasis. 
The combination has been shown to be more effective and safe as compared to 
monotherapies. 1-3
 However, so far few reports are available on the mode of action of the 
combination of calcipotriol with a topical corticosteroid vs calcipotriol monotherapy 
and corticosteroid monotherapy. 
 The psoriatic lesion is characterized by epidermal proliferation (increased 
recruitment of cycling epidermal cells) abnormal keratinization with a decreased 
compartment of normally differentiated cells (keratin-10 positive epidermal surface) 
and inﬂammation with a prominent role of T-cells, in particular activated memory 
effector T-cells.4
 The effect of vitamin D3 analogues and corticosteroids on aspects of 
epidermal proliferation and keratinization as well as some T-cell subsets have been 
studied.5-12 However the conclusions from these studies are at varians. Furthermore 
the effect of the combination therapy on epidermal proliferation keratinization as well 
as T-cell subsets has not yet been investigated by immunohistochemistry. 
Therefore, a within subject study of three treatments was initiated to compare:
(i) The combination of calcipotriol ointment (50 micrograms/g) once daily and 
betamethasone dipropionate (0.64 mg/g) ointment once daily.
(ii) Calcipotriol (50 micrograms/g)  ointment twice daily.
(iii) Betamethasone dipripionate(0.64 mg/g) ointment twice daily.
The treatments were carried out during four weeks and a punch biopsy was taken 
before and after treatment from the test lesions, treated with the three schedules.
 One limitation of past studies was the lack of quantiﬁcation and uniformity in 
the assessment of immunohistochemical results. Recently, quantitative image analysis 
provided new possibilities for more reproducible scoring of immunohistochemical 
results. To study epidermal proliferation and differentiation we used quantitative 
image analysis. 
The following features were studied:
(i) Epidermal proliferation was assessed by counting de Ki-67 positive nuclei 
per mm basement membrane by quantitative image analysis, which characterizes 
those epidermal cells which have escaped from the resting G
o
 population. In previous 
studies it has been shown that this phenomenon is crucial to epidermal proliferation in 
psoriasis.13
(ii) Epidermal differentiation was studied by measuring the keratin-10 positive 
epidermal surface. In the psoriatic plaque the epidermal cell layers expressing keratin-
10 are reduced.
(iii) The T-cell is of major pathogenic signiﬁcance. Recently, speciﬁc T-cell 
targeted treatments have been shown to improve psoriasis. In early psoriasis CD4+ 
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T-cells and in chronic plaques CD8+ T-cells dominate.14 In particular activated T-cells 
(CD2 and CD25) belonging tot the memory effector subset (CD45RO) have been 
shown to play a major role. 4                                                                                        
 Natural killer cells, belonging to innate immunity have been suggested to be 
of relevance to psoriasis. The natural killer cell receptors on T-cells (CD94 and CD161) 
have been suggested to represent important cross talks between innate immunity and 
acquired immunity. 4;15;16
Methods
In our study 7 patients participated with stable plaque psoriasis with an extent of at 
least 5 %. They did not receive any systemic treatment for at least 4 weeks and no 
topical therapy for about two weeks before the start of the study. All patients were able 
to understand care instructions.
 They were asked to apply betamethasone dipropionate ointment two 
times a day to the psoriatic lesions at the right side of the body, the combination of 
betamethasone  dipropionate ointment once a day and calcipotriol ointment once a day 
to the lesions at the left side of the body and calcipotriol ointment twice a day to an 
arbitrary chosen lesion for four weeks long. After having applied the ointment of one 
treatment schedule, the patient was asked to wash his/her hands before applying the 
ointment for the other treatment schedule. Before and after treatment the target lesions 
were observed and scored for the degree of erythema, desquamation and induration. 
The score may range from slight, 1, to very severe, 4. The total score, of erythema, 
desquamation and induration, the SUM-score, was used for clinical assessment.
 Biopsies were taken from the three target lesions corresponding to the three 
different topical treatments. This was performed before and after treatment.
 Biopsies were embedded in Tissue Tek OCT compound (Miles Scientiﬁc, 
Naperville, USA), snap frozen in liquid nitrogen and stored at –80°C until use.
Sections were sliced 6 μm thick and were air-dried for 30 minutes. Then the sections 
were ﬁxed in cold acetone for 10 minutes. After blocking 5 minutes for endogenous 
peroxidase, using 0.2% sodium azide, they were washed in PBS for 10 minutes. 
Subsequently sections were incubated with the primary antibodies for 1 hour. The 
following primary antibodies (mouse anti-human) were used, diluted in 1% bovine 
serum albumin (Sigma, St Louis, USA)/PBS: anti-CD2 (1:50) (clone MT910), anti-
CD4 (clone MT310) (1:25), anti-CD8 (clone DK25) (1:25), anti-CD45RO (clone 
UCHL1) (1:25), anti-CD45RA (clone 4KB5) (1:25), anti-CD94 (clone HP-3D9) 
(1:25), anti-CD25 (clone ACT-1) (1:25), Ki67 (clone MIB-1) (1:100),  (all obtained 
from DAKO, Copenhagen Denmark), keratine-10 (clone RKSE60) (1:100) (Monosan 
Laboratories Uden Netherlands), anti-CD161 (clone 191B8) (1:25) (Immunotech 
Marseille France).
 Sections were washed in PBS for 15 minutes. Secondary IgG labeled polymer, 
HRP (anti-mouse) was added for 30 minutes. (Envision-kit: DAKO Copenhagen 
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Denmark)  The sections were washed for 15 minutes in PBS. To visualize the staining 
we used AEC + High Sensitivity Substrate Chromogen for 10 minutes (DAKO 
Copenhagen Denmark). Counterstaining was performed with Mayer’s Haematoxylin 
(Sigma St Louis USA). The sections were washed in tap water and dried. Sections 
were ﬁnally mounted in glycerol gelatin (Sigma St Louis USA). Furthermore, from 
each patient we performed a hematoxiline-eosine staining. After dehydration in 
alcohol and histosafe, these sections were mounted in Permount.
Immuno-histochemical scoring
Quantiﬁcation of the number of cells positive for CD2, CD4, CD8, CD25, CD45RO, 
CD45RA, CD94 and CD161 was performed. At 200X magniﬁcation positive cells in 
the epidermis were counted from the basement membrane up to the stratum corneum 
across the whole section. Cells in the dermis were counted from the basement 
membrane down to 100 um under the basement membrane also across the whole 
section. Quantiﬁcation was done in the unit: Positive cells per mm length.
Quantitative image analysis 
For K10 digital photographs were made at 50X magniﬁcation and for Ki67 digital 
photographs were made at 100X magniﬁcation. Each photograph was analyzed using 
IP-lab software. For quantiﬁcation of the number of cells positive for K10, we used 
the following procedure: After choosing a representative “region of interest”(ROI), all 
positive segments in the ROI were marked with a color and counted. We subtracted 
the present dermal surface in the ROI. The ROI is chosen in the center of the section. 
Quantiﬁcation was measured as a % of ROI as unit. 
 For Ki67 a line following the stratum basale was drawn after again choosing 
a ROI and all positive cells above this line were counted. Quantiﬁcation was done in 
the unit: Positive cells per mm length of basement membrane.
Statistical analysis 
We used a two-sided paired T-test to compare the number of positive cells,  % of 
K10 positive epidermal surface before and after treatment. P<0.05 was considered as 
statistical signiﬁcant. P<0.01 was considered as highly statistical signiﬁcant. 
Results
For all three treatment modalities, there was a signiﬁcant decrease in SUM-score. The 
mean percentage decrease in SUM-score was 71% for the combination therapy, 66% 
for betamethasone dipropionate and 67% for calcipotriol. Reduction of the SUM-
score for combination therapy gave the smallest p-value. (combination: p=6,57*10-7) 
(calcipotriol: p=9,5*10-6) (betamethasone dipropionate: p=2,97*10-5)
 There was a statistically signiﬁcant decrease in the number of Ki-67 
positive cells (proliferating keratinocytes) for the combination treatment (p<0.01) 
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and monotherapy with calcipotriol (p<0.001). (ﬁgure 1) There was no statistically 
signiﬁcant decrease of Ki-67 positive keratinocytes per mm basement membrane 
after monotherapy with betamethasone dipropionate. Concerning differentiation there 
was a statistically signiﬁcant increase of the keratin-10 positive epidermal surface 
after all three treatment modalities. For the two monotherapies, there was a highly 
signiﬁcant (p<0.001) increase of keratin-10 positive epidermal surface. (ﬁgure 2) For 
the combination, therapy the increase was also signiﬁcant (p<0.05). 
 All T-cell subsets decreased during treatment with the combination therapy 
(ﬁgure 3), betamethasone dipropionate ointment (ﬁgure 4) and calcipotriol ointment 
(ﬁgure 5).
 The combination resulted in a highly signiﬁcant reduction of CD8+, CD2+ 
and CD25+ T-cells in the epidermis and CD2+, CD25+ and CD94+ T-cells in the 
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Figure 1 Ki-67 positive keratinocytes 
per mm basement membrane before and 
after treatment with combination therapy 
(p<0.01), betamethasone dipropionate 
2dd (no statistical signiﬁcance) and 
calcipotriol 2dd (p<0.001, Mean ± SEM) 
Figure 2 K10 positive epidermal 
surface before and after treatment 
with combination therapy (p<0.05), 
betamethasone dipropionate (p<0.001) 
and calcipotriol (p<0.001, mean ± SEM )
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Figure 3a T-lymphocytes in the 
epidermis before and after combination 
therapy. CD8+, CD2+ and CD25+ T-
cell subsets did show a highly signiﬁcant 
decrease (p<0.01). CD4+, CD45RO+ and 
CD45RA+ T-cells did show a signiﬁcant 
decrease (p<0.05). CD94+ and CD161+, 
NK-T-cell receptors were not signiﬁcantly 
reduced. (Mean ± SEM )   
Figure 3b T-lymphocytes in the dermis 
before and after combination therapy. 
All T-cell subsets did show a statistical 
signiﬁcant decrease (p<0.05), except for 
CD2+ CD25+ CD94+ T-cells, which 
showed a highly signiﬁcant decrease 
(p<0.01, Mean ± SEM)  
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dermis (p<0.01). CD4+, CD45RO+, CD45RA+ T-cells showed a signiﬁcant reduction 
in dermis and epidermis (p<0.05). CD8+ and CD161+ T-cells reduced signiﬁcantly 
exclusively in the dermis (p<0.05). No signiﬁcant reduction was shown for CD94+ and 
CD161+ T-cells in the epidermis. Betamethasone dipropionate ointment did not result 
in a highly signiﬁcant reduction of T-cell subsets. Apart from a signiﬁcant reduction of 
CD94+ and CD161+ T-cells in the epidermis (p<0.05), the reduction of T-cell subsets 
in dermis and epidermis did not reach the level of statistical signiﬁcance. Calcipotriol 
ointment caused a highly signiﬁcant reduction of  CD45RO+ T-cells in dermis and 
epidermis and a highly signiﬁcant reduction of CD8+ T-cells in the dermis (p<0.01). 
CD8+, CD25+, CD45RA+, CD94+ and CD2+ T-cells in the epidermis and CD4+, 
CD25+, CD94+ and CD161+ T-cells in the dermis reached a statistically signiﬁcant 
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Figure 4a T Lymphocytes in the 
epidermis before and after treatment with 
betamethasone dipropionate. There is a 
statistical signiﬁcant decrease (p<0.05) 
for CD94 and CD161, natural killer T-cell 
receptors. (Mean ± SEM)  
Figure 4b T-lymphocytes in the 
dermis before and after treatment 
with betamethasone dipropionate. No 
statistical signiﬁcant decrease in T-cell 
subsets. (Mean ± SEM is shown)  
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Figure 5a T-lymphocytes in the 
epidermis before and after treatment with 
calcipotriol. Almost all T-cell subsets did 
show a statistical signiﬁcant decrease 
(p<0,05) except for CD45RO+ T-cells, 
which showed a highly signiﬁcant 
reduction (p<0.01). CD94+ and CD161+ 
T-cells did not show a signiﬁcant 
reduction. (Mean ± SEM)   
Figure 5b T-lymphocytes in the dermis 
before after treatment with calcipotriol. 
Almost all T-cell subsets did show a 
statistical signiﬁcant decrease (p<0.05) 
except for CD45RO+ and CD8+ T-
cells, which showed a highly signiﬁcant 
reduction (p<0.01). CD45RA+ and CD2+ 
did not show a signiﬁcant reduction 
(Mean ± SEM is shown)
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reduction (p<0.05). CD4+ and CD161+ T-cells in the epidermis and CD45RA+ and 
CD2+ T-cells in the dermis did not show a statistically signiﬁcant reduction. 
 In ﬁgure 6 the percentage decrease of T-cell subsets has been shown. It can 
be seen that all T-cell subsets show a more impressive reduction following calcipotriol 
as compared to betamethasone dipropionate both in dermis and epidermis with 
exception of CD4+ T-cells in the epidermis (ﬁgure 6a) and CD45RA+, CD94+ and 
CD161+ T-cells in the dermis (ﬁgure 6b). In the epidermis the reductions were more 
expressed following treatment with the combination with the exception of CD94+ 
and CD161+ T-cells. In the dermis all T-cell subsets showed the most impressive 
reduction following treatment with the combination, although the reduction of CD4+, 
CD8+ and CD45RO+ were approached by the reduction after calcipotriol ointment 
only.
Discussion
In the present investigation using a 4-week treatment period the combination 
of calcipotriol- and betamethasone-dipropionate ointment, monotherapy with 
betamethasone dipropionate ointment and calcipotriol ointment resulted in a 
substantial and statistically signiﬁcant reduction of the SUM score. Although no 
statistically signiﬁcant difference could be shown between the three treatments, the 
most signiﬁcant improvement was reached by the combination. This observation 
reconﬁrms several observations by other groups that the combination is more effective 
as compared to monotherapy with either calcipotriol ointment or a potent topical 
corticosteroid. 1-3;17-20
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Figure 6a Mean percentage decrease 
of epidermal inﬁltrate for the three 
different topical treatments.
Figure 6b Mean percentage decrease of 
dermal inﬁltrate for the three different 
topical treatments.
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 Calcipotriol proved to induce a highly signiﬁcant inhibition of epidermal 
proliferation and to cause a highly signiﬁcant increase of keratin-10 positive epidermal 
surface (Figures 1,2). In previous studies it was shown that Ki-67 positive nuclei 
decreased 1;12;21, keratin-10 positive cell layers increased10, involucrin positive cells 
increased1;21  and keratin 16 expression decreased12;21;22 during calcipotriol treatment. 
Although some authors have suggested that calcipotriol has a preferential effect on 
epidermal proliferation and keratinization11;12;23 other authors have suggested that the 
effect on T-cells is relevant to the mode of action of calcipotriol.1;7;10 
 Reduction of CD3+, CD45RO+ and CD4+ T-cells7;10;21, reduction of CD8+ 
T-cells10, reduction of CD2+ T-cells1;9;12, reduction of HLADR+ epidermal cells by 
vitamin D3 analogues have been reported.8 One group failed to show a reduction 
of CD45RO+ T-cells by calcipotriol.11 In the present study calcipotriol proved to 
have a highly signiﬁcant reduction of CD45RO+ T-cells in dermis and epidermis 
and a highly signiﬁcant reduction of CD8+ T-cells in the dermis as outstanding 
features. Although most T-cell subsets showed a statistically signiﬁcant reduction 
during calcipotriol treatment, CD4+ and CD161+ T-cells in the epidermis showed 
a reduction below the level of statistical signiﬁcance and also in the dermis the 
slight reductions of CD45RA+ and CD2+ T-cells were not statistically signiﬁcant. 
These observations suggest that calcipotriol has a substantial effect on epidermal 
proliferation and keratinization, whereas the effect on T-cell subsets is more selective 
with a major effect on CD45RO+ and CD8+ T-cells. In this respect it is of importance 
that CD45RO+ T-cells, that is the memory effector cells, constitute a pathogenically 
relevant T-cell subset and that selective apoptosis of these cells by alefacept results in 
improvement of psoriasis.24-26 CD8+ T-cells have been shown to be the dominating T-
cell population in chronic plaque psoriasis whereas the CD4+ T-cell is more common 
in early psoriatic lesions.14
 Treatment with betamethasone dipropionate did not result in a statistically 
signiﬁcant reduction of the number of Ki-67 positive keratinocytes, although the 
increase of the percentage keratin-10 positive epidermal surface was highly signiﬁcant. 
Previous studies have shown substantial reductions of keratin-16 and keratin-10 
positive cells during treatment with potent and ultra potent topical corticosteroids, 
approximating the reduction of calcipotriol.10;23 Previous studies on the assessment 
of Ki-67 positive nuclei during treatment with topical corticosteroids revealed that 
ultra potent topical corticosteroids may have a substantial effect on Ki-67 positive 
nuclei.13;27 It can be concluded that betamethasone dipropionate results in a substantial 
change in compartmentalization of the psoriatic epidermis without a signiﬁcant effect 
on the recruitment of cycling epidermal cells as assessed by Ki-67 expression. The 
effect of topical corticosteroids on T-cells has been studied before. De Jong et al did 
not show a signiﬁcant effect on CD2+ T-cells following treatment with the ultrapotent 
topical corticosteroid budesonide.13 In the present study the effect of betamethasone 
dipropionate on T-cell subsets showed exclusively a statistically signiﬁcant reduction 
of CD94+ and CD161+ T-cells in the epidermis. CD94 and CD161 are natural killer 
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T-cell receptors and may play an important role in the cross talk between innate 
immunity and acquired immunity. 4;15;16 Activation of natural killer T-cell receptors 
may inhibit cytotoxic T-cells to release Th1 cytokines.15 This inhibition is lost when 
NK T-cell receptors are reduced. Therefore, the signiﬁcant reduction of NK T-cell 
receptors in the epidermis by betamethasone dipropionate might be an explanation for 
the tachyphylaxis.  
 From the proﬁle of actions on epidermal proliferation, keratinization and T-
cell subsets it is attractive to speculate that calcipotriol and betamethasone dipropionate 
are complementary. The highly signiﬁcant effect of calcipotriol on epidermal 
proliferation vs the limited effect of betamethasone dipropionate is an example in this 
respect. The substantial effect of calcipotriol on all T-cell subsets except CD4+ and 
CD161+ T-cells vs the pronounced effect of topical corticosteroids on CD94+ and 
CD161+ T-cells without affecting other T-cell subsets is another example.
 The combination of calcipotriol and betamethasone dipropionate resulted in 
a highly signiﬁcant reduction of the proliferation marker Ki-67, although the increase 
of the keratin-10 population was statistically signiﬁcant but less pronounced as 
compared with both monotherapies. 
 It can be concluded that the combination of treatments does not result in 
an additional reduction of the proliferationmarker and increase of the keratinization 
marker beyond the reductions by both monotherapies. However, all T-cell subsets, 
including the CD4+ T-cell population showed a signiﬁcant or highly signiﬁcant 
reduction in dermis and epidermis except for the CD94+ and CD161+ populations in 
the epidermis. Whereas betamethasone dipropionate showed a preferential reduction 
of these natural killer T-cell receptors, in the combination this aspect seemed to be lost. 
Comparing the effects of the three treatments (ﬁgure 6a, ﬁgure 6b) it can be seen that 
all T-cell subsets following treatment with the combination show the most impressive 
reductions with the exception of CD94+ and CD161+ T-cells in the epidermis, whereas 
the reduction of CD4+, CD8+ and CD45RO+ T-cells was approached by the reduction 
of calcipotriol monotherapy.
 In the comparison between calcipotriol ointment and betamethasone 
dipropionate ointment in combination vs monotherapies it should be reconciled that 
the combination implied a reduction of the frequency of the individual treatment from 
twice daily (monotherapy) to once daily (combination therapy).
 Recently in some countries, the formulation dovobet® became available which 
is a unique formulation providing optimal bioavailability and stability of the individual 
active treatments. As twice or once daily principle this treatment is more effective as 
compared to both monotherapies.28;29 In a previous study, using ﬂowcytometry, it was 
shown that this new combination principle causes a major reduction of inﬂammatory 
cells, whereas the advantage on epidermal proliferation is limited as compared to 
monotherapies.6 
 Although the combination of calcipotriol and betamethasone dipropionate 
has no advantage on epidermal proliferation and keratinization, the broad range of 
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effects on T-cell subsets cannot be explained by a simple addition of effects but rather 
suggest a synergistic principle of the combination. 
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5.1 TOPICAL TREATMENT OF PSORIASIS WITH 
TACROLIMUS PREPARATIONS AND CALCIPOTRIOL 
OINTMENT: THE EFFECT ON SUM-SCORE, EPIDERMAL 
PROLIFERATION, KERATINISATION, T-CELL SUBSETS 
AND HLA-DR EXPRESSION.
Abstract
Background Tacrolimus, a calcineurin antagonist, is studied and compared to 
calcipotriol, a vitamine D
3
 derivative, as topical treatment for mild to moderate 
plaque psoriasis. Tacrolimus is able to inhibit several cellular processes thought to be 
important in the pathogenesis of psoriasis, e.g. the transcription of pro-inﬂammatory 
cytokines, keratinocyte hyperproliferation and the expression of HLA-DR in lesional 
psoriatic skin. 
Method In a pilot study we investigated the effects of preparations of tacrolimus 
and calcipotriol on SUM-score, hyperproliferation (Ki-67 positive keratinocytes) 
keratinisation (% K10 positive epidermal surface), T-cell subsets (CD4, CD8, CD45RO, 
CD45RA, CD2, CD25, cells expressing NK-receptors and HLA-DR expression. The 
following three topical treatments were studied in chronic plaque psoriasis over a 12 
week treatment period: Calcipotriol ointment (0.005%) bid., tacrolimus gel (0.3%) 
bid., tacrolimus cream (0.5%) bid.
 Results The mean reductions in SUM-score between day 0 and week 12 for calcipotriol 
ointment, tacrolimus gel and cream did reach statistical signiﬁcance. Already at day 5, 
calcipotriol induced a signiﬁcant reduction in SUM-score. Calcipotriol ointment and 
tacrolimus cream had a signiﬁcant effect on epidermal proliferation (Ki-67 positive 
cells) at week 12, in contrast to the effect induced by tacrolimus gel, which did not 
reach statistical signiﬁcance. Calcipotriol and tacrolimus gel induced a signiﬁcanct 
reduction of several T-cell susbets. Tacrolimus cream induced a highly signiﬁcant 
reduction of epidermal CD4+ T-cells. All preparations reduced HLA-DR expression 
signiﬁcantly at week 12.
Conclusions With respect to the effect on K10 expression, T-cell subsets and HLA-DR 
expression, calcipotriol ointment and tacrolimus gel have similar proﬁle. The effect of 
Tacrolimus cream on keratinization and T cell subsets was more modest. In view of 
the small number of evaluable patients treated with tacrolimus cream (4 patients), no 
deﬁnite conclusion can be drawn on the effect of this formulation. 
Introduction
Recently, Tacrolimus ointment (Protopic®) was introduced, as a new effective topical 
treatment for atopic dermatitis.1 This compound acts by inhibiting calcineurin, 
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a cytosolic enzyme, leading ultimately to a reduced production of inﬂammatory 
cytokines by activated T-lymphocytes.1-3 The efﬁcacy of this calcineurin inhibitor, as 
systemic treatment in chronic plaque psoriasis was discovered in four organ transplant 
subjects, with concomitant psoriasis, receiving systemic tacrolimus.4 In several pilot 
studies and a phase II study the efﬁcacy of systemic tacrolimus (Prograf®) was proven 
for the treatment of chronic plaque psoriasis.5 Furthermore, it has been shown recently, 
that tacrolimus ointment is effective for the topical treatment of facial psoriasis and 
ﬂexural psoriasis.6
 Although tacrolimus ointment (0.3%) had an antipsoriatic effect in a double 
blind, vehicle-controlled, microplaque assay test 7, Zonneveld et al. found that the 
efﬁcacy of tacrolimus ointment (0.3%) in chronic plaque psoriasis was comparable to 
the placebo ointment.8 The authors suggested that this lack of efﬁcacy was due to the 
molecular weight of 822,5 dalton, however more factors inﬂuence the penetration of 
substances in the skin, such as the vehiculum, the type of skin and occlusion amongst 
other factors. Therefore, it is worthwhile to reinvestigate the potential antipsoriatic 
efﬁcacy of topical tacrolimus in plaque psoriasis. Several in vitro studies have shown 
that tacrolimus affects cellular processes and cell types involved in the pathogenesis 
of psoriasis. Indeed, tacrolimus is able to inhibit the transcription and release of 
interleukin-2 amongst other cytokines (IL3, IL4, IL5, IFNγ, TNF-α, GM-CSF).9 
Tacrolimus is also able to prevent the release of histamine and inhibit de novo synthesis 
of prostaglandin D2 and leukotriene C4 in mast cells and/or basophils. 10 The release 
of cytokines by keratinocytes and hyperproliferation of keratinocytes is inhibited by 
this compound. 11 Moreover, tacrolimus induces a decrease in the expression of HLA-
DR, ICAM-1 and E-selectin in the vascular epithelium of lesional skin.12,13 In vivo 
studies have shown that tacrolimus, administred topically as solution, ointment or gel 
is able to strongly inhibit T-cell mediated inﬂammation in mice, guinea pigs, and farm 
pigs.14
 Current topical treatments, e.g. vitamin D3 derivatives, corticosteroids, 
tazarotene, dithranol and coal tar, can be successful in treating psoriasis. 15 Unfortunately 
these treatments are also associated with some disadvantages such as thinning of skin 
and tachyphylaxis with corticosteroid use, irritation when using dithranol, tazarotene 
or calcipotriol and cosmetic drawbacks when using coal tar. Tacrolimus ointment does 
not induce skin atrophy and its irritative properties are less pronounced as compared to 
dithranol, tazarotene or calcipotriol.16 Therefore, topical Tacrolimus is an interesting 
and innovative candidate for the treatment of plaque psoriasis, especially applicable 
in sensitive skin regions.
 The aim of the present study was to investigate the in vivo effects of topical 
preparations of tacrolimus, with improved bioavailability, versus the effects of the 
established ﬁrst line topical treatment induced by calcipotriol, with respect to several 
immuno-histochemical parameters. In the present study we investigated the effects 
of tacrolimus preparations and calcipotriol on hyperproliferation (Ki-67 positive 
keratinocytes) keratinisation (% K10 positive epidermal surface), T-cell subsets (CD4, 
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CD8, CD45RO, CD45RA, CD2, CD25), cells expressing NK-receptors (CD161, 
CD94) and HLA-DR expression. The effects of these treatments were studied in 
relation to the clinical responses (SUM-score). The following compounds were 
studied for topical use in plaque psoriasis over a 12-week treatment period: 
    1. Calcipotriol ointment (0.005%) bid.
    2. Tacrolimus gel (0.3%) bid.
    3. Tacrolimus cream (0.5%) bid.
Material and methods
Patients
Eighteen patients with plaque psoriasis participated in the present study, which was 
part of a multicenter open label, observer blinded, randomized, parallel-group study 
to assess efﬁcacy and safety of Calcipotriol ointment 0.005% versus Tacrolimus Gel 
0.3% versus Tacrolimus cream 0.5% in the treatment of mild to moderate plaque 
psoriasis. Unfortunately two patients were withdrawn from the study, one receiving 
tacrolimus cream because of irritation of the skin and another patient, receiving 
tacrolimus cream, was not available anymore. Patients had to fulﬁll the following 
inclusion criteria: Patients having chronic plaque psoriasis (>18 years old) with an 
affected body surface index of ≤ 10%. The target lesion, between 40 and 200 cm2, 
had to be located on trunk or extremities. Furthermore the severity of the target lesion 
had to be ≥ 5 (SUM-score). Excluded from this study were the following patients: 
Those having another inﬂammatory disorder in the areas to be treated. Patients with 
any dermatosis that might result in a defective epidermal barrier. Patients with facial 
psoriasis were also excluded. Moreover, patients having a medical condition, or 
using medication, interfering with the severity of plaque psoriasis, were excluded. In 
addition patients that were pregnant or breast-feeding were excluded. 
Clinical score and biopsy procedure
Sum-scores were performed to assess clinical efﬁcacy of the 3 topical treatments. 
The SUM-score comprises the total of scores for erythema (0-4), scaling (0-4) and 
induration (0-4). Punch biopsies 4 mm in diameter were taken from the chronic 
plaque lesion on day 0, day 7 and after12 weeks using xylocain/adrenaline as local 
anaesthetic. Biopsy specimens were stored at -80°C before use.
Immunohistochemistry
The following markers were investigated;
(i) T-cell subsets: CD4, CD8, CD45RO, CD45RA, CD2 and CD25. 
(ii) Cells expressing NK-receptors: CD94, CD161.  
(iii) Epidermal proliferation: Ki-67 positive keratinocytes.
(iiii)Epidermal differentiation: Keratine-10 positive epidermis. 
Biopsies were embedded in Tissue Tek OCT compound (Miles Scientiﬁc, Naperville, 
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USA), snap frozen in liquid nitrogen and stored at –80°C until use.
Sections were sliced 6 μm thick and were air-dried for 30 minutes. Then the sections 
were ﬁxed in cold acetone for 10 minutes. After blocking 5 minutes for endogenous 
peroxidase, using 0.03 % hydrogen peroxide containing sodium azide, they were 
washed in PBS (phosphate buffered saline) for 10 minutes. Subsequently sections were 
incubated with the primary antibodies for 1 hour. The following primary antibodies 
(mouse anti-human) were used, diluted in 1% bovine serum albumin (Sigma, St Louis, 
USA)/PBS: anti-CD2 (1:200) (clone MT910), anti-CD4 (clone MT310) (1:200), anti-
CD8 (clone DK25) (1:200), anti-CD45RO (clone UCHL1) (1:100), anti-CD45RA 
(clone 4KB5) (1:200), anti-CD94 (clone HP-3D9) (1:100), anti-CD25 (clone ACT-
1) (1:200), Ki67 (clone MIB-1) (1:200),  (all obtained from DAKO, Copenhagen 
Denmark), keratine-10 (clone RKSE60) (1:100) (Monosan Laboratories Uden 
Netherlands), anti-CD161 (clone 191B8) (1:200) (Immunotech Marseille France).
 Sections were washed in PBS for 15 minutes. Secondary IgG labeled polymer, 
HRP anti-mouse EnVision+ (DAKO Copenhagen Denmark) was added for 30 
minutes.17 The sections were washed for 15 minutes in PBS. To visualize the staining 
we used AEC+ (3-amino-9-ethylcarbazole) High Sensitivity Substrate Chromogen 
for 10 minutes (DAKO Copenhagen Denmark). Counterstaining was performed with 
Mayer’s Haematoxylin (Sigma St Louis USA). The sections were washed in tap water 
and dried. Sections were ﬁnally mounted in glycerol gelatin (Sigma St Louis USA). 
Furthermore, from each patient we performed a hematoxiline-eosine staining. After 
dehydration in alcohol and histosafe, these sections were mounted in Permount.
Immunohistochemical scoring
For the quantitative analysis of the T-lymphocyte markers we used the following 
procedure: One section of the slide is chosen and all immunocytes with 200 x 
magniﬁcation in the epidermal compartment were counted. Epidermal immunocytes in 
the stratum corneum were not counted. The immunocytes in the dermal compartment 
were also counted. Positive dermal T-lymphocytes were counted between the basement 
membrane and 100 um under the basement membrane. The HLA-DR marker was 
analysed in the following way: A score of 0-3 (0 = no staining, 1 = slight staining, 2 = 
moderate staining, 3 = abundant staining) was designated to the epidermal area above 
the basement membrane, which was divided in two parts. The ﬁrst part was choosen, 
one third of the area above the basement membrane, the second part consisted of all 
epidermal surface left. The dermis was scored in the same manner (score from 0-3). 
Finally the percentage of the HLA-DR positive surface was observed.  More then 60% 
HLA-DR positive dermal inﬁltrate was designated as a score of 1 and less then 60% as 
a score of 0. The total of the scores in epidermal and dermal zones was computed.
Image Analysis
For analysing Ki-67 positive keratinocytes three representative digital photographs 
are made at 100x magniﬁcation. Each photograph was analysed using IP-lab software. 
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A line was drawn, with a known length, following the stratum basale, and all positive 
cells above this line were counted. Quantiﬁcation was done in the unit: positive cells 
per mm length of basement membrane.
 For quantiﬁcation of keratine-10 positive cells, photographs were made at 
50x magniﬁcation. For counting the keratine-10 positive epidermal surface, only the 
epidermal compartment was used as region of interest (ROI). Using IP-lab software 
a deﬁned window was set for the analysis of the differentiation marker from an area, 
which is representative for the section. This window was designated as Region of 
Interest (ROI). The dermal surface is subtracted if it is present in the epidermal 
compartment. Quantiﬁcation was measured as a % of epidermal surface as unit.
Statistical analysis
The reduction of the number of T-cell subsets (unit: pos. cells per mm.), the number of 
Ki-67 (pos. cells per mm. basement membrane), the semiquantitative HLA-DR score 
and the SUM-score were analysed over the 12 week treatment course. The increase of 
the % K10 epidermal surface was also analysed over the 12 week treatment course. 
Statistical analysis was performed using the one way analysis of variance for repeated 
measurements (ANOVA). In case of statistical signiﬁcance we performed Duncans 
post hoc comparison. 
Results
The results for the SUM-score are shown in ﬁgure 1. The mean reductions in SUM-
score between day 0 and week 12 for calcipotriol ointment, tacrolimus gel and 
tacrolimus cream were 49.60 %, 61.90 % and 36.90 % respectively. The reduction 
induced by calcipotriol ointment reached statistical signiﬁcance at day 7 (p<0.05) and 
week 12 (p<0.01) as compared to day 0. The reduction caused by tacrolimus gel at 
week 12 was highly signiﬁcant (p<0.01) compared to day 0 and day 7. At week 12, 
tacrolimus cream signiﬁcantly (p<0.05) reduced the SUM-score compared to day 0. 
In ﬁgure 2, photographs of three patients, at day 0, 7 and week12, using calcipotriol 
ointment (2a, b and c), tacrolimus gel (2d, e and f) or tacrolimus cream (2g, h and i) 
respectively, are depicted.
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Figure 1 Reduction of SUM-
score (± SEM) by calcipotriol 
ointment, tacrolimus gel and 
tacrolimus cream on day 0, day 
7 and week 12.
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Figure 2 Clinical severity of the target lesions at day 0, day 7 and week 12 during treatment with 
calcipotriol ointment (a,b and c), tacrolimus gel (d,e and f) and tacrolimus cream (g,h and i).
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 In ﬁgure 3 the results for the reduction of Ki-67 positive keratinocytes are 
seen. After 7 days, no signiﬁcant reduction was observed. The mean reductions for Ki-
67 positive cells between day 0 and week 12 for calcipotriol ointment, tacrolimus gel 
and tacrolimus cream were 37.87 %, 20.55 % and 30.95 % respectively. calcipotriol 
induced a signiﬁcant (p<0.05) reduction of Ki-67 positive cells at week12 as compared 
to day 0. Nevertheless, the reduction of Ki-67 positive cells by tacrolimus gel did 
not reach statistical signiﬁcance. Tacrolimus cream induced a signiﬁcant reduction 
(p<0.05) of Ki-67 positive keratinocytes at week 12 compared to day 0. 
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Figure 3 Reduction of the number 
of Ki-67 positive keratinocytes 
per mm. basement membrane (± 
SEM) by calcipotriol ointment, 
tacrolimus gel and tacrolimus 
cream on day 0, day 7 and week 
12.
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Figure 4 Increase of the 
percentage Keratin-10 positive 
epidermal surface (± SEM) by 
calcipotriol ointment, tacrolimus 
gel and tacrolimus cream on day 
0, day 7 and week 12.
Marker Calcipotriol ointment Tacrolimus gel Tacrolimus cream 
epidermis dermis epidermis dermis epidermis dermis 
CD4 46.99 29.33 58.38* 35.36 41.92** 41.04 
CD8 64.58 27.72 60.17 29.82 -6.15 -29.65 
CD45RO 63.73** 30.36 69.21 59.15* 41.15 27.13 
CD45RA 63.04 38.23 45.30 60.84* -31.82 32.81 
CD2 68.49** 33.85 56.56 56.59* 17.77 28.91 
CD25 76.34** 42.75 72.77** 63.40** 7.82 31.15 
CD161 65.73* 6.18 57.65 27.86 33.73 18.82 
CD94 55.74 35.56 48.00 54.62 60.00 42.39 
Table 1 The mean percentage decrease of the T-cell subsets in both epidermis and dermis, 
between day 0 and week 12 has been listed. (**=p<0.01 and*=p<0.05).
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 The percentage increase of K10 positive epidermal surface for all three topical 
treatments is depicted in ﬁgure 4. The mean increases in percentage K10 positive 
epidermal surface for calcipotriol ointment, tacrolimus gel and tacrolimus cream are 
57.77 %, 28.99 % and 4.36 % respectively. Calcipotriol induced a signiﬁcant increase 
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Figure 5 (A-D) Reduction of CD4+, CD8+, CD45RO+ and CD45RA+ epidermal T-cell subsets 
and cells expressing NK-receptors per mm. by calcipotriol, tacrolimus gel and tacrolimus cream 
on day 0, day 7 and week 12.
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Figure 6 (A-D) Reduction of CD2+, CD25+, CD94+ and CD161+ epidermal T-cell subsets and 
cells expressing NK-receptors per mm. by calcipotriol, tacrolimus gel and tacrolimus cream on 
day 0, day 7 and week 12.
 A  B
CD94+ epidermal cells
0
10
20
30
40
50
60
70
Day 0 Day 7 Week 12
ce
lls
 p
er
 m
m
.
Calcipotriol ointment
Tacrolimus gel
Tacrolimus cream
CD161+ epidermal cells
0
10
20
30
40
50
60
70
Day 0 Day 7 Week 12
ce
lls
 p
er
 m
m
.
Calcipotriol ointment
Tacrolimus gel
Tacrolimus cream
 C  D
Chapter 5 - Antipsoriatic effects of some innovative topical treatments
143
at day 7 (p<0.05) and a highly signiﬁcant increase at week 12 (p<0.01) as compared 
to day 0. Nevertheless the increases induced by tacrolimus gel on day 7 and week 12 
were both highly signiﬁcant (p<0.01) compared to day 0. The increases induced by 
tacrolimus cream did not reach statistical signiﬁcance. 
 The results showing the mean reduction in T-cell subsets and cells expressing 
NK-receptors by treatment with calcipotriol ointment, tacrolimus gel and tacrolimus 
cream are shown in ﬁgure 5, 6 and 7 respectively. In addition, in table 1 the mean 
percentage decrease of these markers, between day 0 and week 12 has been listed. 
In the epidermal compartment (ﬁgure 5 and 6) calcipotriol ointment induced a 
reduction of all T-cell subsets. The percentage decrease from day 0 to week 12 of 
CD8+, CD45RO+ (p<0.01), CD45RA+, CD2+ (p<0.01), CD25+ (p<0.01) and CD161+ 
(p<0.05) T-cells was between 60% and 80%. Furthermore, the percentage decrease 
for CD4+ T-cells (p<0.05) and CD94+ cells was between 40% and 60%. In the dermal 
compartment (ﬁgure 7 and 8) calcipotriol ointment induced a percentage decrease 
between 20% and 40% of all T-cell subsets except for CD161+ T-cells, that was lower 
then 20%.  
 Tacrolimus gel also induced a reduction of all T-cell subsets in the epidermis 
(ﬁgure 5 and 6). The percentage decrease of CD8+, CD45RO+, CD25+ (p<0.01) T-
cells from day 0 to week 12 was between 60% and 80%.
 In addition, the percentage decrease of CD4+ (p<0.05), CD45RA+, CD2+, 
CD161+ T-cells and CD94+ cells was between 40% and 60%. The reduction in the 
dermal compartment by tacrolimus gel (ﬁgure 7 and 8) of CD45RO+ (p<0.05), 
CD45RA+ (p<0.05), CD2+ (p<0.05), CD25+ (p<0.01) T-cells and CD94+ cells was 
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Figure 7(A-D) Reduction of CD4+, CD8+, CD45RO+ and CD45RA+ dermal T-cell subsets 
and cells expressing NK-receptors per mm. by calcipotriol, tacrolimus gel and tacrolimus cream 
on day 0, day 7 and week 12.
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between 60% and 80%. For CD4+, CD8+ and CD161+ dermal T-cells the percentage 
decrease was between 20% and 40%. 
 The effect induced by tacrolimus cream on T-cell subsets was more modest in 
epidermis as well as dermis (ﬁgure 5-8). In the epidermis tacrolimus cream induced a 
reduction of 60% for CD94+ T-cells, a reduction between 40-60% for CD4+ (p<0.01) 
and CD45RO+ T-cells, between 20-40% for CD161+ cells and less than 20% for CD2+ 
and CD25+ T-cells. (Table 1) Remarkably there was an increase of CD8+ and CD45RA+ 
epidermal T-cells. In the dermis tacrolimus cream induced a reduction between 40-60 
% for CD4+ and CD94+ cells, between 20-40% for CD45RO+, CD45RA+, CD2+ and 
CD25+ T-cells, and less than 20% for CD161+ cells.  Tacrolimus cream induced an 
increase of CD8+ dermal T-cells. 
 The minimal reductions in T-cell subsets and cells expressing NK-receptors 
at day 7, were not statistically signiﬁcant for the three studied topical treatments. 
 Finally, the mean reduction in HLA-DR expression for all three topical 
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Figure 8 (A-D) Reduction of CD2+, CD25+, CD94+ and CD161+ dermal T-cell subsets and 
cells expressing NK-receptors per mm. by calcipotriol, tacrolimus gel and tacrolimus cream on 
day 0, day 7 and week 12.
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Figure 9 Decrease in HLA-
DR expression (± SEM) by 
calcipotriol ointment, tacrolimus 
gel and tacrolimus cream on day 
0, day 7 and week 12.
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treatments is presented in ﬁgure 9. The mean reductions in HLA-DR expression 
for calcipotriol ointment, tacrolimus gel and tacrolimus cream are 30.36%. 44.46%, 
30.95% respectively. calcipotriol and tacrolimus gel both reached a highly signiﬁcant 
reduction (p<0.01) at week 12, whereas the reduction by tacrolimus cream was only 
signiﬁcant (p<0.05). 
Discussion
In the present investigation the clinical efﬁcacy of calcipotriol ointment, tacrolimus 
gel were grosso modo similar, both inducing a highly signiﬁcant reduction at week 12 
(p<0.01), whereas the effect induced by tacrolimus cream at week 12 was signiﬁcant 
(p<0.05).  We have to realise that the study groups are relatively small. In particular the 
group treated with tacrolimus cream comprised only 4 patients as 2 patients dropped 
out. Therefore, we will restrict the analysis to a within group comparison in order to 
ﬁnd out trends of various immunohistochemical characteristics of the psoriatic lesion 
during treatment. 
 Calcipotriol ointment induced a signiﬁcant reduction of Ki-67 positive cells 
at week 12. Other investigators have also reported a signiﬁcant reduction of Ki-67 
positive cells by calcipotriol 18,19, although they found this signiﬁcant effect already 
after 1-2 weeks of treatment. Tacrolimus gel induced a reduction of Ki-67 cells after 
12 weeks, which did not reach the level of statistical signiﬁcance. Tacrolimus cream 
had a signiﬁcant effect on Ki-67 positive cells after 12 weeks. 
 Calcipotriol was effective in normalizing the process of keratinization at week 
12, conﬁrming the observations by other investigators. 18,19 Nevertheless, tacrolimus 
gel already at day 7 induced a highly signiﬁcant increase in the expression of K10, 
whereas the effect by calcipotriol was signiﬁcant at day 7 and highly signiﬁcant at 
week 12. The 4 patients treated with tacrolimus cream, did not show a statistical 
signiﬁcant increase at day 7 or week 12, however a clear tendency of an increase was 
observed at day 7 and week 12 . 
 Regarding the effects on T-cell subsets, calcipotriol ointment induced a highly 
signiﬁcant reduction of CD45RO+, CD2+, CD25+ epidermal T-cells and a signiﬁcant 
reduction of CD4+ epidermal T-cells. Other investigators also found a signiﬁcant 
reduction of CD45RO+, CD4+ and CD2+ T-cells by calcipotriol ointment.18-20 
 Tacrolimus gel induced a comparable effect with a highly signiﬁcant reduction 
of CD25+ T-cells and a signiﬁcant reduction of CD4+ T-cells in the epidermis. In 
addition, in the dermis there was a highly signiﬁcant reduction of CD25+ T-cells and 
a signiﬁcant reduction of CD45RO+, CD45RA+ en CD2+ T-cells. It is intriguing that 
the effect of tacrolimus gel on dermal T-cells is substantial, whereas calcipotriol 
did not induce signiﬁcant effects on dermal T-cells. So far, there are to the best of 
our knowledge no studies available, investigating the effect of topical tacrolimus 
on aspects of inﬂammation in lesional psoriatic skin. Furthermore our data are in 
agreement with a study by Thomson et al., who found a marked reduction of CD4+, 
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CD8+ and a signiﬁcant fall of CD25+ T-cells in lesional psoriatic skin after 4-8 weeks 
of treatment with systemic tacrolimus.13
 The effect of tacrolimus gel on HLA-DR expression, is in consonance with 
the study conducted by Thomson et al., who found a signiﬁcant fall in the number of 
lesional cells expressing HLA-DR by systemic tacrolimus.13 In the aforementioned 
study, tacrolimus was also able to achieve a reduction in the expression of E-selectin 
and ICAM-1 on the vascular endothelial membrane. 
 In summary, tacrolimus gel and cream and calcipotriol ointment all reduced 
the SUM-score. With respect to epidermal proliferation and HLA-DR expression all 
topical agents induced a signiﬁcant decrease at week 12. The percentage reduction in 
T-cell subsets was comparable between calcipotriol and tacrolimus gel, both topical 
treatments being substantially more effective than tacrolimus cream. Analyzing the 
immunohistochemical data in the present study we may conclude that especially 
tacrolimus gel is a promising new compound for the treatment of plaque psoriasis.
Chapter 5 - Antipsoriatic effects of some innovative topical treatments
147
Reference List
1. Reitamo S. Tacrolimus: a new topical immunomodulatory therapy for atopic dermatitis. 
J Allergy Clin Immunol 2001;107:445-8.
2. Reynolds NJ, Al Daraji WI. Calcineurin inhibitors and sirolimus: mechanisms of action 
and applications in dermatology. Clin Exp Dermatol 2002;27:555-61.
3. Bornhovd EC, Schuller E, Bieber T, Wollenberg A. [Immunosuppressive macrolides 
and their use in dermatology]. Hautarzt 2000;51:646-54.
4. Abu-Elmagd K, van Thiel D, Jegasothy BV, Ackerman CD, Todo S, Fung JJ et al. 
FK 506: a new therapeutic agent for severe recalcitrant psoriasis. Transplant Proc 
1991;23:3322-4.
5. Thomson AW, Nalesnik M, Abu-Elmagd K, Starzl TE. Inﬂuence of FK 506 on T 
lymphocytes, Langerhans' cells and the expression of cytokine receptors and adhesion 
molecules in psoriatic skin lesions: a preliminary study. Transplant Proc 1991;23:3330-
1.
6. Freeman AK, Linowski GJ, Brady C, Lind L, Vanveldhuisen P, Singer G et al. Tacrolimus 
ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad 
Dermatol 2003;48:564-8.
7. Remitz A, Reitamo S, Erkko P, Granlund H, Lauerma AI. Tacrolimus ointment improves 
psoriasis in a microplaque assay. Br J Dermatol 1999;141:103-7.
8. Zonneveld IM, Rubins A, Jablonska S, Dobozy A, Ruzicka T, Kind P et al. Topical 
tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 
1998;134:1101-2.
9. Tocci MJ, Matkovich DA, Collier KA, Kwok P, Dumont F, Lin S et al. The 
immunosuppressant FK506 selectively inhibits expression of early T cell activation 
genes. J Immunol 1989;143:718-26.
10. de Paulis A, Cirillo R, Ciccarelli A, de Crescenzo G, Oriente A, Marone G. 
Characterization of the anti-inﬂammatory effect of FK-506 on human mast cells. J 
Immunol 1991;147:4278-85.
11. Kaplan A, Matsue H, Shibaki A, Kawashima T, Kobayashi H, Ohkawara A. The effects 
of cyclosporin A and FK506 on proliferation and IL-8 production of cultured human 
keratinocytes. J Dermatol Sci 1995;10:130-8.
12. Schulz BS, Michel G, Wagner S, Suss R, Beetz A, Peter RU et al. Increased expression 
of epidermal IL-8 receptor in psoriasis. Down-regulation by FK-506 in vitro. J Immunol 
1993;151:4399-406.
13. Thomson AW, Nalesnik MA, Rilo HR, Woo J, Carroll PB, Van Thiel DH. ICAM-1 and 
E-selectin expression in lesional biopsies of psoriasis patients responding to systemic 
FK 506 therapy. Autoimmunity 1993;15:215-23.
14. Data on ﬁle: Fujisawa internal study reports.  2004. 
15. Van De Kerkhof PC, Vissers WH. The topical treatment of psoriasis. Skin Pharmacol 
Appl Skin Physiol 2003;16:69-83.
16. Reitamo S, Rissanen J, Remitz A, Granlund H, Erkko P, Elg P et al. Tacrolimus ointment 
does not affect collagen synthesis: results of a single-center randomized trial. J Invest 
Dermatol 1998;111:396-8.
17. Kammerer U, Kapp M, Gassel AM, Richter T, Tank C, Dietl J et al. A new rapid 
immunohistochemical staining technique using the EnVision antibody complex. J 
Histochem Cytochem 2001;49:623-30.
Chapter 5 - Antipsoriatic effects of some innovative topical treatments
148
18. van der Vleuten CJ, De Jong EM, Van De Kerkhof PC. Epidermal differentiation 
characteristics of the psoriatic plaque during treatment with calcipotriol. Arch Dermatol 
Res 1996;288:366-72.
19. De Jong EM, Van De Kerkhof PC. Simultaneous assessment of inﬂammation and 
epidermal proliferation in psoriatic plaques during long-term treatment with the vitamin 
D3 analogue MC903: modulations and interrelations. Br J Dermatol 1991;124:221-9.
20. Vissers WH, Berends M, Muys L, van Erp PE, De Jong EM, Van De Kerkhof PC. The 
effect of the combination of calcipotriol and betamethasone dipropionate versus both 
monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic 
plaque psoriasis. Exp Dermatol 2004;13:106-12.
Chapter 5 - Antipsoriatic effects of some innovative topical treatments
149
5.2 THE NEW VITAMIN D
3
 ANALOGUE ZK 156942 
(TISOCALCITATE) HAS PRONOUNCED EFFECTS ON 
EPIDERMAL PROLIFERATION, KERATINIZATION AND 
HLA-DR EXPRESSION, WITHOUT CAUSING REDUCTION 
OF T-CELL SUBSETS IN LESIONAL PSORIATIC SKIN.
Abstract
Background ZK 156942 is a new vitamin D
3 
analogue, developed for the topical 
treatment of plaque psoriasis. Previous studies have indicated that this vitamin D
3 
analogue possesses comparable efﬁcacy to calcipotriol but may have superior local 
and systemic tolerability. Objective The present study compares the clinical (SUM-
score) and immunohistochemical effect of the following topical treatments during an 
8 week course: Vitamin D
3
 analogue calcipotriol ointment bid; SH F597 PD vehicle 
ointment bid; SH F597 F ointment (containing ZK 156942) bid; SH F597 F ointment 
and SH F597 PD vehicle od. 
Methods Two patients applied calcipotriol bid, 4 patients SH F597 F bid, 5 patients 
SH F597 F od and placebo od and 5 patients placebo bid. On day 0, day 5 and week 
8 biopsies were taken from the skin lesions to investigate markers of keratinocyte 
differentiation and proliferation. We also investigated T-cell subsets (CD4+, CD8+, 
CD45RO+, CD45RA+, CD2+, CD25+ T-cells) and cells expressing NK-receptors 
(CD94+ and CD161+ cells). 
Results Whereas calcipotriol had a substantial effect on SUM-score, epidermal 
proliferation, keratin 10 expression, HLA-DR expression, and T-cell subsets in lesional 
skin, SH F597F had a more selective effect, characterized by a pronounced effect on 
epidermal proliferation and keratin 10 expression, which had a faster onset compared 
to calcipotriol, as well as by a substantial effect on HLA-DR expression. Conversely, 
compared to calcipotriol there was no tendency for a reduction of T-cell subsets. 
Conclusions Results from this relatively small group indicate that: SH F597 F has anti-
proliferative effects of a magnitude comparable to calcipotriol; however these effects 
are reached more rapidly following treatment with SH F597 F. SH F597 F bid was 
able to signiﬁcantly reduce HLA-DR expression (P<0.05) in a manner comparable 
to calcipotriol However, in contrast to calcipotriol, no tendency was observed for 
a reduction of T-cell subsets by SH F597 F. Key words: Psoriasis, tisocalcitate, T-
lymphocytes, keratinocyte. 
Introduction
Vitamin D3 analogues are currently the ﬁrst line choice for the topical treatment of 
chronic plaque psoriasis. Calcipotriol has been studied extensively in vitro as well 
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as in vivo and recommended as a safe and effective mainstay treatment for chronic 
plaque psoriasis.1 
 In the search for new promising vitamin D
3 
derivatives, SH F597 F 
(Tisocalcitriol) has been developed as a new candidate in the topical treatment 
of psoriasis. In preclinical pharmacology studies SH F597 F was as effective 
as calcipotriol and tacalcitol with regard to the binding afﬁnity to the Vitamin D
3
 
receptor. Furthermore a clinical study using the cumulative irritant patch test has 
shown that SH F597 F is well tolerated and possessed a better local tolerability proﬁle 
than calcipotriol ointment.2 Systemic tolerability was excellent, revealing that total 
daily doses of 2100 μg SH F597 F in 42 g of ointment applied twice daily on 45 % 
body surface over 14 days did not have an impact on the calcium excretion in the 24 
hour urine nor on serum calcium levels in the serum of patients.3;4  Furthermore the 
clinical efﬁcacy of SH F597 F was assessed and compared to calcipotriol by a 28 
day modiﬁed Psoriasis Plaque Test. Both topical treatments had the same efﬁcacy in 
reducing erythema, desquamation and inﬁltration. In summary, initial results indicated 
that SH F597 F has potential advantages compared to other Vitamin D
3 
analogues as a 
result of a better local and systemic tolerability proﬁle, with at least the same clinical 
efﬁcacy compared to calcipotriol.
 Vitamin D
3
 analogues exert their action via the vitamin D
3
 receptor (VDR), 
which is a nuclear receptor that acts as a ligand-inducible transcription factor.5 In 
vivo, it is generally believed that they exert their antipsoriatic action by normalisation 
of keratinocyte differentiation and inhibition of keratinocyte hyperproliferation.6 
Nevertheless in vitro studies showed that vitamin D
3
 analogues have a strong 
immunomodulatory effect and are able to inhibit autoimmune disease in animal 
models.7;8 Indeed, several immunocytes, including monocytes, Langerhans cells and 
activated T-cells (CD45RO+ T-cells), that all play a pivotal role in the pathogenesis 
of psoriasis, express the vitamin D
3
 receptor.9 In vitro studies have shown that 1,25-
(OH)
2
D
3
 treatment of freshly isolated mononuclear cells and puriﬁed monocytes, 
results in a decreased production of IL-1α, TNF-α and IL-6 after stimulation, due to 
less stability of the speciﬁc mRNA.10-12 Furthermore it has been shown that vitamin D
3 
derivatives are able to inhibit IL-12 production by activated macrophages and blood 
dendritic cells in vitro.13 This is of utmost importance, since IL-12 plays an important 
role in inducing T-helper lymphocytes (CD4+ T-cells) and cytotoxic T-cells (CD8+ 
T-cells) of type 1, that are involved in the immuno-pathogenesis of psoriasis.14 The 
inﬂuence of Vitamin D
3
 analogues on monocyte function and HLA-DR expression 
by monocytes has been investigated in vitro. After calcitriol treatment, stimulated 
monocytes showed decreased HLA-DR expression.15 It has also been shown that 
monocyte accessory cell function decreased after calcitriol treatment.15;16 In addition, 
results  from another in vivo study indicated that cells from lesional psoriatic skin 
treated with calcipotriol for 7 days produce an increased amount of IL-10, which is 
a Th2 cytokine capable of inhibiting production of Th1 cytokines. The same study 
showed that calcipotriol inhibited IL-8 production, a known chemotactic factor of 
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polymorphonuclear leucocytes (PMN’s) and T-lymphocytes. In 1986 it was already 
shown that vitamin D
3
 analogues are able to interfere with IL-2 (a ligand to the CD25 
receptor on activated T-cells) production and IL-2 thymocyte interaction in vitro, 
inhibiting T-lymphocyte proliferation.17 Therefore there is ample evidence that vitamin 
D
3
 derivatives could have direct anti-inﬂammatory properties in vivo. Whether vitamin 
D
3
 analogues achieve their immunomodulatory effect in vivo directly on immunocytes 
or indirectly via keratinocytes, remains to be elucidated. 
 In order to understand the in vivo actions of SH 597 F on epidermal 
proliferation, keratinization and T-lymphocyte accumulation, an immunohistochemical 
study was conducted in order to investigate short-term (5 days) and long-term (56 days) 
effects of SH F 597 F on these cell biological aspects in comparison to calcipotriol and 
vehicle.
 The present (sub)study was carried out to compare the clinical and 
immunohistochemical effects of the following topical treatments during 8 weeks of 
treatment: calcipotriol (Daivonex Leo Pharma bv.) ointment bid; vehicle (SH F597 
PD ointment) bid; vitamin D
3
 analogue SH F597 F ointment bid; SH F597 F ointment 
od and vehicle (SH F597 PD) od; On day 0, day 5 and week 8 skin biopsies were taken 
to investigate markers of keratinocyte differentiation (% K10 of epidermal surface) 
and proliferation (Ki67 positive keratinocytes). In addition, we investigated several 
T-lymphocyte subsets (CD4+, CD8+, CD45RO+, CD45RA+, CD2+, CD25+ T-cells) 
and cells expressing NK-receptors (CD94+ and CD161+ cells). Furthermore HLA-
DR expression was studied in epidermis as well as dermis. The aforementioned T-cell 
subsets were investigated, because they play an important role in the pathogenesis of 
psoriasis. T-cells in the psoriatic lesion consist of T-helper cells (CD4) or cytotoxic 
T-cells (CD8), and mostly belong to the memory effector subset (CD45RO).18;19 
Memory effector T-cells are for example selectively targeted by the fusion protein 
alefacept, and interestingly, the reduction of this T-cell subset correlates with the 
clinical amelioration of psoriasis.20 Furthermore, CD25 (IL-2 receptor) and HLA-DR 
(MHC-II) are markers for the activated state of T-cells. In addition, the CD25 receptor 
is a marker of early activation, whereas HLA-DR is expressed later on. 21-25 CD2 on T 
cells interacts with CD58 (LFA-3) e.g. on mature dendritic cells, mediates intercellular 
adhesion and provides an important co-stimulatory signal. Cells that express NK-
receptors CD94 and CD161 have speciﬁcally been identiﬁed in the psoriatic lesion 
although their precise role in psoriasis remains to be elucidated.26-28 
 We hypothesize that the in vitro effects of the SH F597 and/or calcipotriol on 
these T-cell subsets can be extrapolated to the in vivo situation.
Material and methods
Patients
Sixteen patients with plaque psoriasis participated in the present study, which was part 
of a double blind, randomized, vehicle- and active-controlled, multicenter, parallel-
Chapter 5 - Antipsoriatic effects of some innovative topical treatments
152
group study of once daily versus twice daily SH F597 F ointment (containing 50 μg/g 
ZK 156942) versus twice daily application of  calcipotriol ointment (containing 50 μg/
g calcipotriol) in patients with plaque type psoriasis. The main study was conducted to 
evaluate clinical efﬁcacy (PASI-score).
 Two patients were treated with calcipotriol bid, 4 patients with SH F597 F bid, 
5 patients with SH F597 F od and SH F597 PD vehicle od, and 5 patients with solely 
vehicle bid. Inclusion criteria included: written informed consent, minimum age of 18 
years old, stable plaque type psoriasis of at least 3 months duration, patients with mild 
to severe psoriasis according to the “Static Investigator’s Global Assessment Scale”, 
body surface area covered with 5% to 30% of psoriatic lesions, wash-out of 1 month 
for systemic treatments and 2 weeks for topical treatments, wash out of at least one 
month since participation in an investigational drug study, normal laboratory tests, 
negative pregnancy test, clinical stable psoriasis between screening- and baseline 
visits. Exclusion criteria were: alcohol abuse, medication that induces psoriasis e.g 
β-blockers, antimalarials, NSAID’s and lithium. 
Clinical score and biopsy procedure
Sum-scores were performed to assess clinical efﬁcacy of the Vitamin D
3 
analogues. 
The SUM-score comprises the total of scores for erythema (0-4), scaling (0-4) and 
induration(0-4). Punch biopsies 4 mm in diameter were taken from the chronic plaque 
lesion on day 0, day 5 and after12 weeks using xylocain/adrenaline as local anaesthetic. 
Biopsy specimens were stored at -80°C before use.
Immunohistochemistry
The following markers were investigated;
(i) T-cell subsets: CD4, CD8, CD45RO, CD45RA, CD2 and CD25. 
(ii) Cells expressing NK-receptors: CD94, CD161.  
(iii) Epidermal proliferation: Ki-67 positive keratinocytes.
(iiii)Epidermal differentiation: Keratine-10 positive epidermis. 
Biopsies were embedded in Tissue Tek OCT compound (Miles Scientiﬁc, Naperville, 
USA), snap frozen in liquid nitrogen and stored at –80°C until use.
 Sections were sliced 6 μm thick and were air-dried for 30 minutes. Then 
the sections were ﬁxed in cold acetone for 10 minutes. To counteract endogenous 
peroxidase, 0.03 % hydrogen peroxide containing sodium azide was used and they 
were washed in PBS (phosphate buffered saline) for 10 minutes. Subsequently 
sections were incubated with the primary antibodies for 1 hour. The following primary 
antibodies (mouse anti-human) were used, diluted in 1% bovine serum albumin 
(Sigma, St Louis, USA)/PBS: anti-CD2 (1:200) (clone MT910), anti-CD4 (clone 
MT310) (1:200), anti-CD8 (clone DK25) (1:200), anti-CD45RO (clone UCHL1) 
(1:100), anti-CD45RA (clone 4KB5) (1:200), anti-CD94 (clone HP-3D9) (1:100), 
anti-CD25 (clone ACT-1) (1:200), Ki67 (clone MIB-1) (1:200),  (all obtained from 
DAKO, Copenhagen Denmark), keratine-10 (clone RKSE60) (1:100) (Monosan 
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Laboratories Uden Netherlands), anti-CD161 (clone 191B8) (1:200) (Immunotech 
Marseille France). False positive staining was excluded by use of isotype control 
antibodies.
 Sections were washed in PBS for 15 minutes. Secondary IgG labeled polymer, 
HRP anti-mouse EnVision+ (DAKO Copenhagen Denmark) was added for 30 
minutes.29 The sections were washed for 15 minutes in PBS. To visualize the staining 
we used AEC+ (3-amino-9-ethylcarbazole) high sensitivity substrate chromogen for 
10 minutes (DAKO Copenhagen Denmark). Counterstaining was performed with 
Mayer’s Haematoxylin (Sigma St Louis USA). The sections were washed in tap water 
and dried. Sections were ﬁnally mounted in glycerol gelatin (Sigma St Louis USA). 
Furthermore, from each patient we performed a hematoxiline-eosine staining. After 
dehydration in alcohol and histosafe, these sections were mounted in Permount.
Immunohistochemical scoring.
For the quantitative analysis of the T-lymphocyte markers we used the following 
procedure: One section of the slide is chosen and all immunocytes with 200x 
magniﬁcation in the epidermal compartment were counted. Epidermal immunocytes in 
the stratum corneum were not counted. The immunocytes in the dermal compartment 
were also counted. Stained dermal T-lymphocytes were counted in an area 100 µm 
under the basement membrane number of positive cells per mm). The HLA-DR marker 
was analysed in the following way: A score of 0-3 (0 = no staining, 1 = slight staining, 
2 = moderate staining, 3 = abundant staining) was designated to the epidermal area 
above the basement membrane, which was divided into two parts. The ﬁrst part was 
chosen, one third of the area above the basement membrane, the second part consisted 
of the remaining epidermal surface. The dermis was scored in the same manner (score 
from 0-3). Finally the percentage of the HLA-DR positive surface was assessed. 
More then 60% HLA-DR positive dermal inﬁltrate was designated as a score of 1 
and less then 60% as a score of 0. The total score in epidermal and dermal zones was 
computed.
Image Analysis
For analysing Ki-67 positive keratinocytes three representative digital photographs 
were made at 100x magniﬁcation. Each photograph was analysed using IP-lab 
software. A line of deﬁned length was drawn along the stratum basale, and all positive 
cells above this line were counted. Quantiﬁcation was done in the unit: positive cells 
per mm length of basement membrane.
 For quantiﬁcation of keratine-10 positive cells, photographs were made at 
50x magniﬁcation. For assessment of the keratine-10 positive epidermal surface, 
only the epidermal compartment was considered. Using IP-lab software, a deﬁned 
window was set for the analysis of an area, which was representative for the section. 
This window was designated as Region of Interest (ROI) The dermal surface was 
subtracted if it was present in the epidermal compartment. The quantiﬁcation was 
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shown in the unit % of epidermal surface. 
Statistical analysis
Change of numbers of T-cells expressing the marker of interest (CD4, CD8, 
CD45RO,CD45RA, CD2, CD25, CD161, CD94) (unit: pos. cells per mm, the number 
of Ki67 (pos. cells per mm. basement membrane), the semi quantitative HLA-DR score 
and the SUM-score were compared between day 0, day 5 and day 56 of treatment. There 
were only two patients using calcipotriol ointment, therefore no statistical analysis 
could be performed in this group. The increase of the % K10 epidermal surface was 
also analysed and compared between day 0, day 5 and day 56 of treatment. Statistical 
Calcipotriol bid SH F597 PD bid SH F597 F bid SH F597 F od
D a y 
0
D a y 
5
D a y 
56
D a y 
0
D a y 
5
D a y 
56
D a y 
0
D a y 
5
D a y 
56
D a y 
0
D a y 
5
D a y 
56
SUM 10.5 9.5 1.5 9.8 9 8.8 9.5 8.5 6.25 9.8 9.8 6.6
KI67 48 42 16 58 33 42 67 36 22 52 31 30
K10 51 69 74 41 66 53 42 74 52 51 55 57
HLA-
DR
3 3 1.7 7 6 5.4 6.75 6.75 4.25 5.2 4.2 4
Table 1 Values for the SUM-score, epidermal proliferation (Ki67 positive cells per mm 
basement membrane) and differentiation (% keratin 10 positive epidermal surface) and HLA-
DR expression for calcipotriol bid (N=2), SH F597 PD bid (N=5), SH F597 F bid (N=4), SH 
F597 F od (N=5) at day 0, day 5 and day 56.
Calcipotriol bid SH F597 PD bid SH F597 F bid SH F597 F od
Epidermis Day 
0
Day 
5
Day 
56
Day 
0
Day 
5
Day 
56
Day 
0
Day 
5
Day 
56
Day 
0
Day 
5
Day 
56
CD4 47 39 10 64 26 38 42 47 27 33 27 21
CD8 20 12 2 40 22 22 19 36 10 19 26 14
CD45RO 46 39 4 67 30 35 47 52 25 44 39 25
CD45RA 8 3 1 13 6 7 7 7 3 10 6 4
CD2 46 42 5 78 26 43 55 62 19 37 44 29
CD25 15 10 1 25 8 13 16 20 12 11 8 5
CD161 10 7 1 14 5 6 4 5 3 5 10 3
CD94 8 4 1 9 3 4 6 6 2 4 5 2
Table 2 Cell counts (positive cells per mm) for T-cell subsets in the epidermis at day 0, day 5 
and day 56 during treatment with calcipotriol bid (N=2), SH F597 PD bid (N=5), SH F597 F 
bid (N=4) and SH F597 F od (N=5).
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analysis was performed using one-way analysis of variance (ANOVA). In case of 
statistical signiﬁcance we performed Duncan’s post hoc comparison. The percentage 
decrease on day 5 and 56 as compared to day 0 is depicted in ﬁgures for each of the 
analysed markers. 
Results
Baseline values, counts at day 5 and day 56 are shown in table 1-3 for all parameters 
in the treatment groups; calcipotriol bid, vehicle bid, SH F597 F od and SH F597 F 
bid.  
 The SUM-scores as a percentage of SUM scores before treatment are 
summarized in ﬁgure 1. At day 5 the SUM scores of the 4 treatments were comparable 
with the scores on day 0, ranging between 89 % and 100 % of the scores before 
treatment. However, at day 56 calcipotriol treated patients (n = 2) had a SUM score of 
14 % of the untreated values in contrast to vehicle (SH F597 PD bid) treated patients 
(n = 5) who had a SUM score of 90% of the untreated values. Patients who had been 
Calcipotriol bid SH F597 PD bid SH F597 F bid SH F597 F od
Dermis Day 
0
Day 
5
Day 
56
Day 
0
Day 
5
Day 
56
Day 
0
Day 
5
Day 
56
Day 
0
Day 
5
Day 
56
CD4 93 144 32 229 161 208 155 168 133 158 156 102
CD8 33 40 15 100 83 99 69 85 81 53 53 50
CD45RO 109 129 29 241 162 192 164 132 124 172 146 106
CD45RA 12 17 4 52 27 33 33 35 25 45 43 25
CD2 109 157 46 190 148 261 201 186 156 190 149 120
CD25 21 26 11 69 32 48 36 57 49 40 31 21
CD161 19 24 4 41 15 19 18 17 8 11 15 6
CD94 8 10 3 21 8 9 8 9 5 5 6 5
Table 3 Cell counts (positive cells per mm) for T-cell subsets in the dermis at day 0, day 5 and 
day 56 during treatment with calcipotriol bid (N=2), SH F597 PD bid (N=5), SH F597 F bid 
(N=4) and SH F597 F od (N=5).
SUM-score
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PD  od
Figure 1 SUM-scores as a 
percentage of SUM scores before 
treatment for the studied topical 
treatments.
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treated with SH F597 F bid reached a statistical signiﬁcant reduction in SUM-score 
at day 56 (P<0.05). Furthermore SH F597 F od reached also a statistical signifcant 
reduction at day 56, as compared to baseline values (P<0.05). The reductions by 
vehicle were not statistically signiﬁcant.
 Scoring proliferation (Ki-67 expression by keratinocytes)(ﬁgure 2) showed 
a modest decrease at day 5 of treatment with calcipotriol (88 % of untreated value) 
and an impressive reduction at day 56 (34 % of untreated value). With respect to the 
reduction of Ki-67+ cells in vehicle (SH F597 PD bid) treated patients, after 5 days 
and 56 days this score was 57% and 73 % of the untreated value, respectively. The 
proliferation scores in patients treated with SH F597 F bid were markedly reduced after 
5 days (54 % of untreated value), improving at day 56 to 32 % of the untreated value, 
reaching an improvement faster than calcipotriol and at end of treatment achieving 
results at least as favourable as calcipotriol. Treatment with SH F597 F od was similar 
to vehicle. No statistical signiﬁcance was reached in any group with respect to the 
reduction of Ki67 positive keratinocytes.
 K10 expression (% keratin 10 positive epidermal surface)(ﬁgure 3) by 
calcipotriol bid had increased to 135 % at day 5 and had reached 146 % of the 
untreated value at day 56. The vehicle (SH F597 PD bid), however even had increased 
K10-positive surface more substantially after 5 days of treatment, reaching a score 
comparable to the one following calcipotriol treatment after 56 days. SH F597 F 
bid showed the most powerful induction of keratin 10 reaching a score of 176 % of 
the untreated value after 5 days, which response faded to 123 % of untreated values 
at day 56. Once daily treatment with SH F597 F od had a rather modest effect on 
Ki67
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Figure 2 Scores for the 
proliferation marker Ki-67 as a 
percentage of the scores before 
treatment for the studied topical 
treatments.
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Figure 3 K10 expression as a 
percentage of the scores before 
treatment for the studied topical 
treatments.
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K10 expression. Again, no signiﬁcance was reached in any group for the percentage 
increase of K10 positive epidermal surface.
 The effect of vitamin D
3
 analogues and vehicle on T-cell subsets in the 
epidermis is summarized in ﬁgure 4 and 5. At day 5 calcipotriol resulted in a score 
of at least 75 % of baseline for the markers: CD4, CD45RO, CD2, in a score of a 
50%-75% for the markers CD8, CD25, CD161 and CD94 and a score of 25-50% 
for CD45RA. On day 56 a reduction of all markers was seen, all below 25 % of pre-
treatment values. 
 A pronounced difference was seen with the response to vehicle (SH F597 
PD bid). Already after 5 days only CD8+ cells had a score of above 50% of untreated 
values whereas all other parameters were between 25-50 % of untreated values, with 
a signiﬁcant reduction of CD2+ T-cells (P<0.05) and a highly signiﬁcant reduction of 
CD4+ T-cells (P<0.01). However after 56 days the response to placebo (SH F597 PD 
bid) showed that all parameters were between 50-75% of untreated values. 
 The response to SH F597 F bid is strikingly different from placebo. After 
5 days all markers except CD45RO were above 100% of untreated values, CD8+ 
T-cells nearly doubling in value. On day 5, SH F 597 F od also appeared to result in 
an increase of CD8, CD2, CD161 and CD94 above 100% of the untreated values, 
whereas CD4, CD45RO, CD45RA and CD94 had values between 50-100% of pre-
treated values, well above placebo. After 56 days for SH F597 F od T-cell markers 
in the epidermis were all between 50%-75% of the untreated values, approaching the 
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Figure 4 The effect of vitamin D3 analogues and placebo on T-cell subsets in the epidermis. 
At day 5 and day 56 the percentage of the score of the untreated value is depicted for treatment 
with Calcipotriol bid , SH F597 PD bid , SH F597 F bid, SH F597 F od and SH F597 PD od for 
the T-cell subset CD4 (A), CD8(B), CD45RO(C), CD45RA(D) .
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Figure 5 The effect of vitamin D3 analogues and placebo on T-cell subsets in the epidermis. 
At day 5 and day 56 the percentage of the score of the untreated value is depicted for treatment 
with Calcipotriol bid, SH F597 PD bid, SH F597 F bid, SH F597 F od and SH F597 PD od for 
the T-cell subset CD2 (A), CD25 (B), CD94(C), CD161(D) .
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Figure 6 The effect of vitamin D3 analogues and placebo on T-cell subsets in the dermis. At day 
5 and day 56 the percentage of the score of the untreated value is depicted for treatment with 
Calcipotriol bid , SH F597 PD bid , SH F597 F bid, SH F597 F od and SH F597 PD od for the 
T-cell subset CD4 (A), CD8(B), CD45RO(C), CD45RA(D)
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vehicle effect. 
 In ﬁgure 6 and 7 the effect of the tested vitamin D
3 
analogues and vehicle on 
T-cell subsets in the dermis is summarized. In contrast to the marked reduction on day 
5 of epidermal T-cell subsets, calcipotriol bid showed an increase of above 100% of 
pre-treatment values for all dermal T-cell subsets on day 5. On day 56 calcipotriol bid 
resulted in a major reduction with a score for all markers between 10 % and 60 % of 
pre-treatment values. 
 Again a marked difference was seen with the response to SH F597 PD bid. 
Effects by SH F597 PD bid on day 5 were less impressive than in the epidermis 
with a score of at least 75% of baseline for the markers: CD8 and CD2, in a score 
between 50%-75% for the markers CD45RA and CD45RO and a score of 25-50% 
for the markers: CD161, CD94 and CD25. However after 56 days again scores for T 
cell subsets were increased to more than 100% of the pre-treatment values for CD2, 
between 75-100% of the untreated values for the markers: CD45RO, CD4 and CD8, 
and less than 75% of the untreated values for CD45RA, CD161 and CD94. 
 The response to SH F597 F bid in the dermis was again strikingly different, 
with all markers on day 5 above 100% of the pre-treatment values, with the exception 
of the markers: CD45RO, CD2 and CD161 with a score between 75-100% of the pre-
treatment values. On day 56, the response was comparable to the score reached by SH 
F597 PD, with a signiﬁcant reduction of CD94+ cells (P<0.05) as compared to day 5 
and day 56. For SH F597 F od effects on dermal T-cell subsets were also comparable 
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Figure 7 The effect of vitamin D3 analogues and placebo on T-cell subsets in the dermis. At day 
5 and day 56 the percentage of the score of the untreated value is depicted for treatment with 
Calcipotriol bid, SH F597 PD bid, SH F597 F bid, SH F597 F od and SH F597 PD od for the 
T-cell subset CD2 (A), CD25 (B), CD94(C), CD161(D) .
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on day 56 to the effects by SH F597 F bid, with a signiﬁcant reduction of CD161+ 
cells (P<0.05) as compared to day 5.
 The HLA-DR expression in both dermis and epidermis is shown in ﬁgure 
8. Calcipotriol and SH F597 F bid did not alter HLA-DR-positive surface at day 5 
but lead to a reduction to 56% and 63% respectively after 56 days. In this respect the 
reduction in HLA-DR expression was signiﬁcant for SH F597 F bid (p<0.05). The 
reductions by SH F597 PD and SH F597 F od were less pronounced
Discussion
The present study suggests that SH F597 F bid and od both were able to signiﬁcantly 
reduce the SUM-score at day 56 (p<0.05), in comparison to vehicle. Furthermore 
after 5 days, SH F597 F bid had an immediate effect on epidermal proliferation (Ki-
67) and keratinisation (K10), which was superior to calcipotriol. Moreover, after 8 
weeks SH F597 F bid reduced epidermal hyper-proliferation to the same extent as did 
calcipotriol, and was more pronounced than SH F597 F od and vehicle bid. Whereas 
SH F597 F bid reduced HLA-DR expression signiﬁcantly at day 56, it did not elicit 
a more than marginal reduction of T-cell subsets. At day 56 there was a reduction 
of CD8+ T-cells by ca. 50%, however, this was also observed in the vehicle-treated 
control group. We can therefore only conclude that SH F597 F had no effect on this 
T-cell subset.  
 We frequently encountered strong vehicle effects by SH F597 PD. The effect 
by the vehicle on epidermal differentiation is remarkable. Already after 5 days, K10 
expression improved with approximately 160%. The vehicle induced a strong effect 
on virtually all T-cell subsets after 5 days of treatment, inducing a highly signiﬁcant 
reduction of epidermal CD4+ T-cells. It is possible that the soothing effect of the 
vehicle in combination with the natural course of psoriasis induces the aforementioned 
improvement of epidermal differentiation and reduction of inﬂammation already at 
day 5.
 Treatment with calcipotriol bid, although only applied in 2 patients and 
therefore of limited interpretation, resulted in a substantial improvement of SUM score, 
proliferation (Ki-67), keratinization (K10) and all T-cell subsets and cells expressing 
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Figure 8 The effect of the studied 
topical treatments on HLA-DR 
expression, as a percentage of the 
untreated scores.
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NK-receptors well beyond placebo (SH F597 PD) after 56 days. This observation is 
in keeping with those from earlier studies, in which a signiﬁcant reduction of several 
T-cell subsets after treatment with calcipotriol bid could be shown.30-32 
In conclusion, the investigated vitamin D
3
 analogues SH F597 F and calcipotriol did 
not show a quick onset effect on T-cell subsets at day 5, in contrast to the quick onset 
of effect on keratinocyte hyperproliferation. This ﬁnding is in accordance with a study 
by de Jong et al., who found a signiﬁcant reduction of CD2+ T-cells only after 4 weeks 
of treatment with calcipotriol,30 although some other investigators found a reduction 
of T-cell subsets in an earlier phase, already after 1 week33 or 2 weeks31 of treatment. 
In addition these data fail to show an effect by SH F597 F on T-cell subsets.
 In a later phase, at day 56, calcipotriol had a substantial effect on T-cell 
subsets and HLA-DR expression, whereas SH F597 F bid only on HLA-DR expression. 
More research is needed to elucidate whether the in vivo effects on lesional T-cell 
subsets and HLA-DR expression by calcipotriol and other vitamin D3 derivatives 
are due to a direct effect on T-cells, or indirectly via normalisation of keratinocyte 
hyperproliferation and disturbed differentiation. 
 One-dimensional staining was used to study several T-cell subsets, and 
therefore overlap exists between several T-cell subsets characterized. For instance 
T-helper cells, monocytes and macrophages all express the CD4 receptor. In addition 
the CD8 receptor is expressed by cytotoxic T-cells and NK-cells. The CD25 receptor 
A B
C
E F
D
Figure 9 Images of 
lesional memory effector 
T-cells (CD45RO) at 50x 
magniﬁcation during treatment 
with SH F597 F ointment bid 
at day 0 (A), day 5(C) and 
day 56(E) and calcipotriol 
ointment bid at day 0 (B), day 
5 (D) and day 56 (F).
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is present on both activated B and T-cells. Some of the CD25+ T-cells also express 
CD4 and belong to the population of regulatory T-cells.34 Their role in psoriasis 
has not yet been elucidated, although this subset is able to inhibit the activation of 
CD25+CD4- T-cell subsets and CD8+ T-cells.35 The CD2 receptor is expressed on 
T-cells and NK cells.36 Memory effector T-cells are of the helper (CD4) or cytotoxic 
type (CD8). Double staining techniques are adequate for identifying T-cell subsets. 
In future studies double staining techniques may elucidate the targeted T-cell subset 
more precisely.
 In earlier studies it was shown that ZK 156942 had the same binding afﬁnity 
as calcipotriol. We can only speculate about the cause of the less anti-inﬂammatory 
efﬁcacy by SH F597 F. Less penetration of the substance is probably not the cause 
of diminished anti-inﬂammatory efﬁcacy, because SH F597 F was able to reduce 
epidermal hyperproliferation, and these cycling keratinocytes reside in the stratum 
basale. Although the binding afﬁnity of both SH F597 F and calcipotriol were 
comparable, the pharmacodynamics of both substances is also determined by other 
parameters, possibly explaining the difference in anti-inﬂammatory properties.  
 SH F597 F bid had a fast and potent effect on epidermal proliferation and 
keratinisation without a marked effect on T-cell subsets. As such, SH F597 F remains 
an interesting new vitamin D
3
 analogue, which in addition to the treatment of chronic 
plaque psoriasis might also have important effects on other disorders characterized by 
epidermal proliferation and abnormal keratinisation.
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6.1 THE EFFECT OF ALEFACEPT ON T-CELL SUBSETS 
AND CELLS EXPRESSING NK-RECEPTORS IN LESIONAL 
PSORIATIC SKIN; EFFECTS OF MONOTHERAPY AND 
COMBINATION TREATMENT WITH CALCIPOTRIOL 
CREAM
Summary
Background New biologic agents, such as alefacept, have been developed for the 
treatment of psoriasis. Alefacept,  a fully human fusion protein, is an effective and 
safe treatment. To enhance clinical efﬁcacy, alefacept may be combined with a topical 
vitamin D3 derivative, such as calcipotriol cream. Biological and clinical aspects of 
alefacept monotherapy and the combination are under investigation in the present 
study.
Objectives To investigate the effect of weekly alefacept monotherapy 15 mg i.m. 
on epidermal hyperproliferation, keratinisation, T-cell subsets and cells expressing 
NK-receptors during 12 weeks of treatment. Furthermore, the addition of calcipotriol 
cream to alefacept treatment was studied and compared with alefacept monotherapy.
Patients and methods Five patients participated in this study, and used weekly 
alefacept 15 mg i.m. combined with calcipotriol cream up to a maximum of 100g 
per week. Biopsies from 2 lesions (one treated and another lesion not treated with 
calcipotriol cream) were taken at week 0 and week 12. We investigated the number 
of T-cell subsets (CD4, CD8, CD45RO, CD45RA, CD2, CD25), cells expressing NK 
receptors (CD94 and CD161), the proliferation marker Ki-67 and the keratinisation 
marker Keratin 10.
Results Alefacept monotherapy induced a statistically signiﬁcant reduction of CD4+, 
CD45RO+ and CD2+ cells in dermis and epidermis and CD8+ cells in epidermis at 
week 12. Furthermore, the Keratin 10 positive epidermal surface was signiﬁcantly 
increased at week 12. The combination of alefacept and calcipotriol cream induced a 
statistically signiﬁcant reduction of only CD4+ and CD45RO+ cells at week 12.
Discussion The number of Memory effector T-cells in the psoriatic lesion is 
signiﬁcantly decreased by alefacept, and calcipotriol cream does not seem to have 
an additional effect on this reduction. Cells expressing NK receptors are virtually not 
targeted by alefacept monotherapy or the combination.
Introduction
Psoriasis is an inﬂammatory skin disease, characterized by epidermal hyper proli-
feration disturbed keratinisation and a mononuclear cell inﬁltrate, mainly consisting 
of T-lymphocyte subsets. The pivotal role of T-lymphocytes in the pathogenesis 
of psoriasis has been shown by several study reports. For instance the efﬁcacy of 
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treatments, which target T-lymphocytes such as cyclosporin A has focussed interest of 
investigators on T-lymphocytes.1
 Therefore, the population of T-cell subsets present in dermis as well as 
epidermis in the psoriatic lesion has been investigated extensively. CD4+ and CD8+ 
T-lymphocytes, present in psoriatic skin, express several markers of activation. For 
instance the CD45RO receptor, representing the memory effector subset is abundantly 
expressed in the psoriatic epidermis, and expresses the CD2 receptor, which is a co-
stimulatory molecule on memory effector T-cells. Other markers of activation are 
the IL-2 receptor (CD25) and HLA-DR, a MHC-II complex.2-4 The IL-2 receptor is 
expressed early in the process of activation, whereas HLA-DR is expressed relatively 
late.
 Since traditional antipsoriatic treatments do not have a speciﬁc immuno-
modulatory action new treatment strategies were developed, speciﬁcally targeting T-
lymphocytes such as alefacept (Amevive®). Alefacept is a recombinant, fully human 
fusion protein. It has a dual action, on the on the one hand it reduces the memory 
effector T-cell subset by inhibiting the co-stimulatory CD2-LFA-3 interaction, on the 
other hand it facilitates the NK mediated lyses of memory effector T-cells.5;6 
Krueger et al. have investigated the clinical efﬁcacy of alefacept. They showed 
in a placebo controlled study that the mean psoriasis area severity index (PASI) 
progressively decreases in patients receiving alefacept during a 12-week treatment 
period and continued to decrease further after the last dose. A second course of 12 
weeks had an additional beneﬁt, reducing the mean PASI even more.7 Alefacept 
treatment has a positive effect on quality of life and may result in long-term remissions 
of psoriasis.8 Furthermore it appears to be safe, since no clinical signiﬁcant signs of 
immunosuppression, opportunistic infections or increase in malignancy have been 
reported.
 Several investigators have studied the effect of alefacept on peripheral blood 
T-cells and T-cells in lesional skin. Alefacept treatment at therapeutical doses results 
in a selective reduction of memory effector T-cells (CD45RO+) in peripheral blood, 
which is correlated with clinical improvement.5;9 Alefacept as i.v. treatment 7,5 mg 
per week proved to reduce the number of CD8+ cells in epidermis and CD4+ cells in 
dermis, reaching a statistically signiﬁcant reduction after 92 days. The CD45RO+ T-
cells, according to these investigators, showed a reduction in those patients reaching 
a decrease of PASI by at least 50% (n=3) whereas the other 8 patients did not show a 
signiﬁcant response of CD45RO+ cells.10 Krueger et al. reported a reversal of Keratin 
16 expression, again in i.v. treated patients in lesional epidermal skin by alefacept 
during 12 weeks. In the 5 responders out of 13 patients, a substantial decrease of 
CD8+ and CD103+ cells were observed in lesional skin.11
 Alefacept has been reported to promote selectively NK cell mediated 
deletion of CD45RO human T cells.6 As psoriatic lesions contain cells expressing NK 
receptors, it may be relevant to the mode of action of alefacept whether the number of 
these cells change during alefacept treatment. Therefore, studies of alefacept on cells 
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expressing NK receptors seem to be worthwhile. The ﬁrst aim of the present study is 
to investigate the effect of i.m. alefacept (15 mg per week) on T-cell subsets in the 
psoriatic lesion, also comprising cells with NK-cell receptors, epidermal proliferation 
and keratinization.
 In a previous study we have shown a substantial effect of calcipotriol on 
epidermal proliferation, normalization of keratinisation and decrease of T-cell subsets, 
with a signiﬁcant reduction of memory effector T-cells, which response was reinforced 
by corticosteroids.12 The combination of a vitamin D3 derivative, a ﬁrst-line topical 
treatment for psoriasis, with alefacept may have advantages. At the molecular 
level the effect of alefacept on CD45RO+ cells in lesional skin may be reinforced 
by calcipotriol. Furthermore calcipotriol normalizes keratinisation and decreases 
epidermal proliferation, processes not directly targeted by alefacept. Currently no 
data are available about the clinical and biological effects of the combination of 
alefacept and vitamin D3 derivatives. It is possible that combination of biologicals 
with the current armamentarium of antipsoriatic treatments may lead to improved 
control of psoriasis, longer remissions and signiﬁcant amelioration of quality of life.13 
Therefore, the second aim of this study was to ﬁnd out whether an additional effect of 
calcipotriol cream to alefacept can be found  with respect to the clinical efﬁcacy, T-
cell subsets, cells expressing NK receptors, epidermal proliferation and keratinisation 
in the psoriatic lesion. 
Material and Methods
Patients
Five patients with moderate-to-severe plaque psoriasis used alefacept 15 mg weekly 
for a period of 12 weeks, and applied a maximum of 100g of calciporiol cream per 
week, which in general implied once daily every other day (Daivonex®, 50 μg/g 
cream, Leo Pharmaceutical Products, Denmark). One lesion was not treated with 
calcipotriol cream. Furthermore, patients had stopped topical treatment 2 weeks before 
the investigation. Systemic treatment or UV-radiation had been stopped at least one 
month before start of the investigation. They did not use any medication that could 
interfere with the severity of psoriasis. 
Clinical score and biopsy procedure
After receiving informed consent, the SUM-scores of two target lesions, one treated 
with calcipotriol ointment, were assessed. Two symmetrical test lesions were deﬁned 
Erythema, scaling and induration were assessed on a 5 point scale and the sum of these 
scores were calculated (SUM-score). Punch biopsies 4 mm in diameter were taken 
from the chronic plaque lesion after local anaesthesia with 1% adrenaline xylocaine. 
Biopsy specimens were stored at -80°C before use. 
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Immunohistochemistry
The following markers were investigated;
(i) T-cell subsets: CD4, CD8, CD45RO, CD45RA, CD2 and CD25. 
(ii) Cells expressing NK receptors: CD94, CD161.  
(iii) Epidermal proliferation: Ki-67 positive keratinocytes.
(iiii)Epidermal differentiation: Keratine-10 positive epidermis. 
Biopsies were embedded in Tissue Tek OCT compound (Miles Scientiﬁc, Naperville, 
USA), snap frozen in liquid nitrogen and stored at –80°C until use.
 Sections were sliced 6 μm thick and were air-dried for 30 minutes. Then 
the sections were ﬁxed in cold acetone for 10 minutes. After blocking 5 minutes for 
endogenous peroxidase, using 0.2% sodium azide, they were washed in PBS for 10 
minutes. Subsequently sections were incubated with the primary antibodies for 1 
hour. The following primary antibodies (mouse anti-human) were used, diluted in 1% 
bovine serum albumin (Sigma, St Louis, USA)/PBS: anti-CD2 (1:50) (clone MT910), 
anti-CD4 (clone MT310) (1:25), anti-CD8 (clone DK25) (1:25), anti-CD45RO (clone 
UCHL1) (1:25), anti-CD45RA (clone 4KB5) (1:25), anti-CD94 (clone HP-3D9) 
(1:25), anti-CD25 (clone ACT-1) (1:25), Ki67 (clone MIB-1) (1:100),  (all obtained 
from DAKO, Copenhagen Denmark), keratine-10 (clone RKSE60) (1:100) (Monosan 
Laboratories Uden Netherlands), anti-CD161 (clone 191B8) (1:25) (Immunotech 
Marseille France).
 Sections were washed in PBS for 15 minutes. Secondary IgG labeled 
polymer, HRP anti-mouse EnVision+ (DAKO Copenhagen Denmark) was added 
for 30 minutes.14 The sections were washed for 15 minutes in PBS. To visualize the 
staining we used AEC + High Sensitivity Substrate Chromogen for 10 minutes (DAKO 
Copenhagen Denmark). Counterstaining was performed with Mayer’s Haematoxylin 
(Sigma St Louis USA). The sections were washed in tap water and dried. Sections 
were ﬁnally mounted in glycerol gelatin (Sigma St Louis USA). Furthermore, from 
each patient we performed a hematoxiline-eosine staining. After dehydration in 
alcohol and histosafe, these sections were mounted in Permount.
Immunohistochemical scoring.
 For the quantitative analysis of the T-lymphocyte markers we used the 
following procedure: One section of the slide is chosen and all immunocytes with 200 
x magniﬁcation in the epidermal compartment are counted. Epidermal immunocytes 
in the stratum corneum are not counted. The immunocytes in the dermal compartment 
are also counted. Positive dermal T-lymphocytes are counted between the basement 
membrane and 100 um under the basement membrane. 
Image Analysis
For analysing Ki-67 positive keratinocytes three representative digital photographs 
are made at 100x magniﬁcation. Each photograph is analysed using IP-lab software. 
A line is drawn, with a known length, following the stratum basale, and all positive 
cells above this line are counted. Quantiﬁcation is done in the unit: positive cells per 
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mm length of basement membrane.
 For quantiﬁcation of keratine-10 positive cells, photographs are made at 
50x magniﬁcation. For counting the keratine-10 positive epidermal surface, only the 
epidermal compartment is used as region of interest (ROI). Using IP-lab software 
a deﬁned window is set for the analysis of the markers from an area, which is 
representative for the section. This window is designated as Region of Interest (ROI). 
The dermal surface is substracted if it is present in the epidermal compartment. 
Quantiﬁcation is measured as a % of epidermal surface as unit.
Statistical analysis
A Wilcoxon ranking test for paired data was used to determine whether assessments 
before treatment were signiﬁcantly different from the assessments after treatment. 
Furthermore, the values for each marker after additional calcipotriol cream treatment 
were evaluated against no use of calcipotriol cream
Results
Alefacept monotherapy and the combination of alefacept and calcipotriol both reached 
exactly the same reduction of 73,91 %, inducing a signiﬁcant decrease in SUM-score. 
(p<0.05). (ﬁgure 1, table 1)
 With respect to the number of Ki-67 positive epidermal cells alefacept 
monotherapy and the combination of alefacept and calcipotriol induced an 11,15 % 
and 25,39 % decrease respectively, without reaching statistical signiﬁcancy. (ﬁgure 2, 
table 1) The percentage K10 expression in the epidermis signiﬁcantly increased after 
12 weeks of alefacept monotherapy with 24,92 % (p<0.05) and after combination 
P-values Alefacept 
monotherapy 
Combination alefacept 
and calcipotriol 
epidermis dermis epidermis dermis 
SUM-score 0.043 0.043 
Ki67 0.079 0.69 
K10 0.043 0.079 
CD4 0.043 0.043 0.043 0.079 
CD8 0.043 0.068 0.22 0.22 
CD45RO 0.043 0.043 0.043 0.22 
CD45RA 0.067 0.043 0.79 0.14 
CD2 0.043 0.043 0.14 0.079 
CD25 0.14 0.043 0.079 0.22 
CD161 0.043 0.11 0.34 0.079 
CD94 0.50 0.079 0.079 0.22 
Table 1 The p-values 
for the investigated 
markers are depicted, 
during treatment with 
alefacept monotherapy 
and the combination 
of alefacept and calci-
potriol cream at week 0 
and week 12.
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therapy with alefacept and calcipotriol an increase of 22,56 % was observed, which 
did not reach statistical signiﬁcance.(ﬁgure 3, table 1) A statistical analysis of the 
counts for Ki-67 and the percentage K10 expression in the epidermis after 12 weeks of 
treatment with alefacept monotherapy versus the combination, revealed no statistically 
signiﬁcant differences, and even not a tendency for a modulatory effect by calcipotriol 
on alefacept induced changes.
 The number of T-cell subsets at week 0 and week 12 for alefacept 
monotherapy and the combination of alefacept and calcipotriol are depicted in ﬁgure 
4 and 5. CD4, CD8, CD45RO and CD45RA positive cells in the epidermis all showed 
at least a tendency to reduce following alefacept treatment with or without calcipotriol 
(ﬁgure 4A and 4B, table 1) A statistically signiﬁcant reduction (p<0.05) following 
alefacept monotherapy was observed for CD4+ cells, CD8+ cells and CD45RO+ cells. 
Following combination treatment the statistical signiﬁcancy (p<0.05) was restricted 
to the CD45RO+ and CD4+ population. In the dermis (ﬁgure 4C and 4D, table 1) the 
CD4+, CD8+, CD45RO+ and CD45RA+ all tended to reduce after alefacept with and 
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Figure 1 The SUM score for alefacept 
monotherapy and the combination 
of alefacept and calcipotriol cream 
at week 0 and week 12. Alefacept 
monotherapy and the combination both 
induced a signiﬁcant reduction at week 
12. (p<0.05)
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Figure 2 Epidermal proliferation 
(number of Ki67 positive cells per mm 
basement membrane) at week 0 and 
week 12 for alefacept monotherapy 
and the combination of alefacept and 
calcipotriol cream. No signiﬁcant 
reduction of the number of Ki67 
positive cells is observed at week 12 
for both treatments.
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Figure 3 The percentage keratin 
10 epidermal surface at week 0 and 
week 12 for alefacept monotherapy 
and the combination of alefacept and 
calcipotriol cream. Only alefacept 
monotherapy induced a signiﬁcant 
(p<0.05) increase at week 12.
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without calcipotriol. However, statistical signiﬁcancy was observed only for dermal 
CD45RO+ cells and CD4+ cells after monotherapy with alefacept. After combination 
therapy no statistically signiﬁcant reductions were observed in the dermis.
 The CD2+, CD25+ cells in the epidermis tended to reduce during alefacept 
Figure 4 The number of CD4+, CD8+, CD45RO+ and CD45RA+ cells in epidermis (A and B) 
and dermis (C and D) at week 0 and week 12 for alefacept monotherapy and the combination of 
alefacept and calcipotriol cream respectively. (For p-values see table 1).
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Figure 5 The number of CD2+, CD25+, CD94+ and CD161+ cells in epidermis (A and B) and 
dermis (C and D) at week 0 and week 12 for alefacept monotherapy and the combination of 
alefacept and calcipotriol cream respectively. (For p-values see table 1).
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treatment with and without calcipotriol.(ﬁgure 5A and 5B, table 1) A statistically 
signiﬁcant reduction (p<0.05) was found for CD2+ cells after monotherapy only. In 
the dermis (Figure 5C and 5D) monotherapy resulted in a statistically signiﬁcant 
reduction of CD2+ and CD25+ cells, with only a tendency of a reduction following 
combination treatment.
 The cells expressing NK receptors showed only modest changes in epidermis 
and dermis (Figure 5 and table 1). CD94+ cells even did not show a tendency of 
any change and the CD161+ cells showed only in the epidermis after monotherapy 
a statistically signiﬁcant decrease, with a modest tendency of a decrease following 
combination therapy. 
 After 12 weeks of treatment markedly less pronounced reductions of 
CD45RO+ cells were observed after combination therapy as compared to alefacept 
monotherapy (p<0.05). Moreover for the combination treatment the reductions at 12 
weeks tended to be less pronounced for CD8+, CD4+, CD2+ and CD25+ cells, both 
in dermis and epidermis. In contrast, CD161+ and CD94+ cells were similar after 
combination treatment and monotherapy. HLA-DR expression in the epidermis tended 
to decrease after monotherapy and with the combination, however these decreases did 
not reach statistical signiﬁcance.(ﬁgure 6)                                                                    
Discussion
A remarkable observation is the impressive reduction of the SUM score by 73.91% 
both following monotherapy with alefacept and the combination treatment. The 
present investigation was part of a multi-centre study to evaluate the effect of 
alefacept with calcipotriol cream. The overall responses of the individual patients 
on various combinations of alefacept will be reported elsewhere. With respect to the 
patients reported in the present communication, the investigator and the patients were 
impressed about the clinical response. It should be noted from phase 2 and 3 studies 
that between 14% and 28 % of the patients on alefacept have at least a 75% PASI 
reduction after one course of 12 weeks, indicating that in general a large proportion 
of patients on alefacept have an incomplete response.5;7 The similarity in clinical 
efﬁcacy between the combination and alefacept monotherapy is evident. Twice-
daily calcipotriol every day might have had a substantial additional effect. However, 
HLA-DR
0
1
2
3
4
5
6
7
8
WK 0 WK 12
Alefacept and calcipotriol
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Figure 6 HLA-DR expression at 
week 0 and week 12 during treatment 
with alefacept monotherapy and 
the combination of alefacept and 
calcipotriol cream respectively. No 
signiﬁcant reduction could be observed 
for both treatments.
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the maximum weekly quantity of 100 g calcipotriol cream implied that this topical 
treatment had to be restricted to less once daily treatments on alternate days.
 In contrast to the marked clinical improvement of the small group of 
5 patients in the present study, the reduction of proliferation and improvement of 
keratinisation was modest, with only a statistically signiﬁcant increase of Keratin 
10 epidermal surface for monotherapy alefacept. In a previous study of our group, 
however, a signiﬁcant reduction of Ki-67 positive nuclei has been observed during 
alefacept treatment. Moreover, Krueger et al reported a reversal of the proliferation-
associated Keratin16 during alefacept treatment. In our study addition of calcipotriol 
did not result in an increased effect on epidermal growth and differentiation.
 At variance with the modest changes of epidermal growth and differentiation 
but in line with the marked clinical response is the reduction of T-cell subsets. We can 
reconﬁrm the data of two previous pilot studies that alefacept results in a decrease of 
CD4+ and CD8+ cells.10;11 Goedkoop et al. showed that the reduction of CD45RO+ 
cells was conﬁned to those patients who showed a good clinical response and therefore 
was conﬁned to only 3 patients.10 In the present study we showed for alefacept 
monotherapy a major reduction of CD45RO+ cells in the epidermis and dermis of 
84% and 51% respectively, within a group of 5 patients. For comparison, we have 
shown that monotherapy with calcipotriol ointment bid applicated resulted in a 71% 
and 53% reduction in epidermis and dermis respectively. Other T-cell subsets, which 
reduced signiﬁcantly, were: CD2 (dermis and epidermis) and CD25 (dermis), which 
indicates that activated T-cells decrease during alefacept monotherapy. The reduction 
of CD45RA in the dermis could be interpreted by the overall consolidation of the 
psoriatic process during alefacept monotherapy. However the persistence of most 
cells with NK receptors is intriguing in this respect. Exclusively the CD161+ cells 
reduced signiﬁcantly in epidermis during alefacept montherapy. In a previous study, 
calcipotriol ointment did not affect cells expressing NK receptors, whereas topical 
corticosteroids caused a signiﬁcant reduction of these cells. Therefore, the cells with 
NK receptors prove to respond differently to various antipsoriatic treatments.
 The added value of calcipotriol to alefacept with respect to a further reduction 
of T-cell subsets, cells expressing NK receptors and to a better clinical response is 
not evident from this study. In contrast, even a reduction of the effects induced by 
alefacept is suggested by our study. However, we have to reconcile that the design of 
our study has some limitation. Due to the design of our study, the usage of calcipotriol 
cream with a maximum of 100g/week in patients with extensive disease implied a 
reduced frequency of application. The reduced efﬁcacy by the combination therapy 
may be caused by a suboptimal calcipotriol cream usage.
 In conclusion, the present study reconﬁrms that alefacept monotherapy 
results in a signiﬁcant reduction of CD4, CD8, CD45RO+ cells. The present study 
demonstrates that these changes are more pronounced as compared to the changes 
in epidermal proliferation and keratinisation. Furthermore, cells with NK receptors 
seem to be virtually unaffected by alefacept. A low dose calcipotriol treatment does 
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not seem to add to the effects of alefacept. 
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6.2 DERMATOLOGICAL CONDITIONS DURING TUMOR 
NECROSIS FACTOR ALPHA BLOCKING THERAPY 
IN PATIENTS WITH RHEUMATOID ARTHRITIS: A 
PROSPECTIVE STUDY
Abstract
Background Various dermatological conditions have been reported during TNF-α 
blocking therapy, but at present no prospective studies have been performed focusing 
on this aspect.
Objective To investigate the number and nature of clinically important dermatological 
conditions during TNF-α blocking therapy in RA patients.
Methods RA patients, starting on TNF-α blocking therapy, were prospectively followed. 
The number and nature of dermatological events that were reason for a dermatological 
consultancy were recorded. The number of patients with a dermatological event was 
compared to a group of prospectively followed RA control patients, naive to TNF-α 
blocking therapy and matched for follow-up period.
Results 289 RA patients started TNF-α blocking therapy. 128 Dermatological events 
were recorded in 72 patients (25%) during 911 patient-years of follow-up. TNF-α 
blocking therapy was stopped in 19 patients (26%) because of the dermatological 
event. Statistically signiﬁcant more RA patients on TNF-α blocking therapy (25%) 
visited a dermatologist during follow-up, compared to anti-TNF-α naive patients (13%, 
p<0.0005). Events were recorded more often during active treatment (0.16 events per 
patient-year) than during the period of withdrawal of TNF-α blocking therapy (0.09 
events per pt-yr, p<0.0005).
The events recorded most frequently were skin infections (n=33), eczema (n=20) and 
drug eruptions (n=15). Other events with a possible relationship to TNF-α blocking 
therapy included vasculitis, psoriasis, drug-induced SLE, dermatomyositis and a 
lymphomatoid-papulosis like eruption. 
Conclusion This study is the ﬁrst large prospective study focusing on dermatological 
conditions during TNF-α blocking therapy. It shows that dermatological conditions 
are a signiﬁcant and clinically important problem in RA patients on TNF-α blocking 
therapy.
Introduction
The introduction of biological agents, like TNF-α blocking agents, has dramatically 
changed the therapeutic approach of rheumatic diseases over the last years. TNF-α 
blocking therapy has shown a remarkable effect on disease activity in an increasing 
number of rheumatic diseases, like rheumatoid arthritis (RA) 1-3, juvenile idiopathic 
arthritis (JIA) 4, ankylosing spondylitis (AS) 5;6 and psoriatic arthritis (PsA).7 Currently 
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two monoclonal anti-TNF-α antibodies (inﬂiximab and adalimumab) and one soluble 
p75 TNF-α-receptor (etanercept) are being used in rheumatological practice. 
 Various skin conditions have been reported in clinical trials like urticaria, 
rash and stomatitis during inﬂiximab therapy 8, rash and injection site reactions during 
adalimumab therapy 3;9 and injection site reactions during etanercept therapy.2
However, clinical trials are not designed to provide information on the occurrence of 
rare adverse events associated with TNF-α blocking therapy. More severe cutaneous 
reactions like, amongst others, erythema multiforme, discoid and subacute cutaneous 
lupus erythematosus, atopic dermatitis, necrotizing vasculitis and bullous skin lesions 
have been reported, mostly as single case observations.10-15 Larger observational 
studies, like biological registries, are needed to provide information on the nature and 
number of these dermatological adverse events during TNF-α blocking therapy.
 The aim of this study was to investigate whether dermatological conditions 
following TNF-α blocking therapy are a signiﬁcant and clinically important problem 
in RA patients receiving TNF-α blocking therapy.
Patients and methods
Study design
In a prospective cohort study all consecutive RA patients, according to the ACR-
criteria16, starting on TNF-α blocking therapy at the department of rheumatology of the 
Radboud University Nijmegen Medical Centre were followed as part of a Biological 
Registry.17 Approval was obtained by the Ethics committee.
 Patients were required to meet the Dutch guidelines criteria for biological 
therapies: moderate to high disease activity (DAS28 ≥ 3.2) and failure or intolerability 
of at least two disease modifying antirheumatic drugs (DMARDs), including 
methotrexate in adequate dosage regimens. Besides therapy with registrated TNF-α 
blocking agents, like inﬂiximab, etanercept and adalimumab a number of patients was 
treated in clinical trials with lenercept, a soluble p55 TNF-α-receptor.18
 In this cohort the number and nature of dermatological conditions occurring 
during follow-up, which were reason for consultancy of a dermatological specialist, 
were investigated. The number of RA patients with dermatological events was 
compared to a control group, naive to TNF-α blocking therapy. Control patients were 
selected from the Nijmegen inception cohort, in which 500 RA patients have been 
followed since 1985 19. Controls were matched one on one for duration and calendar-
time of follow-up period, using a 2-month window.
Variables
Data collected at the start of TNF-α blocking therapy were age, sex, disease duration, 
rheumatoid factor (RF) (by ELISA, considered positive if > 10 IU/ml), anti-nuclear 
antibody (ANA, by immunoﬂuorescence on Hep-2 cells), the number of previously 
used DMARDs and start date of TNF-α blocking therapy. Furthermore, erythrocyte 
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sedimentation rate (ESR), 28 joint counts for swelling and tenderness and a visual 
analogue scale for general well-being were collected at baseline and the disease 
activity score (DAS28) was calculated.20
 Variables collected during TNF-α blocking therapy were: the use of 
concomitant DMARDs and prednisolone, dose and interval changes of TNF-α 
blocking agents and, if appropriate, date and reason for discontinuation.
 All patients who visited a dermatologist during follow-up were identiﬁed. 
Clinically important dermatological events were deﬁned as any new manifestation or 
exacerbation of pre-existing skin disease during follow-up. The events were recorded 
using a standardized chart review form. The following data were recorded: start date 
of event, dermatological history, medication, morphological description, localization, 
histopathological and immunohistological information if present, working diagnosis, 
additional investigations, topical and systemic therapeutic actions, outcome of event 
and, if present, information on rechallenge.
 Drug eruptions were deﬁned as skin reactions with a probable or deﬁnite 
relationship to the use of TNF-α blocking agents, based on a time relation with the 
administration of the agent, morphological pattern and/or histological information. 
Drug eruptions were classiﬁed morphologically according to Fitzpatrick et al.21 
Furthermore, events were classiﬁed for seriousness into major or minor events. Major 
events were deﬁned as those events requiring hospitalization.
 Patient-years of follow-up were calculated for total follow-up, for time 
on active therapy and for time after discontinuation of therapy (time off therapy). 
The number of events per year of follow-up was calculated for each RA patient for 
total time of follow-up, for time on active treatment and for time off treatment, if 
appropriate.
 In the control group the following baseline characteristics were collected: 
age, sex, disease duration, RF, ANA, DAS28, the number of previously used DMARDs 
and prednisolon use. All patients who visited a dermatologist during follow-up were 
identiﬁed. Events were not recorded in the control group.
Statistical analyses
Baseline characteristics were compared between RA patients on TNF-α blocking 
therapy with and without dermatological events. Chi-square tests were applied for 
dichotomous variables and Student’s T-tests were used for continuous variables. Non-
parametric tests were applied, when appropriate. The number of events per patient-
year (pt-yr) of follow-up was compared between patients on active TNF-α blocking 
therapy and patients off TNF-α blocking therapy using Wilcoxon signed rank statistics. 
Univariate and multivariate logistic regression analyses were performed to identify 
possible predictive factors for the occurrence of a dermatological visit (independent 
variable, dichotomous) in RA patients on TNF-α blocking therapy. Dependent 
variables tested were sex, age at diagnosis, RF, ANA, disease duration, DAS28 at 
baseline, prior number of DMARDs, use of prednisolone and duration of follow-up. 
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Odds ratios (OR) and 95% conﬁdence intervals (95%CI) were calculated.
 The number of patients who visited a dermatologist was compared between 
RA patients on TNF-α blocking therapy and controls using Chi-square test. P-value 
and Odds ratios were calculated.
 All tests were two-sided with a p-value < 0.05 considered statistically 
signiﬁcant. Statistical analyses were performed using SPSS statistical software (v 
12.0.1, SPSS Inc, USA).
Results
Patients
A total of 289 RA patients started TNF-α blocking therapy between June 1994 and 
December 2003. Baseline characteristics are shown in table 1. Dermatological 
conditions prior to start of TNF-α blocking therapy were recorded 56 times in 
34 patients (47%) and included 10 drug reactions (7 on gold, 2 on NSAIDs, 1 on 
methotrexate), 10 eczema’s, 9 mycosis, 3 other infections and 5 chronic venous 
insufﬁciency (CVI), amongst others.
RA pt not on
TNF-α blocking 
therapy
RA pt on
TNF-α blocking therapy
N=289 All RA patients
N=289
RA patients with 
dermatologic 
events
N=72
Male sex, n (%) 110 (38) 89 (31) 20 (28)
Age at diagnosis in yr, mean 
(SD)
54.6 (14.1)# 44.5 (14.7) 43.4 (12.7)
RF positive, n (%) 205 (71)* 249 (87) 68 (94)
Disease duration at baseline in 
yr, median (range)
6.2 (0.0-12.6) # 9.2 (0.1-44.9) 10.3 (0.3-44.9)$
DAS28 at baseline, mean (SD) 3.6 (1.4)# 5.9 (1.1) 6.1 (1.1)
ANA positive at baseline, n 
(%)**
118 (41) 112 (50) 33 (49)
Prior DMARDs, median 
(range)
1 (0-6)# 4 (1-10) 5 (2-8)
Prednisolone at baseline, n (%) 21 (7)# 112 (39) 34 (47)
Table 1: Baseline characteristics
*p<0.001 and #p<0.0001, compared to RA patients on TNF-α blocking therapy. $p<0.001 and 
##p<0.0001, compared to RA patients on TNF-α blocking therapy without dermatological events. 
** ANA at start was present in respectively 261 and 67 patients on TNF-α blocking therapy.
Chapter 6 - Antipsoriatic efﬁ cacy and side effects of biologicals
183
 Median follow-up time was 2.3 years (range 0.02-9.6). Total follow-up time 
was 911 patient-years with 627 patients-years representing active therapy. 70 Out of 
289 RA patients (24%) received more than one TNF-α blocking agent and 8 patients 
(3%) received more than two agents. Inﬂiximab was administered to 167 patients, 
adalimumab was administered to 108 patients, etanercept was administered to 78 
patients and lenercept was administered to 31 patients.
 Dermatological events were recorded in 72 out of 289 RA patients (25%) 
on TNF-α blocking therapy. In the control group (n=289) 37 patients (13%) visited a 
dermatologist. The Odds ratio (OR) of TNF-α blocking therapy for a dermatological 
referral was 2.26 (95%CI 1.46-3.50, p<0.0005). 
Predictive factors
In univariate analyses duration of follow-up (OR 1.27, 95%CI 1.14-1.41, p<0.0005) 
and disease duration (OR 1.03, 95%CI 1.003-1.07, p<0.05) were statistically 
signiﬁcant predictive factors for a dermatological event. In a multivariate model only 
duration of follow-up was a statistically signiﬁcant predictive factor (OR 1.30, 95%CI 
1.12-1.52, p<0.001).
Dermatological events
128 Dermatological events were recorded during follow-up in RA patients on TNF-α 
blocking therapy (0.14 event per pt-yr), as listed in table 2. The event per pt-yr ratio 
was 0.16 during active treatment and 0.10 off treatment (p<0.001). The number of 
events recorded during or after treatment was 56 for adalimumab (0.12 event per pt-
yr), 49 for inﬂiximab (0.14 per pt-yr), 16 for etanercept (0.13 per pt-yr) and 13 for 
lenercept (0.07 per pt-yr). Permanent withdrawal of TNF-α blocking therapy due to 
dermatological events occurred 21 times in 19 patients.
Infections
33 Infections were recorded in 27 patients, consisting of 20 fungal, 11 bacterial and 2 
viral infections (see table 3). Two patients had a previous episode of dermatomycosis. 
None of the patients required hospitalization. One patient, temporarily discontinuing 
adalimumab monotherapy twice because of elective surgery, developed a bacterial 
superinfection of pre-existent eczema after every restart.
Eczema
Eczema was diagnosed 20 times in 19 patients and consisted of various morphological 
patterns. Most events were described as erythematosquamous (n=8) or erythematous 
(n=3) lesions or plaques, localized on hands and feet (n=3), arms and legs (n=5), face 
(n=1), neck (n=1) and buttocks (n=1). Vesicular rash on hands and feet was described 
5 times. A papular rash was described in 3 cases with localization around the eyes, on 
the back and once on back and lower legs. Diagnoses consisted of dyshidrotic eczema 
(n=5), contact (n=4), nummular (n=1), atopic (n=1), papular (n=1) and nonspeciﬁc 
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eczema (n=8). Two patients had a prior history of dyshidrotic eczema.
 Biopsies were performed in 5 events. Histology showed dermatitis and 
spongiosis in all cases with high dermal perivascular inﬁltration in three cases. One 
biopsy also showed mild psoriasiform acanthosis and another showed additional 
keratinocyte necrosis.
 Three patients stopped TNF-α blocking therapy because of the event, after 
which the lesions resolved. Hospitalization was necessary for treatment of eczema 
in one patient. In another patient the eczematous lesions recurred after restart with 
adalimumab therapy. Adalimumab was continued and topical steroids were applied 
with good effect. TNF-α blocking therapy had already been stopped in 4 patients 
prior to onset of eczema and was continued in 13 patients of whom 7 had persisting or 
recurring lesions. Therapy consisted mostly of topical corticosteroids.
Drug eruptions
Drug eruptions occurred frequently during the ﬁrst 5 months of TNF-α blocking 
therapy and were caused by all four TNF-α blocking agents (see table 4). In two 
cases a generalized drug eruption followed subcutaneous injection of etanercept. In 
two cases the eruption developed during infusion (patient no. 8 and 11, table 4). In 
the other cases the time of onset ranged between 2 and 57 days since the most recent 
infusion.
 Most drug eruptions consisted of a combination of morphological patterns, 
including exanthema, urticarial eruptions, lichenoid skin lesions and purpura. 
In four patients an eczematous drug eruption was seen. Classiﬁcation as drug 
eruption was based on a time-relationship with administration of TNF-α blocking 
agent, the morphological pattern and/or histological information. Two patients had 
experienced a previous drug-induced eruption (1 gold-dermatitis, 1 dermatitis after 
indomethacine).
 Histology was compatible with the diagnosis in all cases. Perivascular 
inﬁltrations, predominantly lymphocytic, epidermal exocytosis and hyperothokeratosis 
were described. Interface dermatitis was described three times. One biopsy revealed 
focal inﬁltrations with marked vascular and endothelial proliferation.
 7 Patients stopped and 8 patients continued therapy, 6 of them had a positive 
rechallenge and recurring lesions. One major event was recorded: one RA patient was 
hospitalized for an extensive eczematous eruption with urticaria on arms and legs 
(ﬁgure 1 and nr. 6, table 4). Treatment consisted mostly of topical application of 
corticosteroids and sometimes of systemic antihistaminics.
Tumors and actinic keratosis
Events of skin malignancies were recorded 5 times in 4 patients. One RA patient 
developed three basal cell carcinomas simultaneously on her left arm, right nostril and 
right eyelid after 2.7 years of adalimumab therapy, which was subsequently stopped. 
One 74-year-old RA patient developed Bowen’s disease on his right hand 2 years 
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after stop of adalimumab therapy. The same patient later developed a squamous cell 
carcinoma on the left earlobe after start of etanercept therapy. Other skin malignancies 
recorded were a squamous cell carcinoma (earlobe) after 1.5 months of adalimumab 
therapy and a low-grade basalioma (Pinkus epithelioma) on the leg after 6 months 
of adalimumab therapy. In all cases histology conﬁrmed the diagnosis and therapy 
consisted of excision. No recurrences were seen.
 Actinic keratosis was recorded in ﬁve patients (3 adalimumab, 1 inﬂiximab, 
1 lenercept). Excision or cryotherapy was successful in 4 patients. One patient had 
recurring actinic lesions on the scalp.
 Benign tumors were recorded 7 times during TNF-α blocking therapy. One 
patient experienced an increased growth of a facial teleangiectatic nevus, present since 
childhood, two months after starting etanercept therapy. Seborrhoic keratosis (n=3), 
oral hyperkeratosis (n=1), histiocytoma (n=1) and ﬁbroma (n=1) were also recorded.
Vasculitis
Vasculitis was recorded 5 times: 4 during and 1 after stop of TNF-α blocking 
therapy. The diagnosis was conﬁrmed by biopsy in 4 cases. One patient developed 
ﬁgure 1 Eczematous drug eruption
Eczematous drug eruption in a RA patient after inﬂiximab therapy: Eczematous eruptions on 
the left arm (left upper corner) and right arm (right upper corner) and erythematous eruptions 
with purpura on the left leg (left lower corner) and right leg (right lower corner).
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a superﬁcial necrotizing leukocytoclastic vasculitis with ulceration after 7 months 
of inﬂiximab therapy, with complete recovery after discontinuation of inﬂiximab. 
One patient developed a papular erythema in the groins after 5 years of adalimumab 
therapy. Histological examination was compatible with vasculitis with inﬁltration of 
mononuclear cells and presence of eosinophilic granulocytes. One patient developed 
a purpuric vasculitis on the legs after 1.5 months of lenercept therapy, improving 
spontaneously despite continuation of lenercept. One patient developed isolated digital 
vasculitis on his toes after one year of adalimumab therapy, which was continued. 
The lesions persisted. No biopsy was performed. One patient developed a generalized 
urticarial exanthema after therapy with etanercept two years earlier. Current therapy 
consisted of hydroxychloroquine and prednisolone. Histology showed a mild 
leukocytoclastic vasculitis.
Ulcers
The nine events with ulcers included 4 pressure ulcers, 2 ulcers due to dependency 
edema, one traumatic ulcer, one ulcer secondary to an unguis incarnatus and one ulcer 
without further speciﬁcation. Biopsies were taken in two patients, but no signs of 
vasculitis were found. A patient had a pressure ulcer with secondary infection and a 
ﬁstula to his ankle, which contained osteosynthetic material. The patient was admitted 
to the hospital for intravenous antibiotic therapy and inﬂiximab was stopped for 
several months. After recovery the patient restarted inﬂiximab without recurrence of 
his skin problems. TNF-α blocking therapy was continued in the other 8 patients and 
in 4 patients the ulcers recovered. Follow-up was missing in 4 patients.
Stasis dermatitis, edema, varices and chronic venous insufﬁciency
In 10 patients a dermatological consultancy was recorded for stasis dermatitis 
(n=3), edema (n=3), varices (n=2) or CVI (n=2). In one patient with extensive 
varices inﬂiximab therapy was stopped temporarily because of a complicating 
thrombophlebitis. One patient had edema of both legs of unknown cause with livid 
discoloration and induration. One patient had secondary lymphedema to RA. All other 
events were considered to be related to comorbidity, other than RA.
Psoriasis and psoriasiform eruptions
Psoriatic or psoriasiform eruptions were recorded in 3 RA patients. One patient 
developed a vesiculopustular erythematosquamous rash on hands and feet after 
9 months of adalimumab therapy. Histology showed a mixed psoriasiform and 
spongiotic dermatitis. A second RA patient developed psoriasis guttata-like eruptions 
on her lower legs after 4 years of therapy with adalimumab. The lesions diminished 
after adalimumab was withdrawn. A third patient developed a psoriasiform eruption 
on arms and legs after 16 months of adalimumab therapy. Histology obtained in the 
latter two patients was consistent with psoriasis.
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Other dermatological conditions
Other dermatological conditions that occurred during or after TNF-α blocking 
therapy included, amongst others, dermatomyositis (1), drug-induced SLE (1) and 
lymphomatoid papulosis-like eruption (1). Details are shown in table 5.
 One RA patient developed a macular rash on the inner sides of upper arms 
and legs after 2.5 months of lenercept monotherapy. A skin biopsy showed a non-
speciﬁc chronic dermatitis. A soft-tissue biopsy, including skin, fascia and muscle, 
showed fascial and muscular inﬁltration, consistent with dermatomyositis.
 One RA patient developed a drug-induced SLE after 20 months of inﬂiximab 
therapy in combination with MTX, consisting of discoid lupus erythematosus lesions 
on her hands and scalp, aphtous lesions, conversion to ANA positivity and a positive 
anti-double stranded-DNA (titer 60 U/L). The skin lesions ﬂared within one week 
after infusion and disappeared after discontinuation of inﬂiximab.
 A third RA patient developed macular erythematosquamous lesions on her 
lower arms, upper legs and trunk after 2.6 months of adalimumab monotherapy. 
Histology showed a dermal inﬁltration with CD-30 positive atypical T-cells. Although 
the lesions imposed as lymphomatoid papulosis, they completely disappeared within 
6 weeks. Adalimumab was not stopped. This patient developed a large-cell anaplastic 
non-Hodgkin lymphoma two years later.
Discussion
The present study is the ﬁrst large prospective study focusing on dermatological 
conditions in RA patients on TNF-α blocking therapy. 25% Of the patients needed 
a dermatological consultancy, compared to 13% in a RA control group, naive to 
TNF-α blocking therapy. The number of dermatological events per patient-year 
was signiﬁcantly higher during treatment than after treatment with TNF-α blocking 
therapy. Dermatological events led to withdrawal of TNF-α blocking therapy in 19 
patients (26%). The events recorded most frequently were skin infections, eczema 
and drug eruptions. Also, some interesting events were recorded, like psoriasis, drug-
induced SLE, dermatomyositis and a lymphomatoid-papulosis like eruption.
 RA is known to be associated with dermatological conditions like vasculitis, 
nodulosis, palmar erythema and bullous pemphigoid, amongst others.22;23 At present, 
information on the incidence and prevalence of dermatological conditions in RA 
mainly originates from cross-sectional or retrospective studies.24-26 Few prospective 
studies have been conducted focusing on speciﬁc conditions affecting the skin.27-28
 In establishing a relation between the use of a drug and the occurrence of 
dermatological conditions various factors need consideration. Information on clinical 
and histological patterns, time and dose relationship, dechallenge and rechallenge, 
and analogy with previously reported cases can support in assessing the plausibility 
of such a relationship.29 The underlying disease and concomitant medication also need 
careful consideration, as they can provide alternative explanations.
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 In this study the largest group of dermatological events consisted of skin 
infections, mostly fungal infections and folliculitis. The use of TNF-α blocking 
therapy has raised concerns regarding an increased susceptibility to infections, as 
TNF-α plays an important role in host-defence mechanisms.30 An increased incidence 
in TBC has been described31, as well as a growing number of serious infections with 
fungal, mycobacterial and intracellular bacterial pathogens.32-34 Infections of the skin 
have not been the subject of report in clinical trials and observational studies with 
TNF-α blocking therapy. Cases of severe necrotizing fasciitis have been described. 
35;36
 Skin infections have been reported frequently in the normal population 
and especially in RA patients.24-26 Host-defences impairments resulting from the 
underlying disease might play a role in an increased susceptibility to skin infections in 
RA patients, as well as the use of corticosteroids and DMARDs like MTX 28;37, which 
were recorded frequently in the present study (see table 2). They could provide an 
alternative explanation for the occurrence of skin infections. However, most infections 
occurred during active treatment with TNF-α blocking therapy, which could suggest 
at least a relative contribution to an increased vulnerability to skin infections in the 
study population. In one patient a bacterial superinfection of eczema occurred twice 
immediately after restart of adalimumab, showing a clear time relationship.
 For the description of the recorded drug eruptions a clinico-morphological 
classiﬁcation was chosen.21 Four eruptions with a time relationship and clinically or 
histological distinct drug-induced patterns also showed an eczematous appearance, 
both clinically and histologically. This is an unusual presentation for a drug-induced 
eruption, which warrants further investigation.
 Two drug eruptions occurred during infusion with inﬂiximab or adalimumab, 
whereas all others occurred after infusion. This will most likely not reﬂect the true 
ratio between acute and delayed reactions involving the skin, since acute reactions 
with skin involvement occur in 4% of the infusions and will mostly be treated by the 
rheumatologist without dermatological consultancy.38
 Interestingly, eczema was reported frequently in this study, even with 
various dermatitis conditions, like xerosis cutis, stasis eczema and seborrhoic 
eczema, classiﬁed as separate entities. Previous studies have reported RA, in which 
Th1 immune responses dominate, to be negatively associated with Th2 cell-mediated 
atopic disorders, like eczema39-41, although a similar incidence of eczema in RA and 
non-RA patients has also been reported.42 TNF-α blocking therapy downregulates Th1 
immune responses43, which might induce a shift of the Th1/Th2 balance towards Th2 
dominated immune responses and which might promote an increased susceptibility to 
atopic disorders, like eczema. 
 Although the time between initiation of TNF-α blocking therapy and the 
onset of dermatological conditions varied, a probable relationship was seen in various 
events. These included, besides drug eruptions, events of cutaneous vasculitis, drug-
induced SLE, dermatomyositis and a lymphomatoid papulosis like eruption.
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 An association between the use of TNF-α blocking therapy and the induction 
of systemic LE and discoid LE is strongly suggested by the number of cases that 
have been published.10;11;13;44-46 One case of discoid LE has been described on both 
etanercept and inﬂiximab in the same RA patient.47
 Analogy with previous reports is also present for cutaneous vasculitis 13;47-
49, although it is a known extra-articular manifestation of RA.22,23 In the ﬁrst case 
described a probably relationship with inﬂiximab was present, based on the time-
relationship and positive dechallenge. The other cases described were considered 
possibly related (case 2 and 3) and unlikely (case 4 and 5). Almost all reported ulcers 
were considered secondary to other causes, as described.
 Dermatomyositis has been reported previously in another patient, although 
this patient had a different presentation with raised CPK, muscle atrophy, mechanic 
hands and vasculitis.17
 Another interesting ﬁnding was the occurrence of psoriasiform eruptions in 
three patients on TNF-α blocking therapy. This observation is particularly interesting, 
since etanercept received and inﬂiximab approaches FDA approval for treatment of 
psoriasis after remarkable efﬁcacy results in clinical trials.7;50;51 The occurrence of 
guttate psoriasis has been reported after initiation of etanercept therapy for psoriasis 
in a placebo-controlled trial.51 Another case report described the occurrence of 
psoriasiform eruptions with histologically a lichenoid dermatitis pattern in a patient 
with Crohn’s disease.52
 An exacerbation of psoriasis was also seen in a patient with psoriatic arthritis 
receiving inﬂiximab therapy. An additional analysis showed that 28 patients with 
various non-RA rheumatic diseases, amongst others 12 JIA, 6 PsA and 3 AS, had 
been treated with TNF-α blocking therapy in the study centre. 5 Patients (18%) had 
visited a dermatologist for a dermatological condition during or after TNF-α blocking 
therapy. The events included a drug eruption, eczema and a mycosis in the face in 3 
patients with JIA and a superﬁcial spreading melanoma in a patient with AS. This 
indicates that the occurrence of dermatological events during TNF-α blocking therapy 
is not restricted to RA patients.
 In the present study the control patients were matched for time of follow-up 
period in order to control for time-related effects. A statistically signiﬁcant relationship 
between the use of TNF-α blocking therapy and the occurrence of dermatological 
visits was shown. It must be noted that the two groups differed for most baseline 
characteristics. These differences result from the indication for TNF-α blocking 
agents, which have been preserved for patients who fulﬁll criteria for active disease 
and DMARD failure (see methods section; study design), have a longer disease 
duration and are perhaps more refractory.
 However, it is considered unlikely that these factors inﬂuenced the 
relationship between the use of TNF-α blocking therapy and dermatological visits. In 
a multivariate regression model no baseline characteristic showed a predictive value 
for the occurrence of a dermatological event within RA patients on TNF-α blocking 
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therapy. Also, a statistically signiﬁcant higher number of dermatological events was 
recorded during active treatment with TNF-α blocking therapy, compared to the 
number of events recorded after stopping TNF-α blocking therapy.
Conclusion
This is the ﬁrst prospective study showing a relationship between TNF-α blocking 
therapy and the occurrence of dermatological conditions. Future prospective studies 
are needed to investigate the incidence and the pathogenesis of the encountered 
events, as they are a clinically signiﬁcant problem in RA patients on TNF-α blocking 
therapy.
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7.1 INTRODUCTION
In the present thesis several T-cell subsets and cells expressing NK-receptors have 
been phenotyped and in addition epidermal proliferation and differentiation have been 
characterized in the margin zone of the spreading psoriatic plaque and also during 
treatment with classical and innovative topical or systemic treatments. These studies 
were performed, in order to enlarge the knowledge concerning the role of T-cell 
subsets in relation to epidermal proliferation and differentiation in the pathogenesis 
of psoriasis, and to ﬁnd out which aspects of the psoriatic process are mainly targeted 
by the investigated treatments. Of major importance for our understanding of the 
pathogenesis of psoriasis, is the availability of biologicals in the treatment of psoriasis, 
which speciﬁcally target T-cells or T-cell related processes. These pathogenesis-based 
treatments provide new opportunities with a highly selective action for patients with 
moderate to severe psoriasis, without a broad spectrum of side effects.1 Nevertheless, 
side effects of these new treatments have to be monitored.
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7.2 PATHOGENESIS OF PSORIASIS
7.2.1 Exacerbation of psoriasis after infection, a constitutional trait or a 
variable expression?
In chapter 2.1 the question was addressed whether exacerbations of psoriasis after 
(throat) infections are a constitutional trait or rather a variable expression. It was shown 
that a group of patients with psoriasis exists, which show consistently aggravation 
of psoriasis following infection. This clinical observation suggests a major role of 
bacterial antigens as triggering factor in psoriasis. In this respect it is interesting that 
bacterial super-antigens from β-hemolytic streptococci, often responsible for throat 
infections, are able to induce Th1 responses. Peptides (M-proteins) from this bacterial 
super antigens share epitopes with keratins in the epidermis. Valdimarsson et al. 
therefore hypothesized, that psoriasis is a T-cell mediated autoimmune disease, with 
Vβ restricted T-cells cross reacting with epidermal keratins. These ﬁndings focused 
on the role of T-cells in the pathogenesis of psoriasis.2 Further evidence for a central 
role of the T-cell in the pathogenesis of psoriasis is provided by the fact that classical 
immunotherapies such as cyclosporine and innovative therapies (biologicals) are 
effective in psoriasis. Therefore, we investigated several T-cell subsets and cells 
expressing NK receptors in various phases of the psoriatic lesions. 
7.2.2. What are the dynamics of various T-cell subsets in the context of 
epidermal proliferation and keratinisation in the margin of spreading 
psoriatic plaques?
Studies in the margin zone model of spreading psoriatic plaques permit a description 
of early and late phases in the psoriatic process. The early phases are observed in 
the uninvolved skin surrounding the lesion and the late phases in the clinically 
involved skin. In chapter 3.2, it was shown that memory effector T-cells (CD45RO) 
and cytotoxic T-cells (CD8), CD25+ T-cells (IL-2 receptor) and CD2+ T-cells appear 
already in the early phase and persist in the chronic phase of the psoriatic lesion. In 
contrast, cells expressing NK receptors, epidermal hyper-proliferation and disturbed 
differentiation are restricted to the chronic phase of the psoriatic lesion.
 The signiﬁcance of the dynamics of the psoriatic process with respect to the 
pathogenesis, is that memory effector T-cells and cytotoxic T-cells, cells expressing 
the IL2 receptor (CD25) and CD2+ T-cells may have an important role in the early 
phase of a spreading psoriatic lesion. The aforementioned markers may be interesting 
targets to prevent spreading of unstable psoriatic plaques, or appearance of new 
lesions during a relapse. To answer the question whether T-cells are the initiators 
of the psoriatic process is beyond the scope of the margin zone model. However, as 
presented in the introduction, in particular the transplant experiments and the efﬁcacy 
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of T-cell targeted treatments lend support for the supposition that T-cells have an 
initial role.3-5
 Nevertheless, recently a mouse-model for psoriasis was developed with 
transgenic mice overexpressing Stat3 in activated keratinocytes and immunocytes. 
These mice produced psoriasis-like lesions spontaneously or after inducing minor 
trauma to the skin. By counteracting the overexpression of Stat3 with a decoy 
oligonucleotide, psoriasiform lesions of these mice were cured. This investigation 
suggests that a genetic defect in Stat3 interferes with the functioning of both activated 
keratinocytes and immunocytes, both being equally important in the pathogenesis of 
psoriasis.6
 The spectrum of abnormalities as observed in the psoriatic lesion comprises 
T-cell subsets, cells expressing NK receptors, epidermal hyperproliferation and 
disturbed differentiation. In the following sections it is discussed to what extent the 
spectrum of psoriatic changes is also expressed in psoriasis related disorders, and to 
what extent various treatments have a selective effect on these characteristics.
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7.3 SPECIAL EXPRESSIONS OF PSORIASIS
The pathogenesis of ﬂexural psoriasis and ILVEN have been discussed in the context 
of psoriasis. In chapter 3 it was investigated to what extent these conditions differ 
from psoriasis with respect to markers studied in this thesis.
 Flexural psoriasis is part of the psoriatic spectrum, according to clinical and 
dermatopathological descriptions. In chapter 3.1 T-cell subsets and cells expressing 
NK receptors were phenotyped in relation to epidermal proliferation and differentiation 
in ﬂexural psoriasis as compared to plaque psoriasis. Flexural psoriasis is often 
characterized by colonization with microorganisms, e.g. bacteria or fungi, whereas in 
plaque psoriasis such is not often the case. We studied the inﬁltrate in both psoriasis 
expressions, to ﬁnd out whether the inﬁltrate might contribute to the difference in 
bacterial colonization. Composition of T-cell subsets was similar in both expressions 
of psoriasis. The investigated inﬁltrate was the same in composition and cell number. 
One observation however, was a signiﬁcantly reduced number of CD161+ cells in 
ﬂexural psoriasis compared to plaque psoriasis. It was hypothesized that such might 
be the result of an increased turnover of cells expressing NK receptors in ﬂexural 
psoriasis. However, antibacterial and antifungal agents have not gained the position 
of an established treatment of ﬂexural psoriasis. In contrast, immunosuppressive 
treatments, in particular with calcineurin inhibitors, have been shown to be highly 
effective in ﬂexural psoriasis. Therefore the clinical signiﬁcance of the reduction of 
CD161+ cells in untreated lesions of ﬂexural psoriasis remains unclear. 
 In ILVEN without signs of psoriasis cytotoxic (CD8), memory effector 
(CD45RO+) T-cells as well as CD2+, CD94+ and CD161+ cells were substantially 
less expressed as compared to psoriasis. Therefore, ILVEN can be regarded as 
different from psoriasis also from an immunological point of view. It is hypothesized 
that ILVEN does not improve on anti-psoriatic treatments selectively targeting T-
cells, because of this different immunological phenotype, resulting from the ILVEN 
genotype.
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7.4 CLASSICAL TREATMENTS 
In chapter 4, four classical therapies in the treatment of plaque psoriasis have been 
described, i.e. calcipotriol ointment bid, betamethasone dipropionate ointment bid, the 
combination of the aforementioned treatments and short-contact dithranol treatment. 
Different treatments may differ in action spectrum (table 3). 
 From these results one may conclude that the T-cell is not a universal anti-
psoriatic target, as betamethasonedipropionate and dithranol do not decrease the 
numbers of the T-cell subsets during 4-6 weeks of treatment. However, it is possible 
that functioning of activated T-cells might be affected by dithranol and betamethasone
dipropionate treatment, without affecting the actual cell numbers of the populations. 
 Considering the cells with NK receptors, only the corticosteroid based 
treatment showed an effect. It is intriguing that epidermal proliferation and 
keratinization are affected by all treatments. However, we have to realize that this 
effect can be primary or secondary to other effects of the treatments. Indeed in the 
margin zone of the psoriatic lesion it was shown that the overt epidermal proliferation 
occurred after appearance of T-cell subsets .
 The rate of clinical improvement by topical corticosteroids is fast, with 
maximal efﬁcacy after 2-4 weeks, whereas calcipotriol bid treatment results in 
maximal efﬁcacy after 6-8 weeks. The rate of clinical improvement for dithranol cream 
is intermediary. Maintenance therapy with dithranol and topical corticosteroids is not 
possible for reason of side effects and tolerability, although topical corticosteroids 
may be helpful as intermittent treatment. Calcipotriol has been shown in three long-
term studies to be effective as maintenance treatment up to 12 months7-9, without signs 
of tachyphylaxis. The longterm efﬁcacy of calcipotriol ointment is in agreement with 
its anti-psoriatic targets. (table 3) The aforementioned studies show the efﬁcacy of 
calcipotriol to prevent new lesions. The ability to prevent relapses might be related 
to the potent effect on early pathogenetic markers.  To enhance the rate of clinical 
improvement, a corticosteroid may be added to the treatment regimen, which targets 
mostly late pathogenetic phenomena. 
Chapter 7 - Summary and General Discussion
206
7.5 INNOVATIVE TOPICAL TREATMENTS
With respect to the innovative treatments table 3 summarizes signiﬁcant (p<0.05) 
and highly signiﬁcant (p<0.01) changes for epidermis as well as dermis, during new 
topical treatments. 
 As described in chapter 5 the new vitamin D
3
 derivative ZK 156942 
(Tisocalcitate) did not induce a highly signiﬁcant reduction of any marker. 
Nevertheless, a signiﬁcant reduction of SUM-score was reached after 8 weeks of twice 
daily treatment with SH F597 F, containing ZK 156942. Although no signiﬁcancy was 
reached for the reduction of Ki-67+ cells by SH F597 F bid there was still a marked 
decrease of epidermal hyperproliferation. The increase of keratin 10 expression after 
treatment with SH F597 F was pronounced. Dermal CD94+ cells were signiﬁcantly 
reduced after 8 weeks treatment with SH F597 F bid. Other T-cell subsets showed a 
non-signiﬁcant decrease or increase after treatment with SH F597 F bid.
 Topical treatment with tacrolimus gel induced highly signiﬁcant changes in 
T-cell subsets, including CD4, CD45RO and CD25 as well as a highly signiﬁcant 
increase of keratin 10. The α subunit of the IL2 receptor was signiﬁcantly reduced in 
dermis and epidermis by tacrolimus gel after 12 weeks of treatment. The IL2 receptor, 
as discussed in chapter 1 is an important marker of activation of T-cells, and is 
expressed in an early phase of T-cell activation.10 Tacrolimus reduces the transcription 
of cardinal pro-inﬂammatory cytokines, e.g. IL2, by inhibiting calcineurin. 11;12 By 
a positive feedback loop IL2 upregulates the expression of the IL-2 receptor. It is 
possible that tacrolimus reduces the IL-2 receptor expression by interfering with this 
positive feedback mechanism.
 Tacrolimus cream induced a highly signiﬁcant decrease of CD4+ cells in the 
dermis, but did not affect other T-cell markers. Nevertheless, tacrolimus cream also 
induced a signiﬁcant reduction of Ki-67+ cells at week 12. The formulation of topical 
tacrolimus is crucial for sufﬁcient penetration. Therefore, further development of 
tacrolimus formulations are likely to result in an innovation for the topical treatment 
of psoriasis.
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7.6 INNOVATIVE SYSTEMIC TREATMENTS
During the thesis project, the author has contributed to studies on efﬁcacy and safety 
of several biologics, including etanercept, alefacept and inﬂiximab. In view of the 
dual mode of action of alefacept on LFA3-CD2 interaction and NK cell induced T-cell 
apoptosis, alefacept was selected for the mode of action studies. 
With respect to anti-TNF-α treatments longterm safety data over many years are 
available for rheumatoid arthtritis. A large group of patients with rheumatoid disease 
has been treated with anti TNF-α therapies at the department of Rheumatology. 
Cutaneous side effects of these treatments were evaluated in a multidisciplinary 
collaboration.
7.6.1. The effect of alefacept as new therapy and combination therapy of 
alefacept and calcipotriol.
The changes of T-cell subsets, cells expressing NK receptors and epidermal proliferation 
in lesional psoriatic skin induced by alefacept were modest. Not any change reached 
the level of highly signiﬁcant (p<0.01). Signiﬁcant reductions (p<0.05) were observed 
for CD4, CD45RO, CD2 and CD8 positive cells, without signiﬁcant changes of cells 
expressing NK receptors. The percentage keratin 10 positive epidermal surface 
increased signiﬁcantly, although the reduction of epidermal proliferation did not 
reach the level of statistical signiﬁcancy. On the other hand, we have to realize that 
the relatively small population of 5 patients only warrants preliminary conclusions. 
Nevertheless, this study suggests that memory effector T-cells are targeted, without 
affecting cells expressing NK receptors. The addition of low dose calcipotriol cream 
did not result in enhanced clinical efﬁcacy. Furthermore, the combination was not 
Treatment CD4 CD8 CD45RO CD45RA CD2 CD25 CD94 CD161 Ki67 K10 HLA-DR
Calcipotriol ↓ ↓ ↓↓ ↓ ↓ ↓ ↓ ↓ ↓↓ ↑↑
Betamethason-
dipropionate
↓ ↓ ↑↑
calcipotriol + 
betamethason-
dipropionate
↓ ↓↓ ↓ ↓ ↓↓ ↓↓ ↓↓ ↓ ↓↓ ↑
Dithranol ↓ ↑↑
ZK 156942 bid ↓ ↓
tacrolimus gel ↓ ↓ ↓ ↓ ↓↓ ↑↑ ↓↓
Tacrolimus 
cream
↓↓ ↓ ↓
Alefacept ↓ ↓ ↓ ↓ ↓ ↓ ↑
alefacept +
calcipotriol
↓ ↓
Table 3 Signiﬁcant (p<0.05=↓) or highly signiﬁcant (p<0.01=↓↓) reductions of T-cell subsets 
in epidermis or dermis and epidermal proliferation after treatment with several traditional and 
innovative topical agents and a systemic treatment with alefacept. For epidermal differentiation 
signiﬁcant (p<0.05=↑) or highly signiﬁcant (p<0.01=↑↑) increases are depicted.   
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more effective in reducing T-cell subsets, epidermal hyperproliferation or 
keratinization.
7.6.2. Cutaneous side effects of anti-TNF-α treatments
TNF-α blocking agents are a great advancement in the treatment of psoriasis. 
Experience in the use of TNF-α blocking agents in rheumatology provides important 
knowledge about side effects during these treatments, since in rheumatology TNF-α 
blocking agents are prescribed for a longer time and on a larger scale. We found that 
TNF-α blocking agents induce a plethora of cutaneous side effects in a group of 289 
rheumatoid arthritis patients. Statistically signiﬁcant more patients on TNF-α blocking 
therapy (25%) visited a dermatologist during follow up compared to RA patients, 
who were naive to treatment with TNF-α blocking agents. (13%, p< 0.0005)  TNF-α 
blocking therapy was stopped in 19 patients (26%) because of dermatological events. 
Most recorded cutaneous side effects were skin infections (n=33), eczema(n=20) 
and drug eruptions (sensu strictu) (n=15). Less frequently occurring cutaneous side 
effects consisted of vasculitis, psoriasis, drug-induced SLE, dermatomyositis and a 
lymphomatoid-papulosis like eruption.
 The high frequency of cutaneous infections in RA patients treated with 
TNF-α blocking agents may be caused by the immunosuppression, and impairment 
of innate immunity. Furthermore, the relatively frequent occurrence of eczema may 
be associated with a shift towards Th2 cells in this group of RA patients, induced by 
TNF-α blocking agents.
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7.7 GENERAL DISCUSSION
In chapter 1 we described epidemiology and clinical presentation of psoriasis, followed 
by the (immuno)pathogenesis of psoriasis. Several established and innovative topical 
and systemic treatments relevant to this thesis were discussed. Furthermore, outline 
and objectives were described. Finally, the investigational approach was described. 
In chapter 2 aspects of the pathogenesis of psoriasis were investigated, and the 
following conclusions could be made. 
1. The response of psoriasis patients to ﬂare following infections proved to be 
a constitutional trait, which underscores that, the immuno-pathogenesis of 
psoriasis should be regarded as a constitutional phenomenon. 
2. In an early phase of the development of the psoriatic lesion CD8+, CD45RO+, 
CD2+ and CD25+ cells proved to be present, whereas in a later phase cells 
expressing NK receptors together with epidermal hyperproliferation and 
disturbed keratinization were present.
In chapter 3 two expressions of psoriasis were investigated namely ILVEN and 
ﬂexural psoriasis. It was concluded from these studies that:
3. ILVEN can be regarded as distinct from psoriasis from an immunological point 
of view, and ﬂexural psoriasis is not essentially different from plaque psoriasis 
with respect to T-cell subsets, cells expressing NK receptors and epidermal 
growth and differentiation. 
How classical topical treatments interfere with the immunopathogenesis of psoriasis 
was studied in chapter 4. The available topical treatments proved to have not one 
single target. The number of T-cell subsets is reduced by calcipotriol-based treatments, 
whereas a potent corticosteroid and dithranol did not affect T-cell numbers. Cells 
expressing NK receptors were reduced by corticosteroid based treatments. Epidermal 
proliferation, keratinization were affected by all treatments. 
From these studies we may conclude the following: 
4. Classical anti-psoriatic treatments do not induce the same pattern of changes 
with respect to T-cell subsets, cells expressing NK-receptors and epidermal 
proliferation and differentiation. 
In chapter 5 three innovative topical treatments for plaque psoriasis were studied, and 
compared clinically and immunohistochemically with calcipotriol ointment, resulting 
in the following conclusion:
5. Tacrolimus gel is a very promising treatment for plaque psoriasis, and its clinical 
efﬁcacy implicates a good bioavailability in plaque psoriasis.
Finally, Chapter 6 described the clinical and immunohistochemical effects of 
alefacept on lesional psoriatic skin, and the cutaneous side effects of anti TNF-α 
treatment within a group of RA patients. From these studies it was concluded that:
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6. Alefacept monotherapy is able to reduce lesional memory effector T-cells, and 
the combination with low dose calcipotriol cream did not result in an additional 
effect on T-cell subsets, epidermal growth and differentiation.
7. Cutaneous side effects are a signiﬁcant problem among RA patients using 
anti TNF-α treatment, consisting of skin infections, eczema, drug eruptions 
(sensu strictu), vasculitis, psoriasis, drug-induced SLE, dermatomyositis and a 
lymphomatoid-papulosis like eruption
Chapter 7 - Summary and General Discussion
211
7.8 FUTURE SUGGESTIONS
Further research on the combination of treatments seems to be worthwhile, on the one 
hand to ﬁnd treatments with enhanced clinically efﬁcacy in psoriasis and to induce a 
complete clearance of psoriasis, on the other hand to reduce side effects essential for a 
long-term safe control of psoriasis. A critical study on the effect of monotherapy and 
combinations may help to identify promising combinations. 
 The results from this thesis underscore that T-cells and cells expressing NK-
receptors are relevant to the pathogenesis and treatment of psoriasis. Further studies 
on functional aspects of these cells in the context of epidermis and endothelium may 
contribute to our insight in this complex disease. 
 Side effects, induced by biologicals must be monitored very carefully. It was 
shown in this thesis that within a group of RA patients, cutaneous side effects due 
to anti TNF-α treatment are a signiﬁcant problem. In psoriasis anti TNF-α treatment 
may also be associated with cutaneous side effects, including skin malignancies, as 
indicated by several case-reports.13;14 To study these cutaneous side effects, future 
research may focus on cutaneous side effects within a group of patients with psoriasis 
using anti TNF-α treatment.  
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7.9 SAMENVATTING
In dit proefschrift worden T-lymfocyt subsets, cellen die NK receptoren tot expressie 
brengen gefenotypeerd en proliferatie en differentiatie markers gekarakteriseerd 
in het randzone model van zich uitbreidende psoriasis laesies. Deze markers zijn 
ook toegepast voor het monitoren van klassieke topicale behandelingen evenals 
innovatieve topicale en systemische behandelingen. De verschillende onderzoeken zijn 
uitgevoerd met het doel kennis met betrekking tot de rol van T-lymfocyten in relatie 
tot epidermale groei en differentiatie in de pathogenese van psoriasis te vergroten. 
Het beschrijven van “targets” van de verschillende behandelingen was hierbij ook van 
belang. Innovatieve behandelingen zijn ontwikkeld op basis van kennis aangaande 
de (immuno)pathogenese van psoriasis, terwijl bij de klassieke behandelingen vaak 
als gevolg van serendipiteit de antipsoriatische werking ontdekt werd. De nieuwe 
behandelingen die zeer selectief aangrijpen op de pathogenese van psoriasis hebben 
een minder breed bijwerkingen proﬁel. Toch moeten ook deze innovatieve middelen 
onderzocht worden met betrekking tot het optreden van bijwerkingen.
 In hoofdstuk 1 van dit proefschrift wordt de epidemiologie en klinische 
presentatie van psoriasis beschreven. Voorts wordt ingegaan op de (immuno)pathogenese 
van psoriasis. Verschillende klassieke topicale en systemische behandelingen worden 
genoemd, evenals innovaties op het gebied van de behandeling van psoriasis. Na het 
formuleren van de doelstellingen van dit proefschrift wordt ingegaan op de gebruikte 
onderzoeksmethoden, alsmede de onderzoeksmodellen. 
 In Hoofdstuk 2 staan enkele aspecten van de pathogenese van psoriasis 
centraal. In de eerste plaats wordt ingegaan op de vraag of exacerbaties van psoriasis 
na een infectie een constitutioneel verschijnsel zijn, of eerder op toeval berusten. Er 
werd aangetoond dat er een groep psoriasis patiënten bestaat, die telkens exacerbaties 
hebben na het doormaken van een infectie. Deze klinische observatie doet vermoeden, 
dat bacteriële antigenen een belangrijke rol spelen als uitlokkende factor. In het kader 
hiervan is het interessant te vermelden dat β-hemolytische streptococcen, vaak de 
veroorzaker van een keel infectie, in staat zijn om een Th1 respons te induceren. 
Peptiden (M-proteinen) van deze bacteriële super-antigenen delen epitopen met 
keratines in de epidermis. Deze bevindingen alsmede de effectiviteit van een klassieke 
behandeling met bijvoorbeeld cyclosporine en de effectiviteit van biologicals, is 
bewijzend voor de belangrijke rol die T-cellen spelen in de pathogenese van psoriasis. 
Daarom werden in een volgend onderzoek T-cel susbets, cellen die NK receptoren 
tot expressie brengen, epidermale groei en diferentiatie onderzocht in een zich 
uitbreidende psoriasis laesie.
 Bestudering van het randzone model levert informatie op aangaande de vroege 
en late fases in een zich uitbreidende psoriasis plaque. De niet-lesionale huid rond een 
psoriasis plaque representeert de vroege fase, en de lesionale huid representeert de late 
fase. Memory-effector T-cellen (CD45RO) en cytotoxische T-cellen (CD8), CD25+ T-
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cellen en CD2+ T-cellen zijn al aanwezig  in een vroege fase van een zich uitbreidende 
psoriasis laesie en blijven aanwezig in de chronische fase. Cellen die NK-receptoren 
tot expressie brengen, epidermale hyperproliferatie en gestoorde differentiatie komen 
echter in een latere fase voor.
 De bevindingen uit dit randzone model laten zien dat memory effector T-
cellen en cytotoxische T-cellen mogelijk een belangrijke rol spelen in de vroege fase 
van de pathogenese van psoriasis. De zojuist genoemde markers zouden mogelijk 
interessante targets zijn ter preventie van uitbreiding van niet-stabiele plaque laesies, 
of ter voorkoming van een exacerbatie. Echter het randzone model is niet geschikt 
om de vraag te beantwoorden of de T-lymfocyt daadwerkelijk de initiator is van het 
psoriatische proces. 
 In hoofdstuk 3 worden T-lymfocyt subsets, cellen die NK receptoren 
tot expressie brengen, epidermale groei en differentiatie bestudeerd in psoriasis 
gerelateerde aandoeningen. Psoriasis inversa hoort voor wat betreft klinische en 
dermatopathologische kenmerken binnen het spectrum van psoriasis. Psoriasis inversa 
wordt gekarakteriseerd door kolonizatie met micro-organismen. Wij bestudeerden het 
inﬁltraat in zowel psoriasis inversa als psoriasis vulgaris om te achterhalen of het 
inﬁltraat zou kunnen bijdragen tot verschil in bacteriële kolonisatie. De samenstelling 
van het inﬁltraat in beide aandoeningen is gelijk voor wat betreft kwaliteit en 
kwantiteit.
 In ILVEN zonder tekenen van psoriasis kwamen cytotoxische T-cellen, 
memory effector T-cellen, CD2+, CD94+en CD161+ cellen substantieel minder tot 
expressie dan in psoriasis. ILVEN kan daarom beschouwd worden als verschillend 
van psoriasis vulgaris vanuit een immunologisch oogpunt gezien. Antipsoriatische 
behandelingen die speciﬁek T-cellen als target hebben,  hebben om die redenen geen 
effect op de laesies.
 Hoofdstuk 4 beschrijft 4 klassieke topicale behandelingen voor psoriasis 
vulgaris, en hun effect op T-lymfocyt subsets, cellen die NK receptoren tot expressie 
brengen, epidermale groei en keratinizatie. Bestudeerd wordt een topicale behandeling 
met calcipotriol 2dd, een klasse III corticosteroid 2dd, en de combinatie van beide 1dd. 
Therapie met kort-contact dithranol creme wordt eveneens onderzocht. Resultaten 
uit deze studies tonen aan dat het actie-spectrum tussen de behandelingen verschilt. 
We kunnen eveneens concluderen dat de T-lymfocyt geen universeel antipsoriatisch 
target is, omdat betamethasondipropionaat en ditranol niet de T-lymfocyt subsets doen 
afnemen gedurende een periode van 4-6 weken, en toch een goed klinisch resultaat 
laten zien. Het is echter mogelijk dat beide de functie van de T-lymfocyt subsets 
kunnen beïnvloeden, zonder daadwerkelijk het aantal te verminderen. 
 Enkel behandelingen die gebaseerd zijn op het gebruik van lokale 
corticosteroïden, hadden effect op cellen die NK receptoren tot expressie brengen. 
Alle behandelingen hadden invloed op epidermale groei en differentiatie, waarbij 
opgemerkt moet worden dat dit effect primair of secundair kan zijn. Inderdaad, in het 
randzone model was vooraf aan epidermale hyperproliferatie een T-lymfocyt inﬁltraat 
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aanwezig.
 In hoofdstuk 5 worden de innovatieve topicale behandelingen beschreven. 
ZK 156942 (Tisocalcitate) is een nieuw vitamine D
3
 derivaat dat geen hoog signiﬁcante 
afname induceerde van onderzochte markers. Wel was er een signiﬁcant verbetering 
in SUM-score na 8 weken behandeling met 2dd  SH F597 F (de zalf die ZK 156942 
bevat)
 Tacrolimus gel was daarentegen klinisch effectief in het reduceren van de 
SUM-score, en had eveneens effect op CD4+, CD45RO+, CD45RA+, CD2+, CD25+ 
T-cellen en epidermale groei en differentiatie van de psoriatische huid.
 Gedurende de onderzoeksfase, die vooraf ging aan dit proefschrift zijn 
er studies verricht naar effectiviteit en veiligheid van de verschillende innovatieve 
systemische behandelingen, zoals etanercept, alefacept en inﬂiximab. De effecten 
van alefacept op T-lymfocyt subsets, cellen die NK receptoren tot expressie brengen, 
epidermale groei en differentiatie werden bestudeerd in hoofdstuk 6. Alefacept 
induceerde een signiﬁcante reductie van CD4+, CD45RO+, CD2+ en CD8+ cellen, 
zonder een signiﬁcante afname van cellen die NK receptoren tot expressie brengen. 
Epidermale differentiatie normaliseerde signiﬁcant door alefacept monotherapie. 
Opmerkelijk was dat een lage dosis calcipotriol creme geen additioneel effect had 
op behandeling met alefacept voor wat betreft klinische effectiviteit en reductie van 
T-lymfocyt subsets, epidermale hyperproliferatie en normalisering van keratinizatie. 
 TNF-α blokkerende geneesmiddelen betekenen een grote vooruitgang in de 
behandeling van psoriasis. Ervaring vanuit de reumatologie met TNF-α blokkerende 
geneesmiddelen met betrekking tot bijwerkingen levert belangrijke kennis op. 
Deze geneesmiddelen worden op grotere schaal en al een langere periode toegepast 
door reumatologen. Een onderzoek uitgevoerd door de afdeling reumatologie en 
dermatologie toonde aan dat binnen een groep van 289 reumatoïde artritis patiënten 
die TNF-α blokkerende geneesmiddelen gebruiken, huidaandoeningen signiﬁcant 
vaker voorkomen (25%) dan in een groep RA patiënten die nog nooit TNF-α 
blokkerende geneesmiddelen hebben gebruikt. (13%, p<0,0005) TNF-α blokkerende 
geneesmiddelen werden gestopt in 19 patiënten (26%) vanwege het optreden van 
bijwerken op de huid. Huidafwijkingen die voorkomen in deze groep zijn huidinfecties 
(n=33), eczeem(n=20) en geneesmiddelreacties (sensu strictu)(n=15) Minder frequent 
voorkomende huidaandoeningen waren vasculitis, psoriasis, SLE, dermatomyositis 
en een lymfomatoide papulosis achtige eruptie. De hoge frequentie van huidinfecties 
in RA patiënten, die TNF-α blokkerende geneesmiddelen gebruiken, kan mogelijk 
samenhangen met de immuunsuppressie die deze geneesmiddelen veroorzaken. 
De hoge frequentie van eczeem in deze groep RA patiënten is mogelijk te wijten 
aan de TNF-α blokkerende geneesmiddelen die een immuundeviatie van T-cellen 
veroorzaken, waardoor meer Th2 cellen aanwezig zijn. 
Samenvattend kunnen de volgende conclusies worden getrokken uit de verschillende 
onderzoeken in dit proefschrift:
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1. Exacerbatie van psoriasis na een infectie is een constitutionele eigenschap.
2. In een vroege fase van het ontstaan van een psoriasis laesie zijn met name 
CD8+, CD45RO+, CD2+ en CD25+ T-cellen aanwezig. In een latere fase zijn 
cellen die NK receptoren tot expressie brengen, epidermale hyperproliferatie en 
gestoorde differentiatie aanwezig.
3. Voor wat betreft de samenstelling van het inﬁltraat is ILVEN (inﬂammatoire 
lineaire epidermale naevus) verschillend van psoriasis vulgaris. Psoriasis 
inversa is echter niet verschillend van psoriasis vulgaris voor wat betreft T-
lymfocyt subsets, cellen die NK receptoren tot expressie brengen en epidermale 
groei en differentiatie.
4. Beschreven klassieke topicale middelen voor de behandeling van psoriasis 
hebben verschillende targets in de psoriatische huid.
5. Tacrolimus gel is een veelbelovende behandeling voor psoriasis vulgaris, en de 
klinische effectiviteit ervan impliceert een goede biologische beschikbaarheid 
in de psoriatische huid
6. Alefacept monotherapie is in staat lesionale memory effector T-cellen te 
reduceren, en de combinatie met calcipotriol crème resulteerde niet in een 
toegenomen effect op T-lymfocyt subsets, epidermale groei en differentiatie.
7. Huidaandoeningen bij RA patiënten die TNF-α blokkerende geneesmiddelen 
gebruiken zijn een signiﬁcant probleem, waarbij de volgende dermatosen 
kunnen optreden: huidinfecties, eczeem, geneesmiddelreacties (sensu strictu), 
vasculitis, psoriasis, geneesmiddel geïnduceerde SLE, dermatomyositis en 
lymfomatoide papulosis achtige eruptie. 
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